WO2006082392A1 - Pyrazolylaminopyridine derivatives useful as kinase inhibitors - Google Patents

Pyrazolylaminopyridine derivatives useful as kinase inhibitors Download PDF

Info

Publication number
WO2006082392A1
WO2006082392A1 PCT/GB2006/000334 GB2006000334W WO2006082392A1 WO 2006082392 A1 WO2006082392 A1 WO 2006082392A1 GB 2006000334 W GB2006000334 W GB 2006000334W WO 2006082392 A1 WO2006082392 A1 WO 2006082392A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amino
mmol
formula
compound
Prior art date
Application number
PCT/GB2006/000334
Other languages
French (fr)
Inventor
Audrey Davies
Michelle Lamb
Paul Lyne
Peter Mohr
Bin Wang
Tao Wang
Dingwei Yu
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020077020258A priority Critical patent/KR101302945B1/en
Priority to AT06701619T priority patent/ATE530545T1/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to MEP-2011-563A priority patent/ME02645B/en
Priority to CN2006800101082A priority patent/CN101155800B/en
Priority to CA2595834A priority patent/CA2595834C/en
Priority to PL06701619T priority patent/PL1846394T3/en
Priority to MX2007009437A priority patent/MX2007009437A/en
Priority to US11/815,140 priority patent/US8324252B2/en
Priority to DK06701619.6T priority patent/DK1846394T3/en
Priority to BRPI0606793A priority patent/BRPI0606793A8/en
Priority to EP06701619A priority patent/EP1846394B1/en
Priority to ES06701619T priority patent/ES2375735T3/en
Priority to SI200631240T priority patent/SI1846394T1/en
Priority to NZ561145A priority patent/NZ561145A/en
Priority to AU2006210710A priority patent/AU2006210710B2/en
Priority to JP2007553688A priority patent/JP5139084B2/en
Publication of WO2006082392A1 publication Critical patent/WO2006082392A1/en
Priority to IL184674A priority patent/IL184674A/en
Priority to NO20073791A priority patent/NO341112B1/en
Priority to HK08101578.0A priority patent/HK1114374A1/en
Priority to HR20110962T priority patent/HRP20110962T1/en
Priority to US13/688,790 priority patent/US8835465B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to novel pyrazole derivatives, their pharmaceutical compositions and methods of use.
  • the present invention relates to therapeutic methods for the treatment and prevention of cancers and to the use of these pyrazole derivatives in the manufacture of medicaments for use in the treatment and prevention of cancers.
  • RTK' s Receptor tyrosine kinases
  • Trk's tropomyosin-related kinases
  • Trk's are the high affinity receptors activated by a group of soluble growth factors called neurotrophins (NT).
  • the Trk receptor family has three members - TrkA, TrkB and TrIcC.
  • NTs nerve growth factor
  • TrkA nerve growth factor
  • TrkB brain-derived growth factor
  • TrIcC neurotrophins
  • NT3 neurotrophins
  • Each Trk receptor contains an extra-cellular domain (ligand binding), a trans-membrane region and an intra-cellular domain (including kinase domain).
  • the kinase Upon binding of the ligand, the kinase catalyzes auto-phosphorylation and triggers downstream signal transduction pathways.
  • Trk's are widely expressed in neuronal tissue during its development where Trk's are critical for the maintenance and survival of these cells.
  • Trk's play important role in both development and function of the nervous system (Patapoutian, A. et al Current Opinion in Neurobiology, 2001, 11, 272-280).
  • Trk inhibitors may yield a class of apoptosis-inducing agents specific for androgen- independent prostate cancer (Weeraratna, A. T. et al The Prostate, 2000, 45, 140-148).
  • Trk inhibitors There are a few reports of selective Trie tyrosine kinase inhibitors. Cephalon described CEP-751, CEP-701 (George, D. et al Cancer Research, 1999, 59, 2395-2341) and other indolocarbazole analogues (WOOl 14380) as Trk inhibitors. It was shown that CEP-701 and/or CEP751, when combined with surgically or chemically induced androgen ablation, offered better efficacy compared with mono-therapy alone. GlaxoSmithKline disclosed certain oxindole compounds as Trk A inhibitors in WO0220479 and WO0220513. Recently, Japan Tobacco reported pyrazolyl condensed cyclic compounds as Trk inhibitors (JP2003231687A).
  • Vertex Pharmaceuticals have described pyrazole compounds as inhibitors of GSK3, Aurora, etc. in WO0250065, WO0262789,WO03027111 and WO200437814; and AstraZeneca have reported pyrazole compounds as inhibitors against IGF-I receptor kinase (WO0348133). Summary of the invention
  • novel pyrazole compounds, or pharmaceutically acceptable salts thereof which possess Trk kinase inhibitory activity and are accordingly useful for their anti-proliferation and/or proapoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body.
  • the invention also relates to processes for the manufacture of said pyrazole compounds, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferation and/or proapoptotic effect in warm-blooded animals such as man.
  • the applicants provide methods of using such pyrazole compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer.
  • the properties of the compounds claimed in this invention are expected to be of value in the treatment of disease states associated with cell proliferation such as cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
  • cancers solid tumors and leukemia
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis
  • Kaposi's sarcoma haemangioma
  • atheroma atherosclerosis
  • arterial restenosis autoimmune diseases
  • autoimmune diseases acute and chronic inflammation
  • bone diseases and ocular diseases with retinal vessel proliferation ocular diseases with retinal vessel proliferation.
  • the compounds, or pharmaceutically acceptable salts thereof, of the invention are expected to be of value in the treatment or prophylaxis of cancers selected from congenital fibrosarcoma, mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, melanoma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma and leukaemia
  • R and R 2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C ⁇ alkanoyl, C 1-6 alkanoyloxy, iV-(C 1-6 alkyl)amino, N, ⁇ / ' -(C 1- 6alkyl) 2 amino, C 1-6 alkanoylamino, iV-(C 1-6 alkyl)carbamoyl, iV,iV-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(C 1-6 alkyl)sulphamoyl, N,N-(C 1-6 alkyl) 2 s
  • R 3 is hydrogen or optionally substituted C 1-6 alkyl; wherein said optional substituents are selected from one or more R 11 ;
  • R 4 and R 34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(Ci -6 alkyl)amino, N,N-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, N,N-(C 1-6 alkyl) 2 carbamoyl, C 1-S aIlCyIS(O) 3 wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(C 1 -6 alkyl)sulphamoyl, N,N-(C 1-6 alkyl) 2 sulphamoyl
  • A is a direct bond or C 1-2 alkylene; wherein said C 1-2 alkylene may be optionally substituted by one or more R 14 ;
  • Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 15 ;
  • R 5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C ⁇ alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, N,N-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, JV,N-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(C 1-6 alkyl)sulphamoyl,
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, iV-(C 1-6 alkyi)amino, iV,N-(Ci -6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyi)carbamoyl, ⁇ N-(Ci -6 alkyl) 2 carbamoyl, Ci -6 alkylS(O) a wherein a is 0 to 2, Ci -6 alkoxycarbonyl, N-(C 1-6 alkyl)sulphamoyl, ⁇ N-(C 1-6 alkyl) 2
  • R 6 , R 11 , R 12 , R 14 , R 16 and R 18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, iV,N-(C 1-6 ah 1 cyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyi)carbamoyl, ⁇ N-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(C 1-6 aLkyl)sulphamoyl, iV,iV-(C 1-6 alkyl)
  • R 7 , R 13 , R 15 , R 17 , R 19 and R 21 are independently selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, iV-(C 1-6 alkyl)carbamoyl,
  • R 20 and R 22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Q.ealkyl, C 2-6 alkenyl, C 2-6 alkynyl, Q- ⁇ alkoxy, Q- ⁇ alkanoyl, C 1-6 alkanoyloxy, N,N-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, iV-(C 1-6 alkyl)carbamoyl, N,N-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, Q-ealkoxycarbonyl, N-(C 1-6 alkyl)sulphamoyl, N,N-(Ci -6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamino, C
  • R 2 is selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, JV-(C 1-6 alkyl)carbamoyl, i ⁇ f iV-(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof.
  • R 1 and R 2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C!. 6 alkoxy, C 1-6 alkanoyl, Ci -6 alkanoyloxy, JV-(C 1-6 alkyi)amino, iV,iV-(C 1 .
  • R 3 is hydrogen or optionally substituted Ci -6 alkyl; wherein said optional substituents are selected from one or more R 11 ;
  • R 4 is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 allcyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, T ⁇ iV-(C 1 -6 alkyl) 2 amino, C 1-6 alkanoylamino, iV-(C 1-6 alkyl)carbamoyl, N, N-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, iV-(C 1-6 alkyl)sulphamoyl,
  • A is a direct bond or wherein said C 1-2 alkylene may be optionally substituted by one or more R 14 ;
  • Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 15 ;
  • R 5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, ⁇ /-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, JV-(C 1-6 alkyi)sulphamoyl,
  • R 5 may be optionally substituted on carbon by one or more R 16 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ; n is 0, 1, 2 or 3; wherein the values of R 5 may be the same or different;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, Ci- ⁇ alkanoyl, C ⁇ allcanoyloxy, N-(Ci- 6 alkyl)arnmo, iV,iV-(Ci -6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, N,N-(Ci -6 alkyl) 2 carbamoyl, C 1- OaIlCyIS(O) 3 wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(Ci -6 alkyl)sulphamoyl, N ) iV-(C 1
  • R 6 , R 11 , R 12 , R 14 , R 16 and R 18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C ⁇ allcanoyl, C 1-6 alkanoyloxy, JV-(C 1 -6 alkyl)amino, iV,iV-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, iV-(C 1-6 alkyl)carbamoyl, iV,iV-(Ci -6 allcyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, iV-(C 1-6 alkyl)sulphamo
  • R 7 , R 13 , R 15 , R 17 , R 19 and R 21 are independently selected from Ci -6 alkyl, C 1-6 alkanoyl, C ⁇ alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, iV-(C 1-6 alkyl)carbamoyl,
  • R 20 and R 22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2 - 6 alkynyl, C 1-6 alkoxy, Q ⁇ alkanoyl, C 1-6 alkanoyloxy, TV-(C 1 -6 alkyi)amino, 7V,7V-(C 1-6 alkyl) 2 amino, Q- ⁇ alkanoylamino, JV-(C 1-6 alkyl)carbamoyl, ⁇ iV-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, 7V-(C 1-6 alkyl)sulphamoyl, JV,JV-(Ci.
  • R 20 and R 22 independently of each other may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 24 ;
  • R 25 , R 26 , R 27 and R 28 are independently selected from a direct bond, -O-, -N(R 29 )-, -C(O)-, -N(R 30 )C(O)-, -C(O)N(R 31 )-, -S(O) 8 -, -SO 2 N(R 32 )- or -N(R 33 )SO 2 -; wherein R 29 , R 30 , R 31 , R 32 and R 33 are independently selected from hydrogen or C 1-6 alkyl and s is 0-2;
  • R 23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, ⁇ iV-dimethylcarbamoyl, N,JV-diethylcarbamoyl, N-methyl-7V-ethylcarbamoyL methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsul
  • R 24 is selected from Ci -6 alkyl, Ci -6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, iV-(Ci -6 alkyl)carbamoyl, N,N-(C ⁇ ⁇ alky ⁇ )carbwaoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof.
  • R 1 and R 2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, iV-(C 1-6 alkyl)amino, iV, ⁇ /-(C 1-6 alkyl) 2 amino, Q-galkanoylamino, 7V-(C 1-6 alkyl)carbamoyl, ⁇ N-(C 1-6 alkyl) 2 carbamoyl, Ci.
  • R 3 is hydrogen or optionally substituted C 1-6 alkyl; wherein said optional substiruents are selected from one or more R 1 ! ;
  • R 4 and R 34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Q ⁇ a-kyl, C 2-6 alkenyl, C 2 - 6 alkynyl, Q.ealkoxy, Q ⁇ alkanoyl, Ci -6 alkanoyloxy, N-(Ci -6 alkyl)ammo, N,N-(C 1-6 alkyl) 2 amino, Q ⁇ alkanoylamino, iV-(C 1-6 alkyl)carbarnoyl, iV,N-(C 1-6 alkyl) 2 carbamoyl 5 C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, iV,N-(C 1-6 alkyl) 2 sulphamoyl, C- ⁇ alkylsulphonyla ⁇ i
  • A is a direct bond or C 1-2 alkylene; wherein said C 1-2 alkylene may be optionally substituted by one or more R 14 ;
  • Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 15 ;
  • R 5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, Ci -6 alkanoyloxy, iV-(C 1-6 alkyl)amino, N,AT-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, iV-(C 1-6 alkyl)carbamoyl, ⁇ iV-(Ci -6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, iV-(C 1-6 alkyl)sulpharnoyl,
  • R 5 may be optionally substituted on carbon by one or more R 16 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ; n is 0, 1, 2 or 3; wherein the values of R 5 may be the same or different;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 alkoxy, Ci -6 alkanoyL Ci -6 alkanoyloxy, iV-(C 1-6 alkyl)amino, i ⁇ N-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, 7V-(C 1-6 alkyl)carbamoyl, iV,iV-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, Q.ealkoxycarbonyl, C i , 6 alkylsulphonylamino, carbocyclyl-R 25 - or heterocycly
  • R 6 , R 11 , R 12 , R 14 , R 16 and R 18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 alkoxy, C 1-6 alkanoyl, d- ⁇ alkanoyloxy, iV-(C 1-6 alkyl)amino, ⁇ N-(C 1-6 alkyl) 2 amino, C 1 .
  • R 7 , R 13 , R 15 , R 17 , R 19 and R 21 are independently selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, 7V-(C 1-6 alkyl)carbamoyl, ⁇ iV-(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein
  • R , R , R , R , R and R independently of each other may be optionally substituted on carbon by on or more R 22 ;
  • R 20 and R 22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, Ci -6 alkanoyl, C 1-6 alkanoyloxy, iV-(C 1-6 alkyl)amino, iV,N-(C 1-6 aUcyl) 2 amino, C 1-6 alkanoylamino, JV-(C 1-6 alkyl)carbamoyl, ⁇ iV-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, JV-(C 1-6 alkyl)sulphamoyl, ⁇ N-(Ci -6 alkyl) 2 s
  • R 25 , R 26 , R 27 and R 28 are independently selected from a direct bond, -O-, -N(R 29 )-, -C(O)-, -N(R 30 )C(O)-, -C(O)N(R 31 )-, -S(O) 8 -, -SO 2 N(R 32 )- or -N(R 33 )SO 2 -; wherein R 29 , R 30 , R 31 , R 32 and R 33 are independently selected from hydrogen or C 1-6 alkyl and s is 0-2; R 23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, dieth
  • R 1 and R 2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, ⁇ N-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1 -6 alkyl)carbamoyl,
  • R 3 is hydrogen or optionally substituted C 1-6 alkyl; wherein said optional substituents are selected from one or more R 11 ;
  • R 4 and R 34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2 .
  • A is a direct bond or C 1-2 alkylene; wherein said C 1-2 alkylene may be optionally substituted by one or more R 14 ;
  • Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 15 ;
  • R 5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, Ci- ⁇ alkanoyl, Ci -6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, N,N-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, d ⁇ alkoxycarbon
  • R 5 may be optionally substituted on carbon by one or more R 16 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ; n is 0, 1, 2 or 3; wherein the values of R 5 may be the same or different;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(C 1-6 alkyl)sulphamoyl, NN-(C 1-6 alkyl) 2 Sulphamoyl, Q-e
  • R 6 , R 11 , R 12 , R 14 , R 16 and R 18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2 .
  • R 7 , R 13 , R 15 , R 17 , R 19 and R 21 are independently selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, N-(C 1-6 alkyl)carbamoyl, NN-(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R 7 , R 13 , R 15 , R 17 , R 19 and R 21 independently of each other may be optionally substituted on carbon by on or more R 22 ;
  • R 20 and R 22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, Q-ealkanoyloxy, iV-(C 1-6 alkyl)amino, N ) N-(C 1 .
  • R 23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-iV-ethylammo, acetylamino, iV-methylcarbamoyl, JV-ethylcarbamoyl, iV,JV-dimethylcarbamoyl,
  • R 24 is selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, iV-(C 1-6 alkyl)carbamoyl, ⁇ iV-(C 1-6
  • R 1 is C 1-6 alkoxy or carbocyclyl.
  • R 1 is C ⁇ alkyl, C 1-6 alkoxy and cyclopropyl.
  • R 1 is isopropoxy or cyclopropyl.
  • R 1 is C 1-6 alkoxy.
  • R 1 is cyclopropyl
  • R 1 is isopropoxy.
  • R 1 is methyl, t-butyl, isopropoxy or cyclopropyl.
  • R 2 is hydrogen
  • R 1 and R 2 are independently selected from hydrogen, C 1-6 alkoxy and carbocyclyl.
  • R 1 and R 2 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy and carbocyclyl.
  • R 1 and R 2 are independently selected from hydrogen, C 1-6 alkoxy and cyclopropyl.
  • R 1 and R 2 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy and cyclopropyl.
  • R 1 and R 2 are independently selected from hydrogen, isopropoxy and cyclopropyl.
  • R and R are independently selected from hydrogen, methyl, t-butyl, isopropoxy and cyclopropyl.
  • R 1 is C 1-6 alkoxy or carbocyclyl and R 2 is hydrogen.
  • R 1 is C 1-6 alkyl, C 1-6 alkoxy or carbocyclyl and R 2 is hydrogen.
  • R 1 is C ⁇ alkoxy and cyclopropyl and R 2 is hydrogen.
  • R 1 is C 1-6 alkyl, C 1-6 alkoxy and cyclopropyl and R 2 is hydrogen.
  • R 1 is C 1-6 alkoxy and R 2 is hydrogen.
  • R 1 is isopropoxy and R 2 is hydrogen.
  • R 1 is cyclopropyl and R 2 is hydrogen.
  • R 1 is isopropoxy or cyclopropyl and R 2 is hydrogen.
  • R 1 is methyl, t-butyl, isopropoxy or cyclopropyl and R 2 is hydrogen.
  • R 3 is hydrogen
  • R 3 is optionally substituted C 1-6 alkyl; wherein said optional substituents are selected from one or more R 11 .
  • R 4 is not hydrogen.
  • R 4 is selected from hydrogen or C 1-6 alkyl; wherein R may be optionally substituted on carbon by one or more R 12 ; wherein R 12 is selected from hydroxy.
  • R 4 is selected from hydrogen or C 1-6 alkyl; wherein R 4 may be optionally substituted on carbon by one or more R 12 ; wherein R 12 is selected from hydroxy and R 34 is hydrogen.
  • R 4 and R 34 are independently selected from hydrogen or C 1-6 alkyl; wherein R 4 and R 34 may be independently optionally substituted on carbon by one or more R 12 ; wherein R 12 is selected from hydroxy.
  • R 4 is selected from hydrogen or methyl; wherein R 4 may be optionally substituted on carbon by one or more R 12 ; wherein R 12 is selected from hydroxy.
  • R 4 is selected from hydrogen or methyl; wherein R 4 may be optionally substituted on carbon by one or more R 12 ; wherein R 12 is selected from hydroxy and R 34 is hydrogen.
  • R 4 and R 34 are independently selected from hydrogen or methyl; wherein R 4 and R 34 may be independently optionally substituted on carbon by one or more R 12 ; wherein R 12 is selected from hydroxy.
  • R 4 is selected from hydrogen, methyl or hydroxymethyl.
  • R 4 is selected from hydrogen, methyl or hydroxymethyl and R 34 is hydrogen.
  • R 4 and R 34 are independently selected from hydrogen, methyl or hydroxymethyl.
  • R 34 is selected from hydrogen.
  • R 34 is selected from hydrogen or hydroxymethyl.
  • R 4 is selected from methyl or hydroxymethyl.
  • R 4 is selected from methyl or hydroxymethyl and R 34 is hydrogen.
  • R 4 is selected from methyl and R 34 is hydrogen.
  • R is selected from hydroxymethyl and R 34 is hydrogen.
  • A is a direct bond.
  • A is C 1-2 alkylene; wherein said C 1-2 alkylene may be optionally substituted by one or more R 14 .
  • Ring C is carbocyclyl
  • Ring C is or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 15 ;
  • Ring C is carbocyclyl or heterocyclyl.
  • Ring C is phenyl, pyridyl or pyrimidinyl.
  • Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrirnidin-2-yl. Ring C is phenyl.
  • Ring C is pyridyl
  • Ring C is pyrid-2-yl.
  • R 5 is selected from halo, C 1-6 alkanoylamino, C 1-6 alkylsulphonylamino or carbocyclyl-R 37 -; wherein
  • R 37 is -C(O)N(R 31 )-; wherein R 31 is hydrogen.
  • R 5 is halo
  • R 5 is selected from fluoro, acetylamino, mesylamino or cyclopropyl-R 37 -; wherein R 37 is -C(O)N(R 31 )-; wherein R 31 is hydrogen. R 5 is fluoro.
  • R 5 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino.
  • n is O.
  • n is 1.
  • n is 1 or 2; wherein the values of R 5 may be the same or different.
  • n is 2; wherein the values of R 5 may be the same or different.
  • n is 3; wherein the values of R 5 may be the same or different.
  • Ring C and (R 5 ) n together form 4-fluorophenyl, 5-fluoropyrid-2-yl, 3,5-difluoropyrid-2-yl, 5-fluoropyrimidin-2-yl, 4-fluoro-3-mesylaminophenyl,
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, Ci. 6 aU.cyl, C 1-6 alkanoyl, iV-(C 1-6 alkyl)amino or carbocyclyl-R 25 -; wherein R 8 , R 9 and R 10 independently of each other may be optionally substituted on carbon by one or more R 18 ;
  • R 18 is selected from hydroxy, amino, iV-(Ci. 6 alkyl)amino, C 1-6 alkanoylamino, C 1-6 alkylsulphonylamino, carbocyclyl-R 27 - or heterocyclyl-R 28 -; wherein R 18 may be optionally substituted on carbon by one or more R 20 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 21 ; R 20 is selected from halo, amino, C 1-6 alkyl, N,iV-(C 1-6 alkyl) 2 amino, Ci-ealkylsulphonyl-N- ⁇ i-ealky ⁇ amino, carbocyclyl-R 35 - or heterocyclyl-R 36 -; wherein R 20 may be optionally substituted on carbon by one or more R 23 ;
  • R 21 is selected from C 1-6 alkylsulphonyl; R is dimethylamino or phenyl; and
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and C 1-6 alkyl; wherein R 8 , R 9 and R 10 independently of each other may be optionally substituted on carbon by one or more R ; wherein
  • R 18 is selected from amino, C 1-6 alkanoylamino, C 1-6 alkylsulphonylamino or heterocyclyl-R -; wherein R may be optionally substituted on carbon by one or more R ;
  • R is amino; and R 28 is -C(O)N(R 31 )-; wherein R 31 is hydrogen.
  • R , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, methyl, isopropyl, formyl, methylamino, isopropylamino or cyclopropyl-R -; wherein R , R and R independently of each other may be optionally substituted on carbon by one or more R ; R 1 is selected from hydroxy, amino, methylamino, acetylamino, propionylamino,
  • R 20 is selected from fluoro, amino, methyl, dimethylamino,
  • R 20 may be optionally substituted on carbon by one or more R 23 ;
  • R 21 is selected from mesyl
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, methyl, isopropyl, formyl, methylamino, isopropylamino or cyclopropyl-R 25 -; wherein R 8 , R 9 and R 10 independently of each other may be optionally substituted on carbon by one or more R ;
  • R is selected from hydroxy, amino, methylamino, acetylamino, propionylamino, 3-methylbutanoylamino, mesylamino, cyclopropyl-R 27 -, phenyl-R 27 -, tetrahydrofuran-2-yl-R 28 -, furan-2-yl-R 28 -, pyrrol-2-yl-R 28 -, isoxaxol-5-yl-R 28 -, isoxaxol-4-yl-R 28 -, piperidin-4-yl-R 28 -, thien-2-yl-R 28 -, pyrid-3-yl-R 28 -, pyrid-4-yl-R 28 -, tetrahydro-2H-thiopyran-4-yl-R 28 -, rnorpholino-R 28 - or 2-oxopyrrolidin-5-yl-R 28 -
  • R 20 is selected from fluoro, amino, methyl, dimethylamino, ⁇ f-(isopropyl)-N-(mesyl)amino, N-(ethyl)-N-(mesyl)amino, phenyl-R 35 -, thien-2-yl-R 36 -, thien-3-yl-R 36 -, pyrid-3-yl-R 36 - or morpholino-R 36 -; wherein R 20 may be optionally substituted on carbon by one or more R ; R 21 is selected from mesyl;
  • R 23 is dimethylamino or phenyl
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl and methyl; wherein R 8 , R 9 and R 10 independently of each other may be optionally substituted on carbon by one or more R 18 ; wherein
  • R 18 is selected from amino, acetylamino, mesylamino or 2-oxopyrrolidin-5-yl-R 28 -; wherein R 18 may be optionally substituted on carbon by one or more R 20 ; R 20 is amino; and
  • R 28 is -C(O)N(R 31 )-; wherein R 31 is hydrogen.
  • R , R and R 10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl,
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl,
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminometliyl.
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro and cyano.
  • R 1 and R 2 are independently selected from hydrogen, C 1-6 alkoxy and carbocyclyl
  • R 3 is hydrogen
  • R 4 is selected from hydrogen or C 1-6 alkyl; wherein R 4 may be optionally substituted on carbon by one or more R 12 ;
  • R 34 is hydrogen; A is a direct bond;
  • Ring C is carbocyclyl
  • R 5 is halo; n is 1;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and C 1-6 alkyl; wherein R 8 , R 9 and R 10 independently of each other may be optionally substituted on carbon by one or more R 18 ;
  • R 12 is selected from hydroxy;
  • R 18 is selected from amino, C 1-6 alkanoylamino, C 1-6 alkylsulphonylamino or heterocyclyl-R 28 -; wherein R 18 may be optionally substituted on carbon by one or more R 20 ;
  • R 20 is amino
  • R 28 is -C(O)N(R 31 )-; wherein R 31 is hydrogen; or a pharmaceutically acceptable salt thereof.
  • R 3 is hydrogen
  • R 4 and R 34 are independently selected from hydrogen or C 1-6 alkyl; wherein R 4 and R 34 may be independently optionally substituted on carbon by one or more R 12 ; A is a direct bond;
  • Ring C is carbocyclyl
  • R 5 is halo; n is 1;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and C 1-6 alkyl; wherein R 8 , R 9 and R 10 independently of each other may be optionally substituted on carbon by one or more R 18 ;
  • R 12 is selected from hydroxy
  • R 18 is selected from amino, C 1-6 aUcanoylamino, C 1-6 alkylsulphonylamino or heterocyclyl-R 28 -; wherein R 18 may be optionally substituted on carbon by one or more R 20 ; R 20 is amino; and
  • R 28 is -C(O)N(R 31 )-; wherein R 31 is hydrogen; or a pharmaceutically acceptable salt thereof.
  • R 1 is C 1-6 alkyl, C 1-6 alkoxy or carbocyclyl
  • R 2 is hydrogen
  • R 4 and R 34 are independently selected from hydrogen or C 1-6 alkyl; wherein R 4 and R 34 may be independently optionally substituted on carbon by one or more R 12 ; wherein R 12 is selected from hydroxy; A is a direct bond;
  • Ring C is carbocyclyl
  • R 5 is halo; n is 1;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C 1-6 alkyl, C 1-6 alkanoyl, JV-(C 1-6 all ⁇ yl)amino or carbocyclyl-R 25 -; wherein R 8 , R 9 and R 10 independently of each other may be optionally substituted on carbon by one or more R 18 ;
  • R 18 is selected from hydroxy, amino, N-(C 1-6 alkyl)amino, C 1-6 alkanoylamino,
  • R 20 is selected from halo, amino, Ci. 6 alkyl, N,iV-(C 1-6 alkyl) 2 amino,
  • R 20 may be optionally substituted on carbon by one or more R ;
  • R 21 is selected from C 1-6 alkylsulphonyl;
  • R 23 is dimethylamino or phenyl
  • R 1 is C 1-6 alkyl, C 1-6 alkoxy or carbocyclyl;
  • R 2 is hydrogen;
  • R 3 is hydrogen; R 4 and R 34 are independently selected from hydrogen or C 1-6 alkyl; wherein R 4 and R 34 may be independently optionally substituted on carbon by one or more R 12 ; wherein R 12 is selected from hydroxy;
  • Ring C is carbocyclyl or heterocyclyl
  • R 5 is selected from fluoro, acetylamino, mesylamino or cyclopropyl-R 37 -; wherein R 37 is -C(O)N(R 31 )-; wherein R 31 is hydrogen; n is 1 or 2; wherein the values of R 5 may be the same or different;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C 1-6 alkyl, C 1-6 alkanoyl, iV-(C 1-6 alkyl)amino or carbocyclyl-R 25 -; wherein R 8 , R 9 and R 10 independently of each other may be optionally substituted on carbon by one or more R 18 ;
  • R 18 is selected from hydroxy, amino, N-(C 1-6 alkyl)amino, Ci -6 alkanoylamino, C 1-6 alkylsulphonylamino, carbocyclyl-R - or heterocyclyl-R -; wherein R may be optionally substituted on carbon by one or more R 20 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 21 ;
  • R 20 is selected from halo, amino, C 1-6 alkyl, ⁇ N-(C 1-6 alkyl) 2 amino, C 1-6 alkylsulphonyl-N-(C 1-6 alkyl)amino, carbocyclyl-R 35 - or heterocyclyl-R 36 -; wherein R 20 may be optionally substituted on carbon by one or more R 23 ; R 21 is selected from C 1-6 alkylsulphonyl;
  • R 23 is dimethylamino or phenyl
  • R 1 is isopropoxy or cyclopropyl
  • R 3 is hydrogen
  • R 4 is selected from hydrogen, methyl or hydroxymethyl;
  • R 34 is hydrogen;
  • A is a direct bond
  • Ring C is phenyl
  • R 5 is fluoro; n is 1;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl; or a pharmaceutically acceptable salt thereof. Therefore in a further aspect of the invention there is provided a compound of formula
  • R 1 is methyl, ⁇ -butyl, isopropoxy or cyclopropyl
  • R 2 is hydrogen
  • R 3 is hydrogen
  • R 4 is selected from hydrogen, methyl or hydroxymethyl
  • R 34 is selected from hydrogen or hydroxymethyl
  • Ring C is phenyl
  • R 5 is fluoro; n is 1;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl; or a pharmaceutically acceptable salt thereof.
  • R 1 is methyl, t-butyl, isopropoxy or cyclopropyl;
  • R 2 is hydrogen;
  • R 3 is hydrogen; R 4 and R 34 are independently selected from hydrogen, methyl or hydroxymethyl;
  • A is a direct bond
  • Ring C is phenyl
  • R 5 is fluoro; n is 1 ;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl, (R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, (S)-2-oxopyrrolidin-5-yl-carbonylammomethyl,
  • R 1 is methyl, £-butyl, isopropoxy or cyclopropyl
  • R 3 is hydrogen
  • R 4 and R 34 are independently selected from hydrogen, methyl or hydroxymethyl; A is a direct bond;
  • Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl;
  • R 5 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino; n is 1 or 2; wherein the values of R 5 may be the same or different;
  • R 8 , R 9 and R 10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl, (R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, (S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
  • preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof. In another aspect of the invention, preferred compounds of the invention are any one of Examples 1, 6, 11, 16, 64, 110, 112, 113, 119 and 120 or a pharmaceutically acceptable salt thereof.
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
  • the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of cancer in a warm-blooded animal such as man.
  • the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.
  • cancers solid tumors and leukemia
  • fibroproliferative and differentiative disorders include fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial reste
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the production of an anti-proliferative effect.
  • the present invention provides a method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment of cancer comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • cancers solid tumors and leukemia
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation,
  • the present invention provides a method of producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trie activity.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment of cancer.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
  • cancers solid tumors and leukemia
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis,
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the inhibition of Trk activity. In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer.
  • the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm-blooded animal such as man.
  • the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancers (solid tumours and leukaemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.
  • cancers solid tumours and leukaemia
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the production of an antiproliferative effect.
  • Trk activity In one embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk A activity.
  • Trk activity In another embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk B activity.
  • the treatment (or prophylaxis) of cancer is referred to, particularly it refers to the treatment (or prophylaxis) of mesoblastic nephroma, mesothelioma, acute myeloblasts leukemia, acute lymphocytic leukemia, multiple myeloma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma thyroid cancer including papillary thyroid cancer, mesothelioma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibro
  • L is a displaceable group, suitable values for L are for example, a halo or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.
  • Pg is a nitrogen protecting group. Suitable values for Pg are described herein below.
  • Process c) The s reaction may be carried out in a suitable solvent, for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120°C, in particular in the range from 70-100 0 C.
  • a suitable solvent for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120°C, in particular in the range from 70-100 0 C.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a base such as sodium hydroxide
  • a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art. Definitions
  • alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight chain version only.
  • C 1-6 alkyl and “C h alky! include methyl, ethyl, propyl, isopropyl and t-butyl.
  • references to individual alkyl groups such as 'propyl' are specific for the straight-chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only.
  • a similar convention applies to other radicals.
  • halo refers to fluoro, chloro, bromo and iodo. Where optional substituents are chosen from “one or more” groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
  • a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • heterocyclyl examples and suitable values of the term "heterocyclyl” are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, iV-methylpyrrolyl, 4-pyridone, 1-isoquinolone,
  • heterocyclyl is morpholino, piperazinyl and pyrrolidinyl.
  • a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH 2 - group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • heterocyclyl tetrahydrofuranyl, furanyl, pyrrolyl, isoxaxolyl, piperidinyl, thienyl, pyridyl, tetrahydro-2/J-thiopyranyl, morpholino and 2-oxopyrrolidinyl.
  • a "carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH 2 - group can optionally be replaced by a -C(O)-.
  • Carbocyclyl is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for “carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
  • C m-n or "C m-n group” used alone or as a prefix, refers to any group having m to n carbon atoms.
  • Ci -6 alkanoyloxy is acetoxy.
  • Q-ealkoxycarbonyl include C 1-4 alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
  • C 1-6 alkoxy include C 1-4 alkoxy, C 1-3 alkoxy, methoxy, ethoxy and propoxy.
  • C 1-6 alkoxyimino include C 1-4 alkoxyimino, Ci -3 alkoxyimino, methoxyimino, ethoxyimino and propoxy imino.
  • C 1-6 alkanoylamino examples include formamido, acetamido and propionylamino.
  • Examples of "C 1-6 alkylS(O) a wherein a is 0 to 2” include Ci -4 alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • Examples of “C 1-6 alkylthio” include methylthio and ethylthio.
  • Examples of “C 1-6 alkylsulphonylamino” examples include methylsulphonylamino and ethylsulphsulphonylamino.
  • C 1-6 alkanoyl examples include C 1-4 alkanoyl, formyl, propionyl and acetyl.
  • Examples of "iV-(Ci -6 alkyl)amino” include methylamino and ethylamino.
  • Examples of 'W,N-(C 1 - 6 alkyl) 2 amino include di-iV-methylamino, di-(iV-ethyl)amino and N-ethyl-N-methylamino.
  • Examples of “C 2-6 alkenyl” are vinyl, allyl and 1-propenyl.
  • Examples of “C 2-6 alkynyl” are ethynyl, 1-propynyl and 2-propynyl.
  • Examples of "7V-(C 1-6 alkyl)sulphamoyl” are iV-(methyl)sulphamoyl and iV-(ethyl)sulphamoyl.
  • Examples of "iV-(C 1-6 alkyl) 2 sulphamoyl” are i ⁇ N-(dimethyl)sulphamoyl and iV-(methyl)-N-(ethyl)sulphamoyl.
  • Examples of "iV-(C 1-6 alkyl)carbamoyl” are N-(Ci -4 alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of
  • N-(C 1-6 alkyl) 2 carbamoyl areN,N-(C 1-4 alkyl) 2 carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl.
  • Examples of "Ci_ 6 alkylsulphonyl-iV : -(C 1 - 6 alkyl)amino” include iV-mesyl-N-methylamino and iV-mesyl-TV-isopropylamino.
  • RT or "rt” means room temperature.
  • a suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation
  • a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxye
  • the pyrazoles claimed in this invention are capable to exist in different resonance structures and thus the pyrazoles claimed herein include all possible resonance structures, for example optical isomers, diastereoisomers and geometric isomers and all tautomeric forms of the compounds of the formula (I).
  • Formulations Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
  • the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
  • An effective amount of a compound of the present invention for use in therapy of cancer is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of cancer, to slow the progression of cancer, or to reduce in patients with symptoms of cancer the risk of getting worse.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substance, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
  • Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this invention.
  • acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, meglumine, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulf
  • Base salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as aluminum, calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, ornithine, and so forth.
  • basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl halides like benzyl bromide and others.
  • Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.
  • the salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.
  • a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
  • composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier.
  • this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
  • Liquid form compositions include solutions, suspensions, and emulsions.
  • Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
  • Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical compositions can be in unit dosage form.
  • the composition is divided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • anti-cancer treatment may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy.
  • chemotherapy may include one or more of the following categories of anti-tumour agents:
  • antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and
  • cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, fmtamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 ⁇ -reductase such as finasteride;
  • antioestrogens for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene
  • agents which inhibit cancer cell invasion for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function;
  • inhibitors of growth factor function include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbb2 antibody trastuzumab [HerceptinTM] and the anti-erbbl antibody cetuximab [C225]) , farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD 1839), N-(3 -ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and
  • 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;
  • antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [AvastinTM], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin ⁇ v ⁇ 3 function and angiostatin);
  • vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;
  • antisense therapies for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
  • gene therapy approaches including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
  • GDEPT gene-directed enzyme pro-drug therapy
  • immunotherapy approaches including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
  • cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor
  • (x) other treatment regimes including: dexamethasone, proteasome inhibitors (including bortezomib), isotretinoin (13-cis retinoic acid), thalidomide, revemid, Rituxamab, ALIMTA, Cephalon's kinase inhibitors CEP-701 and CEP-2563, anti-Trk or anti-NGF monoclonal antibodies, targeted radiation therapy with 1311-metaiodobenzylguanidine (131I-MIBG), anti- G(D2) monoclonal antibody therapy with or without granulocyte-macrophage colony- stimulating factor (GM-CSF) following chemotherapy.
  • dexamethasone proteasome inhibitors (including bortezomib), isotretinoin (13-cis retinoic acid), thalidomide, revemid, Rituxamab, ALIMTA, Cephalon's kinase inhibitors CEP-701 and CEP-2563
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the compounds of this invention, or pharmaceutically acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
  • the compounds, or pharmaceutically acceptable salts thereof, of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
  • the compounds, or pharmaceutically acceptable salts thereof, of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Such methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.
  • novel compounds, or pharmaceutically acceptable salts thereof, of this invention may be prepared using the reactions and techniques described herein.
  • the reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected.
  • all proposed reaction conditions including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art.
  • the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed.
  • Such restrictions to the substituents, which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used. Examples
  • chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; (iv) in general, the course of reactions was followed by TLC or liquid chromatography/mass spectroscopy (LC/MS) and reaction times are given for illustration only;
  • NMR data when given, NMR data is in the form of delta values for major diagnostic protons, given in part per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz in DMSO-d 6 unless otherwise stated;
  • TMS tetramethylsilane
  • chemical symbols have their usual meanings;
  • solvent ratio was given in volume: volume (v/v) terms,
  • the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH 3 CN in H 2 O over 400 ml) to give the title compound (0.045g, 50%).
  • the resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml), and a saturated aqueous solution OfNa 2 CO 3 (100 ml) was added. The mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layer was dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH 3 CN in H 2 O over 400 ml) to give the title compound (0.074, 57%).
  • the resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml) and treated with a saturated aqueous Na 2 CO 3 solution (100 ml). The resulting mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH 3 CN in H 2 O over 400 ml) to give the title compound (0.4Og, 66%).
  • the resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml) and treated with a saturated aqueous Na 2 CO 3 solution (100 ml). The mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by reverse- phase column chromatography (5-50% CH 3 CN in H 2 O over 400 ml) to give the title compound (0.7g, 77%).
  • Example 19 dSl-N-((5-Fluoro-2-(l-( ' 4-fluoro ⁇ henyl)ethylammoV6-(5-isopropoxy-l/f-pyrazol-3- ylammo)pyridin-3-vDmethyr)acetamide (5)-3-(Aminomethyl)-5-fluoro-N 2 -(l-(4-fluoro ⁇ henyl)ethyl)- ⁇ / 6 -(5-iso ⁇ ropoxy-lH- pyrazol-3-yl)pyridine-2,6-diamine (Example 18; 0.2Og, 0.49 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.49 mmol) were placed in a THF - DCM solution (1 : 1, 6 ml) at 0 °C.
  • Example 27 Following a similar procedure to Example 26, the following compounds were synthesized from a chloronitropyridine by reacting it with an amine.
  • Example 31 Following a similar procedure to Example 31, the following compounds were synthesized from a nitropyridine by reacting it with zinc dust.
  • Example 37-40 Following a similar procedure to Example 36, the following compounds were synthesized from a chloronitropyridine by reacting it with an amine.
  • Example 41 Following a similar procedure to Example 41, the following compounds were synthesized from a nitropyridine by reacting it with zinc dust.
  • Example 52-54 Following a similar procedure to Example 51 , the following compounds were synthesized from the appropriate starting material and amine.
  • Example 70 (>S r )-3-Chloro-A ⁇ -ri-r4-fluorophenvnethylVN 2 -r5-isopropoxy-lH " -pyrazol-3-ylV5- nitropyridine-2,6-diamine
  • Example 3 The following compounds were prepared by the procedure similar to that of Example 79 using (5)-3 -(aminomethyl)-iV 6 -(5-cyclopropyl- lH-pyrazol-3 -yl)-5-fluoro-N 2 -(l -(4- fluorophenyl)ethyl)pyridme-2,6-diamine (Example 3) and a TFP resin loaded reagent.
  • Example 112 (6 ⁇ -6-( ' 5-Cvclopropyl-l/i-p ⁇ razol-3-ylaminoV5-fluoro-2-(l-f4-fluorophenyl)ethylaminoV4- (isopropylamino)nicotinonitrile
  • Example 122 iV-IS-rd ⁇ -l-dS-Cvano- ⁇ -ffS-cvclopropyl-lH-pyrazol-S-vDaminoi-S-fluoropyridin ⁇ - yl) amino)ethyl]-2-fluorophenyl ⁇ methanesulfonamide and Example 123 iV- ⁇ 5-[(l ⁇ S f )-l-( ⁇ 3-Cyano-6-[(5-cyclopropyl-lH ' -pyrazol-3-yl)ammol-5-iluoropyridin-2- yl ⁇ ammo)ethyl1-2-fluorophenvUmethanesulfonamide
  • the resulting mixture was then purified by silica gel chromatography using 5% MeO ⁇ /DCM.
  • the racemic product obtained was then chirally purified by ⁇ PLC on Chiralcel OJ column (500 x 50mm, 20 microns) using 50:25:25:0.1% of hexane/MeO ⁇ /EtO ⁇ /diethylamine at 118 ml/min.
  • reaction was concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 25-35% EtOAc (20% v/v MeOH) in hexanes to give 180 mg (36% isolated yield) of the title compound.
  • reaction was concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 25-35% EtOAc (20% v/v MeOH) in hexanes to give 267 mg (35% isolated yield) of the title compound.
  • Example 127 ⁇ -rCS-Cvclopropyl-lH-pyrazol-S-vDaminol-S-fluoro ⁇ -irdiS ⁇ -l-f ⁇ -fluoropyridm-S- vDethyliaminolnicotmonitrile and Example 128 ⁇ -IYS-Cyclopropyl- lH-pyrazol-3-vDaminol-5-fluoro-2- ⁇ ⁇ (1R)- 1-f 6-fluoropyridin-3- yl) ethyl] amino ⁇ nicotinonitrile
  • reaction was then concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 1-4% MeOH in DCM to give 380 mg (25% isolated yield) of 6-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-5-fluoro-2- ⁇ [l-(6-fluoropyridin-3-yl)ethyl]amino ⁇ nicotinonitrile.
  • the racemic product obtained was then chirally purified by HPLC on Chiralpak AS column (500 x 50mm, 20 microns) using
  • Example 131 iV-IS-rfl ⁇ -l-flS-Cvano-S-fluoro- ⁇ -rrS-methyl-lH-pyrazol-S-vDaminoipyridin ⁇ - yl I amino)ethyl1 -2-fluorophenyl
  • a solution of 2,5,6-trifluoronicotinonitrile (30.0 g, 189.8 mmol) in ACN (240 ml) was prepared in a 11 3 -neck flask at room temperature and then cooled to -5 0 C using an ice-salt bath.
  • An addition funnel containing triethylamine (29.1 ml, 208.8 mmol) and a second addition funnel containing a solution of S-cyclopropyl-lH-pyrazol- ⁇ -amine (25.7 g, 208.8 mmol) in ACN (160 ml) were placed on top of the reaction flask. A total of 5 ml of triethylamine was added quickly dropwise to the reaction.
  • the reaction was allowed to stir for 5 min, followed by the simultaneous dropwise addition of the remaining triethylamine and 5- cyclopropyl-lH-pyrazol-3-amine solution at a rate slow enough to keep the internal temperature at or below 5 0 C.
  • the reaction was allowed to stir for 1 hour at 0 0 C, at which point no starting material remained, and the reaction was filtered through a fritted funnel.
  • the remaining solids were washed with 0 0 C ACN (3 x 100 ml). The solid product was then dried under vacuum for 30 minutes to give the title compound (25.2 g, 51 %) which was used without further purification.
  • Method 35 r ⁇ -A/ " -ri-C5-Fluoropyridin-2-vDethvDacetamide iV-(l-(5-fluoro ⁇ yridin-2-yl)vinyl)acetamide (Method 36, 11.0 g, 61.1 mmol) in MeOH (120 ml) under N 2 was added (+)-l,2-bis((2S, 5S)-2,5-diethylphospholano)benzene (cyclooctadiene)rhodium(I)trifluoromethanesulfonate (0.441 g, 0.611 mmol). The solution was transferred to a high pressure bomb and charged 150 psi H 2 .
  • 6-Fluoro-iV-methoxy-N-methvmicotmamide To a solution of 6-fluoronicotinic acid (10 g, 70.9 mmol) in DCM (200 ml), was added
  • N,O-Dimethylhydroxylamine hydrochloride (7.3 g, 74.8 mmol), N-(3-Dimethylaminopropyl)- JV'-ethylcarbodiimide hydrochloride (15 g, 78.5 mmol), and triethylamine (22 ml, 156 mmol).
  • the reaction mixture was allowed to stir at room temperature for 16 hours.
  • the reaction was partitioned with water, layers were cut, and organic layer was dried over Na 2 SO 4 , filtered, and concentrated in vacuo.
  • the crude residue obtained was purified by a silica gel filtration using EtOAc-DCM (4:1) to give 7.2 g (55% isolated yield) of the title compound.
  • the aqueous filtrate was then extracted with EtOAc (3 x 100 ml), and then concentrated to a 50 ml volume. This aqueous solution was then cooled to 0 0 C and adjusted to pH 1-2 with 6.0 M HCl. The resulting solid was then collected by filtration, washed with cold water, and dried to give the title compound (2.5 g, 18%) that was used without further purification.
  • a 10 ml microwave vial was charged with 2-chloro-5-fluoropyrimidine (2.0 g, 15.09 mmol), Pd 2 (dba) 3 (0.549 g, 0.6 mmol), DPPF (0.67 g, 1.21 mmol), zinc cyanide (1.15 g, 9.81 mmol), and zinc dust (0.237 mg, 3.62 mmol).
  • the flask was evacuated and backfilled with N 2 , and anhydrous dimethylacetamide.
  • the vial was mounted onto a Personal Chemistry microwave reactor and heated at 100 0 C for 10 hours.
  • the reaction mixture was diluted with EtOAc and then washed with brine three times. The organic layer was obtained and evaporated to dryness.
  • Method 61 N-[5-(l-Aminoethyl)-2-fluorophenyl]methanesulfonamide iV- ⁇ 2-Fluoro-5-[(lZ)-iV-hydroxyethanimidoyl]phenyl ⁇ methanesulfonamide (Method 62, 200 mg, 812 ⁇ mol) was dissolved in 15 ml THF, to which was added Raney nickel 2800 slurry in water (200 ⁇ l). The mixture was charged with nitrogen and stirred over 1 arm of hydrogen. After 1 hour, MeOH (4 ml) was added and the reaction mixture was stirred overnight.
  • Methanesulfonylchloride (505 ⁇ l, 6.53 mmol) was added dropwise and the reaction was stirred at 0°C for 5 minutes and warmed to room temperature and stirred for 3 hours.
  • the compounds of the present invention have utility for the treatment of cancer by inhibiting the tyrosine kinases, particularly the Tries and more particularly Trie A and B.
  • Methods of treatment target tyrosine kinase activity, particularly the Trk activity and more particularly Trk A and B activity, which is involved in a variety of cancer related processes.
  • inhibitors of tyrosine kinase particularly the Tries and more particularly Trk A and B
  • are expected to be active against neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, fibrosarcoma and osteosarcoma.
  • Tyrosine kinase inhibitors, particularly the Trk inhibitors and more particularly Trk A and B inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to autoimmune, inflammatory, neurological, and cardiovascular diseases
  • the compounds of the invention are expected to be of value in the treatment or prophylaxis of cancers selected with up regulated of constitutively activated Trk kinases, including but not limited to, oncogenic rearrangements leading to ETV6-TrkC fusions, TRP-TrkA fusions proteins, AML-ETO (t8;21), autocrine or paracrine signalling leading to elevated serum levels of NGF, BDNF, neurotropins or tumours with constitutively active Trk associated with disease aggressiveness, tumour growth and proliferation or survival signalling.
  • constitutively activated Trk kinases including but not limited to, oncogenic rearrangements leading to ETV6-TrkC fusions, TRP-TrkA fusions proteins, AML-ETO (t8;21), autocrine or paracrine signalling leading to elevated serum levels of NGF, BDNF, neurotropins or tumours with constitutively active Trk associated with disease aggressiveness, tumour growth and proliferation or survival signalling.
  • Trk A kinase activity was measured for its ability to phosphorylate synthetic tyrosine residues within a generic polypeptide substrate using an Amplified Luminescent Proximity Assay (Alphascreen) technology (PerkinElmer, 549 Albany Street, Boston, MA).
  • Trk A kinase activity To measure Trk A kinase activity, the intracellular domain of a HIS-tagged human Trk A kinase (amino acids 442-796 of Trk A, Swiss-Prot Primary Accession Number P04629) was expressed in SF9 cells and purified using standard nickel column chromatography. After incubation of the kinase with a biotinylated substrate and adenosine triphosphate (ATP) for 20 minutes at room temperature, the kinase reaction was stopped by the addition of 30 mM ethylenediaminetetraacetic acid (EDTA).
  • EDTA ethylenediaminetetraacetic acid
  • reaction was performed in 384 well microtitre plates and the reaction products were detected with the addition of strepavidin coated Donor Beads and phosphotyrosine-specific antibodies coated Acceptor Beads using the EnVision Multilabel Plate Reader after an overnight incubation at room temperature.
  • Trk inhibitory activity of the following examples was measured at the following ICs 0 S.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Description

PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
Field of the invention
The present invention relates to novel pyrazole derivatives, their pharmaceutical compositions and methods of use. In addition, the present invention relates to therapeutic methods for the treatment and prevention of cancers and to the use of these pyrazole derivatives in the manufacture of medicaments for use in the treatment and prevention of cancers. Background of the invention Receptor tyrosine kinases (RTK' s) are a sub-family of protein kinases that play a critical role in cell signalling and are involved in a variety of cancer related processes including cell proliferation, survival, angiogenesis and metastasis. Currently up to 100 different RTK' s including tropomyosin-related kinases (Trk's) have been identified.
Trk's are the high affinity receptors activated by a group of soluble growth factors called neurotrophins (NT). The Trk receptor family has three members - TrkA, TrkB and TrIcC. Among the NTs there are (i) nerve growth factor (NGF) which activates TrkA, (ii) brain-derived growth factor (BDNF) andNT-4/5 which activate TrkB and (iii) NT3 which activates TrkC. Each Trk receptor contains an extra-cellular domain (ligand binding), a trans-membrane region and an intra-cellular domain (including kinase domain). Upon binding of the ligand, the kinase catalyzes auto-phosphorylation and triggers downstream signal transduction pathways.
Trk's are widely expressed in neuronal tissue during its development where Trk's are critical for the maintenance and survival of these cells. A post-embryonic role for the Trk/neurotrophin axis (or pathway), however, remains in question. There are reports showing that Trk's play important role in both development and function of the nervous system (Patapoutian, A. et al Current Opinion in Neurobiology, 2001, 11, 272-280).
In the past decade, a considerable number of literature documentations linking Trk signalling with cancer have published. For example, while Trk's are expressed at low levels outside the nervous system in the adult, Trk expression is increased in late stage prostate cancers. Both normal prostate tissue and androgen- dependent prostate tumours express low levels of Trk A and undetectable levels of Trk B and C. However, all isoforms of Trk receptors as well as their cognate ligands are up-regulated in late stage, androgen- independent prostate cancer. There is additional evidence that these late stage prostate cancer cells become dependent on the Trk/neurotrophin axis for their survival. Therefore, Trk inhibitors may yield a class of apoptosis-inducing agents specific for androgen- independent prostate cancer (Weeraratna, A. T. et al The Prostate, 2000, 45, 140-148).
Furthermore, very recent literature also shows that over-expression, activation, amplification and/or mutation of Trie's are associated with secretory breast carcinoma {Cancer Cell, 2002, 2, 367-376), colorectal cancer (Bardelli et al Science, 2003, 300, 949-949) and ovarian cancer (Davidson, B. et al Clinical Cancer Research, 2003, 9, 2248-2259).
There are a few reports of selective Trie tyrosine kinase inhibitors. Cephalon described CEP-751, CEP-701 (George, D. et al Cancer Research, 1999, 59, 2395-2341) and other indolocarbazole analogues (WOOl 14380) as Trk inhibitors. It was shown that CEP-701 and/or CEP751, when combined with surgically or chemically induced androgen ablation, offered better efficacy compared with mono-therapy alone. GlaxoSmithKline disclosed certain oxindole compounds as Trk A inhibitors in WO0220479 and WO0220513. Recently, Japan Tobacco reported pyrazolyl condensed cyclic compounds as Trk inhibitors (JP2003231687A).
In addition to the above, Vertex Pharmaceuticals have described pyrazole compounds as inhibitors of GSK3, Aurora, etc. in WO0250065, WO0262789,WO03027111 and WO200437814; and AstraZeneca have reported pyrazole compounds as inhibitors against IGF-I receptor kinase (WO0348133). Summary of the invention
In accordance with the present invention, the applicants have hereby discovered novel pyrazole compounds, or pharmaceutically acceptable salts thereof, which possess Trk kinase inhibitory activity and are accordingly useful for their anti-proliferation and/or proapoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said pyrazole compounds, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferation and/or proapoptotic effect in warm-blooded animals such as man.
Also in accordance with the present invention the applicants provide methods of using such pyrazole compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer.
The properties of the compounds claimed in this invention are expected to be of value in the treatment of disease states associated with cell proliferation such as cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation. Furthermore, the compounds, or pharmaceutically acceptable salts thereof, of the invention are expected to be of value in the treatment or prophylaxis of cancers selected from congenital fibrosarcoma, mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, melanoma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma and leukaemia; particularly ovarian cancer, breast cancer, colorectal cancer, prostate cancer and lung cancer - NSCLC and SCLC; more particularly prostate cancer; and more particularly hormone refractory prostate cancer. Detailed description of the invention
Accordingly, the present invention provides a compound of formula (I):
Figure imgf000004_0001
(I) wherein:
R and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, Cμβalkanoyl, C1-6alkanoyloxy, iV-(C1-6alkyl)amino, N,Λ/'-(C1-6alkyl)2amino, C1-6alkanoylamino, iV-(C1-6alkyl)carbamoyl, iV,iV-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulρhamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R1 and R2 independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R7; one of X1, X2, X3 and X4 is =N-, the other three are independently selected from
=CR8-, =CR9- and =CR10-;
R3 is hydrogen or optionally substituted C1-6alkyl; wherein said optional substituents are selected from one or more R11;
R4 and R34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(Ci-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-SaIlCyIS(O)3 wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1 -6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, Q.ealkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
A is a direct bond or C1-2alkylene; wherein said C1-2alkylene may be optionally substituted by one or more R14; Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15;
R5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C^alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, JV,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl,
N,N-(C1.6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R37- or heterocyclyl-R38-; wherein R5 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; n is 0, 1, 2 or 3; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, iV-(C1-6alkyi)amino, iV,N-(Ci-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyi)carbamoyl, ΛζN-(Ci-6alkyl)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, Ci-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, ΛζN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R25- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from
R19;
R6, R11, R12, R14, R16 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy,
Figure imgf000006_0001
iV,N-(C1-6ah1cyl)2amino, C1-6alkanoylamino, N-(C1-6alkyi)carbamoyl, ΛζN-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6aLkyl)sulphamoyl, iV,iV-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, R11, R12, R14, R16 and R18 independently of each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R7, R13, R15, R17, R19 and R21 are independently selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, iV-(C1-6alkyl)carbamoyl,
ΛζiV-(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R7, R13, R15, R17, R19 and R21 independently of each other may be optionally substituted on carbon by on or more R22;
R20 and R22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Q.ealkyl, C2-6alkenyl, C2-6alkynyl, Q-βalkoxy, Q-βalkanoyl, C1-6alkanoyloxy,
Figure imgf000006_0002
N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, iV-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, Q-ealkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(Ci-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, C1-6alkylsulphonyl-N-(C1-6alkyl)amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 and R22 independently of each other may be optionally substituted on carbon by one or more R23; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24; R25, R26, R27, R28, R35, R36, R37 and R38 are independently selected from a direct bond, -0-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(O)N(R31)-, -S(O)8-, -NH=CH-, -SO2N(R32)- or -N(R33)SO2-; wherein R29, R30, R31, R32 and R33 are independently selected from hydrogen or C1-6alkyl and s is 0-2; R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, JV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, JV,iV-dimethylcarbamoyl, AξiV-diethylcarbamoyl, N-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,
N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, ΛζiV-diethylsulphamoyl, N-methyl-iV-ethylsulphamoyl or phenyl; and
R2 is selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, JV-(C1-6alkyl)carbamoyl, i\f iV-(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof.
According to a further feature of the present invention there is provided a compound of formula (I) which is a compound of formula (Ia):
Figure imgf000007_0001
(Ia) wherein:
R1 and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C!.6alkoxy, C1-6alkanoyl, Ci-6alkanoyloxy, JV-(C1-6alkyi)amino, iV,iV-(C1.6alkyl)2amino, C1-6alkanoylamino, iV-(C1-6alkyl)carbamoyl, iV,iV-(Ci-6aIkyl)2carbamoyl, C1-OaIlCyIS(O)3 wherein a is 0 to 2, C1-6alkoxycarbonyl, JV-(Ci-6alkyl)sulphamoyl, N1N-(Ci -6alkyl)2sulphamoyl, C1-6alkylsulρhonylamino, carbocyclyl or heterocyclyl; wherein R1 and R2 independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R7; one of X1, X2, X3 and X4 is =N-, the other three are independently selected from
=CR8-, =CR9- and =CR10-;
R3 is hydrogen or optionally substituted Ci-6alkyl; wherein said optional substituents are selected from one or more R11;
R4 is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6allcyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, T^iV-(C1 -6alkyl)2amino, C1-6alkanoylamino, iV-(C1-6alkyl)carbamoyl, N, N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, iV-(C1-6alkyl)sulphamoyl,
N,7V-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R4 may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
A is a direct bond or
Figure imgf000008_0001
wherein said C1-2alkylene may be optionally substituted by one or more R14; Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15;
R5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy,
Figure imgf000008_0002
C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, ΛζΛ/-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, JV-(C1-6alkyi)sulphamoyl,
JV,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R5 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; n is 0, 1, 2 or 3; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, Ci-όalkanoyl, C^allcanoyloxy, N-(Ci-6alkyl)arnmo, iV,iV-(Ci-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, C1-OaIlCyIS(O)3 wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(Ci-6alkyl)sulphamoyl, N)iV-(C1.6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R25- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
R6, R11, R12, R14, R16 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C^allcanoyl, C1-6alkanoyloxy, JV-(C1 -6alkyl)amino, iV,iV-(C1-6alkyl)2amino, C1-6alkanoylamino, iV-(C1-6alkyl)carbamoyl, iV,iV-(Ci-6allcyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, iV-(C1-6alkyl)sulphamoyl, iV,iV-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, R11, R12, R14, R16 and R18 independently of each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R7, R13, R15, R17, R19 and R21 are independently selected from Ci-6alkyl, C1-6alkanoyl, C^alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, iV-(C1-6alkyl)carbamoyl,
ΛζiV-(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R , R , R , R , R and R independently of each other may be optionally substituted on carbon by on or more R22;
R20 and R22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, Q^alkanoyl, C1-6alkanoyloxy, TV-(C1 -6alkyi)amino, 7V,7V-(C1-6alkyl)2amino, Q-βalkanoylamino, JV-(C1-6alkyl)carbamoyl, Λζ iV-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, 7V-(C1-6alkyl)sulphamoyl, JV,JV-(Ci.6alkyl)2sulphamoyl, Ci.6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R20 and R22 independently of each other may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24; R25, R26, R27 and R28 are independently selected from a direct bond, -O-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(O)N(R31)-, -S(O)8-, -SO2N(R32)- or -N(R33)SO2-; wherein R29, R30, R31, R32 and R33 are independently selected from hydrogen or C1-6alkyl and s is 0-2;
R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, ΛζiV-dimethylcarbamoyl, N,JV-diethylcarbamoyl, N-methyl-7V-ethylcarbamoyL methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, iV-methylsulphamoyl, JV-ethylsulphamoyl, N, JV-dimethylsulphamoyl, iV,iV-diethylsurphamoyl or JV-methyl-ΛT-ethylsulphamoyl; and
R24 is selected from Ci-6alkyl, Ci-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, iV-(Ci-6alkyl)carbamoyl, N,N-(C\^alkyϊ)carbwaoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof.
Accordingly to a further feature of the present invention there is provided a compound of formula (I) wherein:
R1 and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, iV-(C1-6alkyl)amino, iV,Λ/-(C1-6alkyl)2amino, Q-galkanoylamino, 7V-(C1-6alkyl)carbamoyl, ΛζN-(C1-6alkyl)2carbamoyl, Ci.6alkylS(0)a wherein a is 0 to 2, C1-6alkoxycarbonyl, iV-(Ci-6alkyl)sulphamoyl, ΛζN-(C1-6alkyl)2sulρhamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R1 and R2 independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R7; one of X1, X2, X3 and X4 is =N-, the other three are independently selected from =CR8-, =CR9- and =CR10-;
R3 is hydrogen or optionally substituted C1-6alkyl; wherein said optional substiruents are selected from one or more R1 ! ;
R4 and R34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Q^a-kyl, C2-6alkenyl, C2-6alkynyl, Q.ealkoxy, Q^alkanoyl, Ci-6alkanoyloxy, N-(Ci-6alkyl)ammo, N,N-(C1-6alkyl)2amino, Q^alkanoylamino, iV-(C1-6alkyl)carbarnoyl, iV,N-(C1-6alkyl)2carbamoyl5 C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl,
Figure imgf000011_0001
iV,N-(C1-6alkyl)2sulphamoyl, C-μδalkylsulphonylaπiino, carbocyclyl or heterocyclyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
A is a direct bond or C1-2alkylene; wherein said C1-2alkylene may be optionally substituted by one or more R14;
Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15;
R5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, Ci-6alkanoyloxy, iV-(C1-6alkyl)amino, N,AT-(C1-6alkyl)2amino, C1-6alkanoylamino, iV-(C1-6alkyl)carbamoyl, ΛζiV-(Ci-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, iV-(C1-6alkyl)sulpharnoyl,
JV,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R5 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; n is 0, 1, 2 or 3; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, Ci-6alkanoyL Ci-6alkanoyloxy, iV-(C1-6alkyl)amino, i\ζN-(C1-6alkyl)2amino, C1-6alkanoylamino, 7V-(C1-6alkyl)carbamoyl, iV,iV-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, Q.ealkoxycarbonyl,
Figure imgf000011_0002
C i ,6alkylsulphonylamino, carbocyclyl-R25- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
R6, R11, R12, R14, R16 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, C1-6alkanoyl, d-βalkanoyloxy, iV-(C1-6alkyl)amino, ΛζN-(C1-6alkyl)2amino, C1.6alkanoylamino, N-(C1-6alkyl)carbamoyl, N, N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, iV,N-(C1-6alkyl)2sulpliamoyl, C1-6alkylsulphonylamino, carbocyclyl-R27- or lieterocyclyl-R28-; wherein R6, Rπ, R12, R14, R16 and R18 independently of each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R7, R13, R15, R17, R19 and R21 are independently selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, 7V-(C1-6alkyl)carbamoyl, ΛζiV-(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein
R , R , R , R , R and R independently of each other may be optionally substituted on carbon by on or more R22;
R20 and R22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, Ci-6alkanoyl, C1-6alkanoyloxy, iV-(C1-6alkyl)amino, iV,N-(C1-6aUcyl)2amino, C1-6alkanoylamino, JV-(C1-6alkyl)carbamoyl, ΛζiV-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, JV-(C1-6alkyl)sulphamoyl, ΛζN-(Ci-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R20 and R22 independently of each other may be optionally substituted on carbon by one or more R23; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24;
R25, R26, R27 and R28 are independently selected from a direct bond, -O-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(O)N(R31)-, -S(O)8-, -SO2N(R32)- or -N(R33)SO2-; wherein R29, R30, R31, R32 and R33 are independently selected from hydrogen or C1-6alkyl and s is 0-2; R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-7V-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, N,N-dimethylcarbarnoyl, N, iV-diethylcarbamoyl, iV-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, iV-methylsulphamoyl, iV-ethylsulphamoyl, ΛζN-dimethylsulphamoyl, AζiV-diethylsulphamoyl or iV-methyl-iV-ethylsulphamoyl; and R24 is selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, iV-(C1-6alkyi)carbamoyl, ΛζN-(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof. According to a further feature of the invention there is provided a compound of formula (I) wherein:
R1 and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, ΛζN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1 -6alkyl)carbamoyl,
N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R1 and R2 independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R7; one of X1, X2, X3 and X4 is =N-, the other three are independently selected from =CR8-, =CR9- and =CR10-;
R3 is hydrogen or optionally substituted C1-6alkyl; wherein said optional substituents are selected from one or more R11; R4 and R34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2.6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N~(C1-6alkyl)amino, N,N-(C i -6alkyl)2amino, C i -6alkanoylamino, N-(C \ -6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N, N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
A is a direct bond or C1-2alkylene; wherein said C1-2alkylene may be optionally substituted by one or more R14;
Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15; R5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, Ci-βalkanoyl, Ci-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d^alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl,
NN-(C 1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R5 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; n is 0, 1, 2 or 3; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2Sulphamoyl, Q-ealkylsulphonylamino, carbocyclyl-R25- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
R6, R11, R12, R14, R16 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2.6alkynyl,
Figure imgf000014_0001
C1-6alkanoyloxy, N-(C1-6alkyl)amino, jV,JV-(C1-6alkyl)2atnino, C^ealkanoylamino, N-(C1-6alkyi)carbamoyl, NN-(C1-6alkyl)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C i -6alkyl)sulphamoyl, NN-(C1 -6alkyl)2sulphamoyl, C i -6alkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, R11, R12, R14, R16 and R18 independently of each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R7, R13, R15, R17, R19 and R21 are independently selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N-(C1-6alkyl)carbamoyl, NN-(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R7, R13, R15, R17, R19 and R21 independently of each other may be optionally substituted on carbon by on or more R22;
R20 and R22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, Q-ealkanoyloxy, iV-(C1-6alkyl)amino, N)N-(C1.6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, iV,iV-(C1-6alkyi)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, iV-(C1-6alkyl)sulphamoyl, ΛζiV-(C1-6alkyl)2Sulphamoyl, C1-6alkylsulphonylamino, C1.6alkylsulphonyl-Λ/'-(C1-6alkyl)ammo, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 and R22 independently of each other may be optionally substituted on carbon by one or more R23; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24;
R2S, R26, R27, R28, R35 and R36 are independently selected from a direct bond, -O-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(O)N(R31)-, -S(O)3-, -NH=CH-, -SO2N(R32)- or -N(R33)SO2-; wherein R29, R30, R31, R32 and R33 are independently selected from hydrogen or C1-6alkyl and s is 0-2;
R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-iV-ethylammo, acetylamino, iV-methylcarbamoyl, JV-ethylcarbamoyl, iV,JV-dimethylcarbamoyl,
7V,iV-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, iV-ethylsulphamoyl, N, N-dimethylsulphamoyl, λζiV-diethylsulphamoyl, Λf-methyl-iV-ethylsulphamoyl or phenyl; and R24 is selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, iV-(C1-6alkyl)carbamoyl, ΛζiV-(C1-6alkyi)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof.
Particular values of the variable groups contained in formula (I) are as follows. Such values may be used, where appropriate, with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
R1 is C1-6alkoxy or carbocyclyl.
R1 is Cμβalkyl, C1-6alkoxy and cyclopropyl. R1 is isopropoxy or cyclopropyl.
R1 is C1-6alkoxy.
R1 is cyclopropyl.
R1 is isopropoxy. R1 is methyl, t-butyl, isopropoxy or cyclopropyl.
R2 is hydrogen.
R1 and R2 are independently selected from hydrogen, C1-6alkoxy and carbocyclyl.
R1 and R2 are independently selected from hydrogen, C1-6alkyl, C1-6alkoxy and carbocyclyl. R1 and R2 are independently selected from hydrogen, C1-6alkoxy and cyclopropyl.
R1 and R2 are independently selected from hydrogen, C1-6alkyl, C1-6alkoxy and cyclopropyl.
R1 and R2 are independently selected from hydrogen, isopropoxy and cyclopropyl.
R and R are independently selected from hydrogen, methyl, t-butyl, isopropoxy and cyclopropyl.
R1 is C1-6alkoxy or carbocyclyl and R2 is hydrogen.
R1 is C1-6alkyl, C1-6alkoxy or carbocyclyl and R2 is hydrogen.
R1 is Cμβalkoxy and cyclopropyl and R2 is hydrogen.
R1 is C1-6alkyl, C1-6alkoxy and cyclopropyl and R2 is hydrogen. R1 is C1-6alkoxy and R2 is hydrogen.
R1 is isopropoxy and R2 is hydrogen.
R1 is cyclopropyl and R2 is hydrogen.
R1 is isopropoxy or cyclopropyl and R2 is hydrogen.
R1 is methyl, t-butyl, isopropoxy or cyclopropyl and R2 is hydrogen. X1 is -N-, X2 is =CR8-, X3 is =CR9- and X4 is =CR10-.
X2 is =N-, X1 is =CR8-, X3 is =CR9- and X4 is =CR10-.
X3 is =N-, X2 is =CR8-, X1 is =CR9- and X4 is =CR10-.
X4 is =N-, X2 is =CR8-, X3 is =CR9- and X1 is =CR10-.
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-.
R3 is hydrogen.
R3 is optionally substituted C1-6alkyl; wherein said optional substituents are selected from one or more R11. R4 is not hydrogen.
R4 is selected from hydrogen or C1-6alkyl; wherein R may be optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy.
R4 is selected from hydrogen or C1-6alkyl; wherein R4 may be optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy and R34 is hydrogen.
R4 and R34 are independently selected from hydrogen or C1-6alkyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy.
R4 is selected from hydrogen or methyl; wherein R4 may be optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy.
R4 is selected from hydrogen or methyl; wherein R4 may be optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy and R34 is hydrogen.
R4 and R34 are independently selected from hydrogen or methyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy.
R4 is selected from hydrogen, methyl or hydroxymethyl.
R4 is selected from hydrogen, methyl or hydroxymethyl and R34 is hydrogen.
R4 and R34 are independently selected from hydrogen, methyl or hydroxymethyl.
R34 is selected from hydrogen. R34 is selected from hydrogen or hydroxymethyl.
R4 is selected from methyl or hydroxymethyl.
R4 is selected from methyl or hydroxymethyl and R34 is hydrogen.
R4 is selected from methyl and R34 is hydrogen.
R is selected from hydroxymethyl and R34 is hydrogen. A is a direct bond.
A is C1-2alkylene; wherein said C1-2alkylene may be optionally substituted by one or more R14.
Ring C is carbocyclyl.
Ring C is or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15;
Ring C is carbocyclyl or heterocyclyl.
Ring C is phenyl, pyridyl or pyrimidinyl.
Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrirnidin-2-yl. Ring C is phenyl.
Ring C is pyridyl.
Ring C is pyrid-2-yl.
R5 is selected from halo, C1-6alkanoylamino, C1-6alkylsulphonylamino or carbocyclyl-R37-; wherein
R37 is -C(O)N(R31)-; wherein R31 is hydrogen.
R5 is halo.
R5 is selected from fluoro, acetylamino, mesylamino or cyclopropyl-R37-; wherein R37 is -C(O)N(R31)-; wherein R31 is hydrogen. R5 is fluoro.
R5 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino. n is O. n is 1. n is 1 or 2; wherein the values of R5 may be the same or different. n is 2; wherein the values of R5 may be the same or different. n is 3; wherein the values of R5 may be the same or different.
Ring C and (R5)n together form 4-fluorophenyl; wherein the fluoro group is para to the A group of formula (I).
Ring C and (R5)n together form 4-fluorophenyl, 5-fluoropyrid-2-yl, 3,5-difluoropyrid-2-yl, 5-fluoropyrimidin-2-yl, 4-fluoro-3-mesylaminophenyl,
6-fluoropyrid-3-yl, 4-fluoro-3-acetylaminophenyl and 4-fluoro-3-cyclopropylcabonylamino.
Ring C and (R5)n together form 5-fiuoropyrid-2-yl; wherein the fluoro group is para to the A group of formula (I).
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, Ci.6aU.cyl, C1-6alkanoyl, iV-(C1-6alkyl)amino or carbocyclyl-R25-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
R18 is selected from hydroxy, amino, iV-(Ci.6alkyl)amino, C1-6alkanoylamino, C1-6alkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R18 may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21; R20 is selected from halo, amino, C1-6alkyl, N,iV-(C1-6alkyl)2amino, Ci-ealkylsulphonyl-N-^i-ealky^amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 may be optionally substituted on carbon by one or more R23;
R21 is selected from C1-6alkylsulphonyl; R is dimethylamino or phenyl; and
R27, R28, R35 and R36 are independently selected from a direct bond, -C(O)N(R31)-, -NH=CH- or -SO2N(R32)-; wherein R31 and R32 are independently selected from hydrogen or C1-6alkyl.
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and C1-6alkyl; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R ; wherein
R18 is selected from amino, C1-6alkanoylamino, C1-6alkylsulphonylamino or heterocyclyl-R -; wherein R may be optionally substituted on carbon by one or more R ;
R is amino; and R28 is -C(O)N(R31)-; wherein R31 is hydrogen.
R , R9 and R10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, methyl, isopropyl, formyl, methylamino, isopropylamino or cyclopropyl-R -; wherein R , R and R independently of each other may be optionally substituted on carbon by one or more R ; R1 is selected from hydroxy, amino, methylamino, acetylamino, propionylamino,
3-methylbutanoylamino, mesylamino, cyclopropyl-R27-, phenyl-R27-, tetrahydrofuran-2-yl-R28-, furan-2-yl-R28-, pyrrol-2-yl-R28-, isoxaxol-5-yl-R28-, isoxaxol-4-yl-R28-, piperidin-4-yl-R28-, thien-2-yl-R28-, pyrid-3-yl-R28-, pyrid-4-yl-R28-, tetrahydro-2H-thiopyran-4-yl-R -, morpholino-R - or 2-oxopyrrolidin-5-yl-R -; wherein R18 may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R20 is selected from fluoro, amino, methyl, dimethylamino,
N-(isopropyl)-iV-(mesyl)ammo, iV-(ethyl)-N-(mesyl)amino, phenyl-R35-, thien-2-yl-R36-, thien-3-yl-R36-, pyrid-3-yl-R36- or morpholino-R36-; wherein R20 may be optionally substituted on carbon by one or more R23;
R21 is selected from mesyl;
R23 is dimethylamino or phenyl; and R27, R28, R35 and R36 are independently selected from a direct bond, -C(O)N(R31)-, -NH=CH- or -SO2N(R32)-; wherein R31 and R32 are independently selected from hydrogen or methyl.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, methyl, isopropyl, formyl, methylamino, isopropylamino or cyclopropyl-R25-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R ;
R is selected from hydroxy, amino, methylamino, acetylamino, propionylamino, 3-methylbutanoylamino, mesylamino, cyclopropyl-R27-, phenyl-R27-, tetrahydrofuran-2-yl-R28-, furan-2-yl-R28-, pyrrol-2-yl-R28-, isoxaxol-5-yl-R28-, isoxaxol-4-yl-R28-, piperidin-4-yl-R28-, thien-2-yl-R28-, pyrid-3-yl-R28-, pyrid-4-yl-R28-, tetrahydro-2H-thiopyran-4-yl-R28-, rnorpholino-R28- or 2-oxopyrrolidin-5-yl-R28-; wherein R18 may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R20 is selected from fluoro, amino, methyl, dimethylamino, λf-(isopropyl)-N-(mesyl)amino, N-(ethyl)-N-(mesyl)amino, phenyl-R35-, thien-2-yl-R36-, thien-3-yl-R36-, pyrid-3-yl-R36- or morpholino-R36-; wherein R20 may be optionally substituted on carbon by one or more R ; R21 is selected from mesyl;
R23 is dimethylamino or phenyl; and
R27, R28, R35 and R36 are independently selected from a direct bond, -C(O)N(R31)-, -NH=CH- or -SO2N(R32)-; wherein R31 and R32 are independently selected from hydrogen or methyl. R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl and methyl; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18; wherein
R18 is selected from amino, acetylamino, mesylamino or 2-oxopyrrolidin-5-yl-R28-; wherein R18 may be optionally substituted on carbon by one or more R20; R20 is amino; and
R28 is -C(O)N(R31)-; wherein R31 is hydrogen.
R , R and R10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl,
(R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminometliyl, isoxaxol-5-yl-carbonylaminomethyl, mesylaminomethyl, morpholinomethyl, benzoylaminomethyl, pyrid-3-yl-carbonylaminomethyl, ό-dimethylaminopyrid-S-yl-carbonylaminomethyl, ό-morpholinopyrid-S-yl-carbonylaniinomethyl, pyrid-4-yl-carbonylaminomethyl,
5-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl,
4-dimethylaminobenzylcarbonylaminometliyl, 2-(JV-(isopropyl)-N-(mesyl)ammo)acetylaminomethyl,
2-(iV-(phenetb.yl)-iV-(mesyl)ammo)acetylaminometliyl, l-mesylpiperidin-l-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl, tetraliydro^H-thiopyran^-yl-carbonylaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl, 3-phenylpropionylaminomethyl, 2-(iV-benzoyl-iV-methylamino)acetylaminomethyl,
4-dimethylaminobenzoylaminometb.yl, phenylsulphonylaminomethyl,
2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl, pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl, (cyclopropylimino)metliyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl,
(2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl, (R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl, mesylaminomethyl, morpholinomethyl, benzoylaminomethyl, pyrid-3 -y 1-carbonylaminomethyl, 6-dimethylaminopyrid-3 -yl-carbonylaminomethyl, 6-moφholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl,
S-methylisoxaxoM-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl,
4-dimethylaminobenzylcarbonylaminomethyl,
2-(N-(isopropyl)-N-(mesyl)amino)acetylaminomethyl, 2-(N-(phenethyl)-N-(mesyl)amino)acetylaminomethyl, 1 -mesylpiperidin- 1 -ylcarbonylaminomethyl, 2-(pyrid-3 -yl)acetylaminomethyl, tetrahydro-2H-thiopyran-4-yl-carbonylaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl, 3-phenylpropionylaminomethyl, 2-(N-benzoyl-iV-methylamino)acetylammomethyl, 4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl, 2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl, pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl, (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminometliyl. R8, R9 and R10 are independently selected from hydrogen, fluoro and cyano.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 and R2 are independently selected from hydrogen, C1-6alkoxy and carbocyclyl;
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-;
R3 is hydrogen;
R4 is selected from hydrogen or C1-6alkyl; wherein R4 may be optionally substituted on carbon by one or more R12;
R34 is hydrogen; A is a direct bond;
Ring C is carbocyclyl;
R5 is halo; n is 1;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and C1-6alkyl; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
R12 is selected from hydroxy; R18 is selected from amino, C1-6alkanoylamino, C1-6alkylsulphonylamino or heterocyclyl-R28-; wherein R18 may be optionally substituted on carbon by one or more R20;
R20 is amino; and
R28 is -C(O)N(R31)-; wherein R31 is hydrogen; or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 and R2 are independently selected from hydrogen, C1-6alkyl, C1-6alkoxy and carbocyclyl; X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from
=CR8-, =CR9- and =CR10-;
R3 is hydrogen;
R4 and R34 are independently selected from hydrogen or C1-6alkyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; A is a direct bond;
Ring C is carbocyclyl;
R5 is halo; n is 1;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and C1-6alkyl; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
R12 is selected from hydroxy;
R18 is selected from amino, C1-6aUcanoylamino, C1-6alkylsulphonylamino or heterocyclyl-R28-; wherein R18 may be optionally substituted on carbon by one or more R20; R20 is amino; and
R28 is -C(O)N(R31)-; wherein R31 is hydrogen; or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein: R1 is C1-6alkyl, C1-6alkoxy or carbocyclyl;
R2 is hydrogen;
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-; R3 is hydrogen;
R4 and R34 are independently selected from hydrogen or C1-6alkyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy; A is a direct bond;
Ring C is carbocyclyl;
R5 is halo; n is 1;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C1-6alkyl, C1-6alkanoyl, JV-(C1-6all<yl)amino or carbocyclyl-R25-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
R18 is selected from hydroxy, amino, N-(C1-6alkyl)amino, C1-6alkanoylamino,
C1-6alkylsulphonylamino, carbocyclyl-R - or heterocyclyl-R -; wherein R may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R20 is selected from halo, amino, Ci.6alkyl, N,iV-(C1-6alkyl)2amino,
C1-6alkylsulphonyl-A/'-(C1-6alkyl)ammo, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 may be optionally substituted on carbon by one or more R ; R21 is selected from C1-6alkylsulphonyl;
R23 is dimethylamino or phenyl; and
R27, R28, R35 and R36 are independently selected from a direct bond, -C(O)N(R31)-, -NH=CH- or -SO2N(R32)-; wherein R31 and R32 are independently selected from hydrogen or C1-6alkyl; or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 is C1-6alkyl, C1-6alkoxy or carbocyclyl; R2 is hydrogen; X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from
=CR8-, =CR9- and =CR10-; R3 is hydrogen; R4 and R34 are independently selected from hydrogen or C1-6alkyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy;
A is a direct bond; Ring C is carbocyclyl or heterocyclyl;
R5 is selected from fluoro, acetylamino, mesylamino or cyclopropyl-R37-; wherein R37 is -C(O)N(R31)-; wherein R31 is hydrogen; n is 1 or 2; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C1-6alkyl, C1-6alkanoyl, iV-(C1-6alkyl)amino or carbocyclyl-R25-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
R18 is selected from hydroxy, amino, N-(C1-6alkyl)amino, Ci-6alkanoylamino, C1-6alkylsulphonylamino, carbocyclyl-R - or heterocyclyl-R -; wherein R may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R20 is selected from halo, amino, C1-6alkyl, ΛζN-(C1-6alkyl)2amino, C1-6alkylsulphonyl-N-(C1-6alkyl)amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 may be optionally substituted on carbon by one or more R23; R21 is selected from C1-6alkylsulphonyl;
R23 is dimethylamino or phenyl; and
R27, R28, R35 and R36 are independently selected from a direct bond, -C(O)N(R31)-, -NH=CH- or -SO2N(R32)-; wherein R31 and R32 are independently selected from hydrogen or Ci-6alkyl; or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 is isopropoxy or cyclopropyl;
R2 is hydrogen; X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from
=CR8-, =CR9- and =CR10-;
R3 is hydrogen;
R4 is selected from hydrogen, methyl or hydroxymethyl; R34 is hydrogen;
A is a direct bond;
Ring C is phenyl;
R5 is fluoro; n is 1; and
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl; or a pharmaceutically acceptable salt thereof. Therefore in a further aspect of the invention there is provided a compound of formula
(I) (as depicted herein above) wherein:
R1 is methyl, ^-butyl, isopropoxy or cyclopropyl;
R2 is hydrogen;
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-;
R3 is hydrogen;
R4 is selected from hydrogen, methyl or hydroxymethyl;
R34 is selected from hydrogen or hydroxymethyl;
A is a direct bond; Ring C is phenyl;
R5 is fluoro; n is 1; and
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl; or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 is methyl, t-butyl, isopropoxy or cyclopropyl; R2 is hydrogen;
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-;
R3 is hydrogen; R4 and R34 are independently selected from hydrogen, methyl or hydroxymethyl;
A is a direct bond;
Ring C is phenyl;
R5 is fluoro; n is 1 ;
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl, (R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, (S)-2-oxopyrrolidin-5-yl-carbonylammomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl, mesylaminomethyl, morpholinomethyl, benzoylaminomethyl, pyrid-3-yl-carbonylaminomethyl, ό-dimethylaminopyrid-S-yl-carbonylaminomethyl, ό-morpholinopyrid-S-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl, 5-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl, 4-dimethylaminobenzylcarbonylaminomethyl, 2-(Λ/-(isopropyl)-N-(mesyl)amino)acetylaminomethyl, 2-(N-(phenethyl)-N-(mesyl)amino)acetylaminomethyl, 1-mesylpiperidin-l-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl, tetrahydro-2H-thiopyran-4-yl-carbonylaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl, 3-phenylpropionylaminomethyl, 2-(iV-benzoyl-iV-methylammo)acetylammomethyl, 4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl, 2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl, pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl, (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino; or a pharmaceutically acceptable salt thereof. Therefore in a further aspect of the invention there is provided a compound of formula
(I) (as depicted herein above) wherein:
R1 is methyl, £-butyl, isopropoxy or cyclopropyl;
R is hydrogen; X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-;
R3 is hydrogen;
R4 and R34 are independently selected from hydrogen, methyl or hydroxymethyl; A is a direct bond;
Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl;
R5 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino; n is 1 or 2; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl, (R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, (S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl, mesylaminomethyl, morpholinomethyl, benzoylaminomethyl, pyrid-3-yl-carbonylaminomethyl, ό-dimethylaminopyrid-S-yl-carbonylaminomethyl, β-morpholinopyrid-S-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl, S-methylisoxaxol^-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl, 4-dimethylaminobenzylcarbonylaminomethyl, 2-(N-(isopropyl)-N-(mesyl)amino)acetylaminomethyl, 2-(N-(phenethyl)-iV-(mesyl)amino)acetylaminomethyl, 1-mesylpiperidin-l-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl, tetrahydro-2H-thiopyran-4-yl-carbonylaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl, 3 -phenylpropionylaminomethyl, 2-(JV-benzoyl-N-methylamino)acetylaminomethyl, 4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl, 2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl, pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl, (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino; or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention there is provided a compound of formula (Ia):
Figure imgf000029_0001
(Ia) wherein Ra is nitro or amino; and other variable groups are as defined herein above.
In a further aspect of the invention there is provided a compound of formula (Ib):
Figure imgf000029_0002
(Ib) wherein Rb is nitro or amino; and other variable groups are as defined herein above.
In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof. In another aspect of the invention, preferred compounds of the invention are any one of Examples 1, 6, 11, 16, 64, 110, 112, 113, 119 and 120 or a pharmaceutically acceptable salt thereof.
In an additional embodiment the present invention provides a compound of formula
(I), or a pharmaceutically acceptable salt thereof, for use as a medicament. In an additional embodiment the present invention provides a compound of formula
(I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the inhibition of Trk activity. In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of cancer in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the production of an anti-proliferative effect.
In an additional embodiment the present invention provides a method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In an additional embodiment the present invention provides a method for the treatment of cancer comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
In an additional embodiment the present invention provides a method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
In an additional embodiment the present invention provides a method for the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In an additional embodiment the present invention provides a method of producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trie activity.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment of cancer.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer. In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the inhibition of Trk activity. In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer.
In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancers (solid tumours and leukaemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the production of an antiproliferative effect.
In one embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk A activity.
In another embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk B activity.
Where the treatment (or prophylaxis) of cancer is referred to, particularly it refers to the treatment (or prophylaxis) of mesoblastic nephroma, mesothelioma, acute myeloblasts leukemia, acute lymphocytic leukemia, multiple myeloma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma thyroid cancer including papillary thyroid cancer, mesothelioma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma including congenital fibrosarcoma and osteosarcoma. More particularly it refers to prostate cancer. In addition, more particularly it refers to SCLC, NSCLC, colorectal cancer, ovarian cancer and / or breast cancer. In a further aspect it refers to hormone refractory prostate cancer. In a further aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of: Process a) reaction of a compound of formula (II):
Figure imgf000033_0001
(II) wherein Pg is a nitrogen protecting group; with a compound of formula (III):
Figure imgf000033_0002
(III) wherein L is a displaceable group;
Process b) for compounds of formula (I) wherein R4 is hydroxymethyl and R34 is hydrogen; reaction of a compound of formula (II) with an epoxide of formula (IV):
Figure imgf000033_0003
(IV)
Process c) reacting a compound of formula (V):
Figure imgf000034_0001
(V) with hydrazine;
Process d) reacting a compound of formula (VI):
Figure imgf000034_0002
(VI) wherein L is a displaceable group; with an amine of formula (VII):
Figure imgf000034_0003
(VII) Process e) reacting a compound of formula (VIII):
Figure imgf000035_0001
(VIII) wherein L is a displaceable group; with an amine of formula (IX):
Figure imgf000035_0002
(IX)
Process J) reacting an amine of formula (X):
Figure imgf000035_0003
(X) with a compound of formula (XI):
Figure imgf000035_0004
(XI) wherein L is a displaceable group; and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt.
L is a displaceable group, suitable values for L are for example, a halo or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.
Pg is a nitrogen protecting group. Suitable values for Pg are described herein below.
Specific reaction conditions for the above reactions are as follows. Process a) Compounds of formula (II) and (III) may be reacted together under standard nucleophilic addition reactions for example in the presence of a suitable base such as potassium carbonate and a suitable solvent such as DMF and at a temperature in the range from 25 to lOO°C.
Compounds of the formula (II) may be prepared according to Scheme 1:
Figure imgf000036_0001
(Ha) (lib)
Scheme 1 wherein Pg is a nitrogen protecting group. Suitable values for Pg are defined below; and wherein L is a displaceable group as defined above.
Compounds of formula (III), (Ha) and (IΙb)are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process b) Compounds of formula (II) and (IV) may be reacted together under epoxide ring opening reaction conditions for example in the presence of a suitable catalyst such as LiClO4, NaClO4, Mg(C104)2 and a suitable solvent such as CH3CN and at a temperature in the range from 25 to 80°C.
Compounds of formula (IV)are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Process c) The s reaction may be carried out in a suitable solvent, for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120°C, in particular in the range from 70-1000C.
Compounds of the formula (V) may be prepared according to Scheme 2:
Figure imgf000037_0001
(Vb)
Scheme 2
Compounds of the formula (Va) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process d) Compounds of formula (VI) and (VII) may be reacted together under the conditions listed in Process a).
Compounds of formula (VI) may be prepared according to Scheme 3:
Figure imgf000037_0002
(Via)
Scheme 3 wherein L is a displaceable group as defined herein above.
Compounds of the formula (Via) and (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process e) Compounds of formula (VIII) and (IX) may be reacted together under the conditions listed in Process a). Compounds of formula (VIII) may be prepared according to Scheme 4:
DIEA, Δ (Via) + (VII) *- (VIII)
Scheme 4
Compounds of the formula (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process f) Compounds of formula (X) and (XI) may be reacted together under the conditions listed in Process a).
Compounds of formula (X) may be prepared according to Scheme 5;
Figure imgf000038_0001
(Xa) Scheme 5 wherein L is a displaceable group as defined herein above.
Compounds of the formula (Xa) and (XI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl. It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine. A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art. Definitions
In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C1-6alkyl" and "Chalky!" include methyl, ethyl, propyl, isopropyl and t-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight-chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only. A similar convention applies to other radicals. The term "halo" refers to fluoro, chloro, bromo and iodo. Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, iV-methylpyrrolyl, 4-pyridone, 1-isoquinolone,
2-pyrrolidone, 4-thiazolidone, pyridine-iV-oxide and quinoline-TV-oxide. Further examples and suitable values of the term "heterocyclyl" are morpholino, piperazinyl and pyrrolidinyl. In one aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH2- group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides. Further examples and suitable values of the term "heterocyclyl" are tetrahydrofuranyl, furanyl, pyrrolyl, isoxaxolyl, piperidinyl, thienyl, pyridyl, tetrahydro-2/J-thiopyranyl, morpholino and 2-oxopyrrolidinyl. A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH2- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
Where "one of X1, X2, X3 and X4 is =N-, the other three are independently selected from =CR8-, =CR9- and =CR10-" it is to be understood that this means one of X1, X2, X3 and X4 is =N-, one of the other three is =CR8-, one of the remaining two is =CR9- and the last is =CR10-. For example the scenario wherein X1 is =N-, X2 is =CR8-, X3 is =CR9- and X4 is =CR* °- is embraced by this definition as is X3 is =N-, X1 is =CR8-, X2 is =CR9- and X4 is =CR10-. The ring containing X1, X2, X3 and X4 is thus a pyridine ring.
The term "Cm-n" or "Cm-n group" used alone or as a prefix, refers to any group having m to n carbon atoms.
The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted.
An example of "Ci-6alkanoyloxy" is acetoxy. Examples of "Q-ealkoxycarbonyl" include C1-4alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of "C1-6alkoxy" include C1-4alkoxy, C1-3alkoxy, methoxy, ethoxy and propoxy. Examples of "C1-6alkoxyimino" include C1-4alkoxyimino, Ci-3alkoxyimino, methoxyimino, ethoxyimino and propoxy imino. Examples of "C1-6alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C1-6alkylS(O)a wherein a is 0 to 2" include Ci-4alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C1-6alkylthio" include methylthio and ethylthio. Examples of "C1-6alkylsulphonylamino" include methylsulphonylamino and ethylsulphsulphonylamino. Examples of "C1-6alkanoyl" include C1-4alkanoyl, formyl, propionyl and acetyl. Examples of "iV-(Ci-6alkyl)amino" include methylamino and ethylamino. Examples of 'W,N-(C1-6alkyl)2amino" include di-iV-methylamino, di-(iV-ethyl)amino and N-ethyl-N-methylamino. Examples of "C2-6alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2-6alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "7V-(C1-6alkyl)sulphamoyl" are iV-(methyl)sulphamoyl and iV-(ethyl)sulphamoyl. Examples of "iV-(C1-6alkyl)2sulphamoyl" are i\ζN-(dimethyl)sulphamoyl and iV-(methyl)-N-(ethyl)sulphamoyl. Examples of "iV-(C1-6alkyl)carbamoyl" are N-(Ci-4alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of
'W,N-(C1-6alkyl)2carbamoyl" areN,N-(C1-4alkyl)2carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "Ci_6alkylsulphonyl-iV:-(C1-6alkyl)amino" include iV-mesyl-N-methylamino and iV-mesyl-TV-isopropylamino. "RT" or "rt" means room temperature.
A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
It should be noted that the pyrazoles claimed in this invention are capable to exist in different resonance structures and thus the pyrazoles claimed herein include all possible resonance structures, for example optical isomers, diastereoisomers and geometric isomers and all tautomeric forms of the compounds of the formula (I).
It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms. Formulations Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
An effective amount of a compound of the present invention for use in therapy of cancer is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of cancer, to slow the progression of cancer, or to reduce in patients with symptoms of cancer the risk of getting worse.
For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
A solid carrier can be one or more substance, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this invention. Examples of such acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, meglumine, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), trifluoroacetate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as aluminum, calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, ornithine, and so forth. Also, basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl halides like benzyl bromide and others. Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product. The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.
In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
In addition to the compounds of the present invention, the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
The term composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier. For example this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
Liquid form compositions include solutions, suspensions, and emulsions. Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art. The pharmaceutical compositions can be in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms. Combinations
The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:
(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);
(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, fmtamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5α-reductase such as finasteride;
(iii) agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
(iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbb2 antibody trastuzumab [Herceptin™] and the anti-erbbl antibody cetuximab [C225]) , farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD 1839), N-(3 -ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and
6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family; (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [Avastin™], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin αvβ3 function and angiostatin);
(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
(x) other treatment regimes including: dexamethasone, proteasome inhibitors (including bortezomib), isotretinoin (13-cis retinoic acid), thalidomide, revemid, Rituxamab, ALIMTA, Cephalon's kinase inhibitors CEP-701 and CEP-2563, anti-Trk or anti-NGF monoclonal antibodies, targeted radiation therapy with 1311-metaiodobenzylguanidine (131I-MIBG), anti- G(D2) monoclonal antibody therapy with or without granulocyte-macrophage colony- stimulating factor (GM-CSF) following chemotherapy. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention, or pharmaceutically acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range. Synthesis
The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Such methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.
The novel compounds, or pharmaceutically acceptable salts thereof, of this invention may be prepared using the reactions and techniques described herein. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are compatible with the reaction conditions, will be readily apparent to one skilled in the art and alternate methods must then be used. Examples
The invention will now be further described with reference to the following illustrative examples in which, unless stated otherwise: (i) temperatures are given in degrees Celsius (0C); operations are carried out at room temperature or ambient temperature, that is, in a range of 18-25 0C; (ii) organic solutions were dried over anhydrous magnesium sulfate; evaporation of organic solvent was carried out using a rotary evaporator under reduced pressure (4.5 - 30 mmHg) with a bath temperature of up to 60 0C;
(iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; (iv) in general, the course of reactions was followed by TLC or liquid chromatography/mass spectroscopy (LC/MS) and reaction times are given for illustration only;
(v) final products have satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectra data; (vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
(vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in part per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz in DMSO-d6 unless otherwise stated; (viii) chemical symbols have their usual meanings; (ix) solvent ratio was given in volume: volume (v/v) terms,
(x) the following abbreviations have been used: EtOAc ethyl acetate; ether diethyl ether;
EtOH ethanol; THF tetrahydrofuran;
TFP tetrafluorophenyl;
DIEA diisopropylethylamine;
DMAP 4-dimethylaminopyridine;
NMP N-methylpyridinone; MTBE methyl tert-butyl ether;
DMF iV,Λ/-dimethylformamide;
HBTU 2-( 1 H-benzotriazole- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium hexafluorophosphate; DCE dichloroethane;
TFP resin tetrafluorophenol resin;
MeOH methanol; and
DCM dichloromethane.
C
J
Example 1
C5^-6-('5-Cvclopropvl-lH-pvrazol-3-vlammo)-5-fluoro-2-Cl-(4-fluoroϋlienvls)ethvlammo) nicotinonitrile
A portion of 2-chloro-6-(5-cyclopropyl-lH"-pyrazol-3-ylamino)-5-fluoronicotinonitrile 0 (Method 1; 0.8g, 2.8 mmol) and (S)-l-(4-fluorophenyl)ethanamine (0.8g, 5.6 mmol) were added to a solution of rc-BuOH (4 ml) and DIEA (0.5g, 3.7 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hrs, then cooled to 25 °C and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.55g, 50%). 1H NMR (400 MHz, CDCl3) δ 8.44 (br s, IH), 7.37-7.33 (m, 2H), 5 7.27 (d, J= 9.6 Hz, IH), 7.07-7.03 (m, 2H), 6.11 (s, IH), 5.24-5.20 (m, 2H), 1.87-1.83 (m, IH), 1.60 (d, J- 6.2 Hz, 3H), 1.01-0.98 (m, 2H), 0.79-0.65 (m, 2H). MS: Calcd.: 380; Found: [M+H]+ 381.
Example 2 0 (5f)-6-r5-Cyclopropyl-lH'-pyrazol-3-ylaminoV5-fluoro-2-(l-r4-fluorophenvDethylamino') nicotinamide
To a solution of (S)-6-(5-cyclopropyl-l/J-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)nicotinonitrile (Example 1; 0.5g, 1.3 mmol) in MeOH (50 ml), was added a 25% aqueous solution (2 ml) of KOH (400 mg) at 25 0C, followed by the addition of 5 0.1 ml of 30% H2O2. The resulting dark red solution was heated to 65 °C for Ih, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.3Og, 60%). 1H NMR (400 MHz, CDCl3) δ 9.06 (d, J= 7.0 Hz, IH), 7.90 (br s, IH), 7.35-7.32 (m, 2H), 7.25 (d, J= 0 7.2 Hz, IH), 7.00-6.95 (m, 2H), 6.00 (br s, IH), 5.66 (br s, 2H), 5.21-5.17 (m, IH), 1.86-1.82 (m, IH), 1.54 (d, J= 6.8 Hz, 3H), 0.96-0.92 (m, 2H), 0.69-0.67 (m, 2H). MS: Calcd.: 398; Found: [M+H]+ 399. Example 3 r^-3-(Aminomethyl)-iV6-('5-cyclopropyl-l//'-pyrazol-3-yl)-5-fluoro-N2-(l-f4-fluorophenyl') ethvDpyridine-2,6-diamme
To a MeOH solution (5 ml) was added (£)-6-(5-cyclopropyl-lH-pyrazol-3-ylamino)- 5-fluoro-2-(l-(4-fluorophenyl)ethylamino)nicotinonitrile (Example 1; 0.15g, 0.4 mmol), cone. HCl (0.1 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.12g). The mixture was then flushed with N2, evacuated, and then placed under 40 psi of H2 for 6 hrs. The reaction was then evacuated, flushed with N2, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml), and a saturated aqueous solution OfNa2CO3 (100 ml) was added, and the mixture was shaken vigorously for 30 min. The layers were then allowed to separate, and the aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 9: 1) to give the title compound (0.09g, 58%). 1H NMR (400 MHz, CD3OD) δ 7.42-7.38 (m, 2H), 7.15 (d, J= 11. Hz, IH), 7.02-6.97 (m, 2H), 5.15-5.08 (m, IH), 3.74 (s, 2H), 1.88-1.81 (m, IH), 1.54 (d, J- 7.0 Hz, 3H), 0.93-0.92 (m, 2H), 0.67-0.63 (m, 2H). MS: Calcd.: 384; Found: [M+H]+ 385.
Example 4 (>S^-./V-((6-('5-Cvclopropyl-7.H-pyrazol-3-ylamino)-5-fluoro-2-(l-('4-fluorophenyl)ethylammo) ρyridin-3-yl)methvDacetamide
A round bottom flask was charged with (<S)-3-(aminomethyl)~JV6-(5-cyclopropyl-lH'- pyrazol-3-yl)-5-fluoro-N2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.08g, 0.2 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.2 mmol) in mixture of THF - DCM (1 : 1, 3 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.045g, 50%). 1H NMR (400 MHz5 CD3OD) δ 7.34- 7.33 (m, 2H), 7.11 (d, J= 10.7 Hz, IH), 7.01-6.97 (m, 2H), 5.14-5.04 (m, IH), 4.30-4.17 (m, 2H), 1.99 (s, 3H), 1.88-1.81 (m, IH), 1.50 (d, J= 6.8 Hz, 3H), 0.94-0.92 (m, 2H), 0.67-0.63 (m, 2H). MS: Calcd.: 426; Found: [M+H]+ 427. Example 5
(5f)-N-((6-(5-Cvclopropyl-li/-pyrazol-3-ylamino)-5-fluoro-2-(l-('4-fluorophenyl)ethylamino) pyridin-3-yl)methvDmethanesulfonamide
A round bottom flask was charged with (<S)-3-(aminomethyl)-iV6-(5-cyclopropyl-lH- pyrazol-3-yl)-5-fluoro-N2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamme (Example 3; 0.025g, 0.065 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.065 mmol), DIEA (0.017g, 0.13 mmol), DMAP (0.09g, 0.072 mmol), and THF (5 ml). The resulting solution was shaken vigorously at 60 °C for 8 hrs. The reaction was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse- phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.016g, 53%). 1H NMR (400 MHz, CD3OD) δ 7.42-7.39 (m, 2H), 7.14 (d, J= 10.7 Hz, IH), 7.01-6.97 (m, 2H), 5.16-5.09 (m, IH), 4.15-4.06 (m, 2H), 2.99 (s, 3H), 1.88- 1.83 (m, IH), 1.52 (d, J= 6.8 Hz, 3H), 0.95-0.93 (m, 2H), 0.66-0.64 (m, 2H). MS: Calcd.: 462; Found: [M+H]+ 463.
Example 6
(i?)-6-(5-Cvclopropyl-lH-pyrazol-3-ylaminoV5-fluoro-2-d-r4-fluorophenyl')-2- hydroxyethylamino^nicotinonitrile 2-Chloro-6-(5-cyclopropyl-lH"-pyrazol-3-ylamino)-5-fluoronicotinonitrile (Method 1;
0.5g, 1.8 mmol) and (i?)-2-amino-2-(4-fluorophenyl)ethanol (0.6g, 3.6 mmol) were added to a solution of rc-BuOH (4 ml) and DIEA (0.3g, 2.3 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hrs, then cooled to 25 0C and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 80 : 1) to give the title compound (0.3g, 40%). 1H NMR (400 MHz, CD3OD) δ 7.37-7.35 (m, 3H), 7.05-7.00 (m, 2H), 5.99 (s, IH), 5.20-5.11 (m, IH), 3.90-3.77 (m, 2H), 1.90-1.86 (m, IH), 1.05-0.96 (m, 2H), 0.73-0.66 (m, 2H). MS: Calcd.: 396; Found: [M+H]+ 397.
Example 7 (i?V6-r5-Cvclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-('l-r4-fluoroρhenylV2- hvdroxyethylamino)nicotmamide
(i?)-6-(5-Cyclopropyl-li3r-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)-2- hydroxyethylamino)nicotinonitrile (Example 6; 0.07g, 0.2 mmol), was placed in MeOH (5 ml) at 25 °C. A 25% aqueous solution (0.2 ml) of KOH (50 nig) was then added, followed by the addition of 0.05 ml of 30% H2O2. The resulting dark red solution was heated to 65 °C for 1 h, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.065g,
90%). 1H NMR (400 MHz, CD3OD) δ 7.69 (d, J= 12.1 Hz, IH), 7.39-7.36 (m, 2H), 7.04-7.00 (m, 2H), 5.94 (s, IH)5 5.22-5.16 (m, IH), 3.87-3.75 (m, 2H)5 1.91-1.84 (m, IH), 0.98-0.96 (m, 2H)5 0.74-0.69 (m, 2H). MS: Calcd.: 414; Found: [M+H]+ 415.
Example 8 ri?*)-2-r3-rAmmomethylV6-(5-cyclopropyl-lH"-ρyrazol-3-ylamino)-5-fluoroρyridm-2- ylammoV2-(4-fluorophenyr)ethanol
The mixture of (i?)-6-(5-cyclopropyl-lH"-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)-2-hydroxyethylamino)nicotinonitrile (Example 6; 0.13g, 0.33 mmol), cone. HCl (0.1 ml), and Pd (10 wt %5 dry basis, on activated carbon, 0.12g) in MeOH (5 ml) was flushed with N2, evacuated, and then placed under H2 (40 psi) for 6 hrs. The reaction was then evacuated, flushed with N2, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml), and a saturated aqueous solution OfNa2CO3 (100 ml) was added. The mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layer was dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.074, 57%). 1H NMR (400 MHz, CD3OD) δ 7.45-7.42 (m, 2H), 7.17 (d, J= 11.1 Hz, IH), 7.04-7.00 (m, 2H), 5.72 (br s, IH), 5.18-5.08 (m, IH), 3.89-3.72 (m, 4H), 1.87- 1.83 (m, IH), 0.94-0.92 (m, 2H), 0.69-0.65 (m, 2H). MS: Calcd.: 400; Found: [M+H]+ 401.
Example 9
(i?)-iVr-r(6-(5-Cvclopropyl-lH"-pyrazol-3-ylamino)-5-fiuoro-2-('l-(4-fluorophenylV2- hvdroxyethylamino)pyridin-3-yl)methyl)acetamide (i?)-2-(3-(Aminomethyl)-6-(5-cyclopropyl-liy-pyrazol-3-ylamino)-5-fluoropyridin-2- ylamino)-2-(4-fluorophenyl)ethanol (Example 8; 0.034g, 0.085 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.085 mmol) were placed in a THF - DCM solution (1 : 1, 3 ml) at 0 0C. The resulting suspension was shaken vigorously at 0 °C for 45 min. The reaction was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.018g, 48%). 1H NMR (400 MHz, CD3OD) δ 7.42- 7.36 (m, 2H), 7.12 (d, J= 9.6 Hz, IH), 7.04-6.99 (m, 2H), 6.09 (br s, IH), 5.19-5.02 (m, IH), 4.36-4.17 (m, 2H), 3.83-3.71 (m, 2H), 1.99 (s, 3H), 1.88-1.83 (m, IH), 0.98-0.87 (m, 2H), 0.72-0.66 (m, 2H). MS: Calcd.: 442; Found: [M+H]+ 443.
Example 10 ri?VN-Cr6-r5-Cvclopropyl-lH"-pyrazol-3-ylamino)-5-fluoro-2-Cl-r4-fluorophenyl)-2- hvdroxyethylammo)pyridin-3-yl)methyl)methanesulfonamide
A round bottom flask was charged with (i?)-2-(3-(aminomethyl)-6-(5-cyclopropyl-lH~- pyrazol-3-ylamino)-5-fluoropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol (Example 8; 0.2Og, 0.50 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.50 mmol), DIEA (0.13g, 1.00 mmol), DMAP (0.067g, 0.067 mmol), and THF (10 ml). The resulting solution was shaken vigorously at 60 0C for 8 hrs. The reaction was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.075g, 31%). 1H NMR (400 MHz, CD3OD) δ 7.50-7.41 (m, 2H), 7.15 (d, J= 9.1 Hz, IH), 7.04-7.00 (m, 2H), 6.09 (br s, IH), 5.22-5.03 (m, IH), 4.20-4.07 (m, 2H), 3.86-3.74 (m, 2H), 2.98 (s, 3H), 1.89-1.85 (m, IH), 1.04-0.92 (m, 2H), 0.78-0.66 (m, 2H). MS: Calcd.: 478; Found: [M+Hf 479.
Example 11
(i?V5-Fluoro-2-(l-(4-fluorophenyl)-2-hvdroxyethylaminoV6-f5-isopropoxy-lH-pyrazol-3- ylamino)nicotinonitrile
2-Chloro-5-fluoro-6-(5-isopropoxy-lH-pyrazol-3-ylamino)nicotinonitrile (Method 2; 1.6g, 5.0 mmol) and (i?)-2-amino-2-(4-fluorophenyl)ethanol (2.Og, 11.0 mmol) were added to a solution of n-BuOH (8 ml) and DIEA (0.8g, 6.0 mmol) in a sealed tube. The reaction was heated to 135 °C for 72 hrs, cooled to 25 °C, and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.7g, 31%). 1H NMR (400 MHz, CD3OD) δ 7.49 (d, J= 9.5 Hz, IH), 7.41-7.38 (m, 2H), 7.07-7.02 (m, 2H), 5.40 (s, IH), 5.10-5.01 (m, IH), 4.62-4.55 (m, IH), 3.91-3.79 (m, 2H), 1.33-1.31 (m, 6H). MS: Calcd.: 414; Found: [M+H]+ 415.
Example 12 (i?)-5-Fluoro-2-('l-('4-fluorophenyl)-2-hvdroxyethylainino)-6-f5-isopropoxy-lH'-pyrazol-3- ylamino'tøicotmamide
(i?)-5-Fluoro-2-(l-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-l//- pyrazol-3-ylamino)nicotinonitrile (Example 11; 0.06g, 0.1 mmol) was placed in MeOH (5 ml) at 25 °C. A 25% aqueous solution (0.2 ml) of KOH (0.05 g, 0.7 mmol) was then added, followed by the addition of 0.05 ml of 30% H2O2. The resulting dark red solution was heated to 65 0C for 1 h, cooled to 25 0C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.037g, 60%). 1HNMR (400 MHz, CD3OD) δ 7.75 (d, J= 11.9 Hz, IH), 7.43- 7.39 (m, 2H), 7.06-7.02 (m, 2H), 5.37 (br s, IH), 5.10-5.02 (m, IH), 4.60-4.54 (m, IH), 3.90- 3.86 (m, IH), 3.79-3.74 (m, IH), 1.32 (d, J= 6.0 Hz, 6H). MS: Calcd.: 432; Found: [M+H]+ 433.
Example 13 (i?)-2-('3-(Aminomethyl)-5-fluoro-6-('5-isopropoxy-lH'-pyrazol-3-ylamino)pyridin-2- ylamino)-2-(4-fluorophenyl*)ethanol
A solution of (i?)-5-fluoro-2-(l -(4-fluorophenyl)-2-hydroxyethylamino)-6-(5- isopropoxy-lH~pyrazol-3-ylamino)nicotinonitrile (Example 11; 0.6Og, 1.44 mmol), cone. HCl (0.3 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.3g) in MeOH (8 ml) was flushed with N2, evacuated, and then placed under of H2 (40 psi) for 6 hrs. The reaction was then evacuated, flushed with N2, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml) and treated with a saturated aqueous Na2CO3 solution (100 ml). The resulting mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.4Og, 66%). 1H NMR (400 MHz, CD3OD) δ 7.47-7.44 (m, 2H), 7.37 (d, J= 10.7 Hz, IH), 7.06-7.02 (m, 2H), 5.10-5.06 (m, IH), 4.57-4.51 (m, IH), 4.28 (d, J= 14.2 Hz, IH), 4.07 (d, J= 14.2 Hz, IH), 3.92-3.80 (m, 2H)5 1.32 (d, J= 3.7 Hz, 6H). MS: Calcd.: 418; Found: [M+H]+ 419.
Example 14 (i?VN-(f5-Fluoro-2-ri-f4-fluorophenylV2-hydroxyethylaniino)-6-('5-isopropoxy-lH-pyrazol- 3 -VIaIrLmO-)PVrJdJn-S - yl)methyl)acetamide
(i?)-2-(3-(Aminomethyl)-5-fluoro-6-(5-isopropoxy-l/i-pyrazol-3-ylamino)pyridin-2- ylamino)-2-(4-fluorophenyl)ethanol (Example 13; 0.175g, 0.42 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.42 mmol) were placed in a THF - DCM solution (1 : 1, 5 ml) at 0 0C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.075g, 39%). 1H NMR (400 MHz, CD3OD) δ 7.42-7.39 (m, 2H), 7.17 (d, J= 10.7 Hz, IH), 7.05-7.01 (m, 2H), 5.26 (s, IH), 5.02-4.95 (m, IH), 4.55-4.53 (m, IH), 4.36 (d, J= 15.0 Hz, IH), 4.22 (d, J= 15.0 Hz, IH), 3.84-3.72 (m, 2H), 2.01 (s, 3H), 1.31 (d, J= 6.0Hz, 6H). MS: Calcd.: 460; Found: [M+H]+ 461.
Example 15 (i?)-iV-((5-Fluoro-2-(l-(4-fluorophenyl)-2-hydroxyethylamino)-6-('5-isopropoxy-lH'-pyrazol- 3 -ylamino)p yridin-3 -yl)methyl)methanesulfonamide
A round bottom flask was charged with (i?)-2-(3-(aminomethyl)-5-fluoro-6-(5- isopropoxy- lH-pyrazol-3 -ylamino)pyridin-2-ylammo)-2-(4-fluorophenyl)ethanol (Example 13; O.lOg, 0.24 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.24 mmol), DIEA (0.062g, 0.48 mmol), DMAP (0.032g, 0.26 mmol), and TΗF (5 ml). The resulting suspension was shaken vigorously at 60 0C for 8 hrs and filtered. The resulting resin was washed with a TΗF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse- phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title coompound (0.075g, 63%). 1H NMR (400 MHz, CD3OD) δ 7.48-7.45 (m, 2H), 7.20 (d, J= 10.9 Hz, IH), 7.05-7.01 (m, 2H), 5.30 (s, IH), 5.04-5.01 (m, IH), 4.56-4.53 (m, IH), 4.20 (d, J= 14.4 Hz, IH), 4.12 (d, J= HA Hz, IH), 3.86-3.73 (m, 2H), 3.01 (s, 3H), 1.32 (d, J= 6.0 Hz, 3H). MS: Calcd.: 496; Found: [M+H]+ 497. Example 16 r5)-5-Fluoro-2-(l-(4-fluorophenyl>)ethylamino)-6-C5-isopropoxy-liJ'-pyrazol-3- ylamino)nicotinonitrile
2-Chloro-5-fluoro-6-(5-isopropoxy-lH'-pyrazol-3-ylaniino)nicotinonitrile (Method 2;
5 1.4g, 5.0 mmol) and (S)-l-(4-fluorophenyl)ethanamine (1.Og, 9.0 mmol) were added to a solution of «-BuOΗ (8 ml) and DIEA (0.8g, 6.0 mmol) in a sealed tube. The reaction was heated to 135 °C for 48 hrs, cooled to 25 0C, and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 80 : 1) to give the title compound (0.9Og, 48%). 1H NMR (400 MHz, CD3OD) δ 7.43 (d, J= 10.5 Hz5 IH), 7.39-7.35 (m, 2H),
LO 7.04-6.99 (m, 2H), 5.47 (s, IH)3 5.12-5.11 (m, IH), 4.60-4.51 (m, IH), 1.56 (d, J= 7.0 Hz, 3H), 1.33-1.30 (m, 6H). MS: Calcd.: 398; Found: [M+H]+ 399.
Example 17
(S)-5-Fluoro-2-(l-(4-fluorophenyl)e1hylamino)-6-(5-isopropoxy-l/Z'-pyrazol-3-
L 5 ylamino)nicotinamide
(5)-5-Fluoro-2-(l-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-lH-pyrazol-3- ylamino)nicotinonitrile (Example 16; 0.15g, 0.38 mmol), was placed in MeOH (7 ml) at 25 0C. A 25% aqueous solution (0.4 ml) of KOH (0.11 g, 1.9 mmol) was then added, followed by the addition of 0.1 ml of 30% H2O2. The resulting dark red solution was heated to
10 65 °C for Ih, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 25 : 1) to give the title compound (0.044g, 28%). 1H NMR (400 MHz, CD3OD) δ 7.75 (d, J= 11.7 Hz, IH), 7.39- 7.36 (m, 2H), 7.04-7.00 (m, 2H), 5.37 (s, IH), 5.11-5.00 (m, IH), 4.61-4.52 (m, IH), 1.53 (d,
>5 J= 7.0 Hz, 3H), 1.31 (m, 6H). MS: Calcd.: 416; Found: [M+H]+ 417.
Example 18
(^-3-(Aminomethyl)-5-fluoro-JV2-(l-(4-fluorophenyl)ethyl)-7V6-(5-isopropoxy-lH'-pyrazol-3- yl)pyridme-2,6-diamine
50 The mixture of (jS)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-l/Z- pyrazol-3-ylamino)nicotinonitrile (Example 16; 0.9Og, 2.26 mmol), cone. HCl (0.3 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.55g) in MeOH (20 ml) was flushed with N2, evacuated, and then placed under H2 (40 psi) for 6 hrs. The reaction was then evacuated, flushed with N2, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml) and treated with a saturated aqueous Na2CO3 solution (100 ml). The mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by reverse- phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.7g, 77%). 1H NMR (400 MHz, CD3OD) δ 7.45-7.41 (m, 2H), 7.35 (d, J= 10.9 Hz, IH), 7.03-6.99 (m, 2H)5 5.35 (s, IH), 5.09-5.04 (m, IH), 4.55-4.49 (m, IH), 4.18 (d, J= 14.2 Hz, IH), 4.08 (d, J= 14.2 Hz, IH), 1.59 (d, J= 6.8 Hz, 3H), 1.31 (d, J= 8.3 Hz, 6H). MS : Calcd. : 402; Found: [M+H]+ 403.
Example 19 dSl-N-((5-Fluoro-2-(l-('4-fluoroρhenyl)ethylammoV6-(5-isopropoxy-l/f-pyrazol-3- ylammo)pyridin-3-vDmethyr)acetamide (5)-3-(Aminomethyl)-5-fluoro-N2-(l-(4-fluoroρhenyl)ethyl)-Λ/6-(5-isoρropoxy-lH- pyrazol-3-yl)pyridine-2,6-diamine (Example 18; 0.2Og, 0.49 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.49 mmol) were placed in a THF - DCM solution (1 : 1, 6 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : I5 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (O.OlOg, 49%). 1H NMR (400 MHz, CD3OD) δ 7.37-7.34 (m, 2H), 7.14 (d, J= 10.9 Hz, IH)5 7.02-6.98 (m, 2H)5 5.25 (s, IH), 4.96-4.95 (m, IH)5 4.55-4.52 (m, IH)5 4.30 (d, J= 14.8 Hz5 IH), 4.21 (d, J= 14.8 Hz5 IH)5 2.01 (s, 3H)5 1.51 (d, J= 6.8 Hz5 3H)5 1.31 (d, J= 6.0 Hz5 6H). MS: Calcd.: 444; Found: [M+H]+ 445.
Example 20
(1Sl-N-(('5-Fluoro-2-(l-f4-fluorophenvπethylammo)-6-f5-isopropoxy-lH'-pyrazol-3- ylamino)pyridm-3-vDmethyl)methanesulfonamide A round bottom flask was charged with (5)-3-(aminomethyl)-5-fluoro-7V2-(l-(4- fluorophenyl)ethyl)-Λ/6-(5-isopropoxy-l/i'-pyrazol-3-yl)pyridine-256-diamine (Example 18; 0.1Og5 0.25 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.25 mmol), DIEA (0.064g, 0.50 mmol), DMAP (O.033g, 0.27 mmol), and THF (5 ml). The resulting suspension was shaken vigorously at 60 0C for 8 hrs and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give (0.82g, 67%). 1H NMR (400 MHz, CD3OD) δ 7.44-7.41 (m, 2H), 7.17 (d, J- 10.7 Hz, IH), 7.02-6.97 (m, 2H), 5.26 (s, IH), 5.01-4.99 (m, IH), 4.56-4.53 (m, IH), 4.16-4.08 (m, IH), 3.01 (s, 3H), 1.52 (d, J= 7.0 Hz, 3H), 1.31 (d, J= 6.0 Hz, 6H). MS: Calcd.: 480; Found: [M+H]+ 481.
Example 21 r^-S^-Dichloro-iv^-rS-cvclopropyl-lH-pyrazol-S-ylVΛ^-α-^-fluorophenvnethvnpyridine- 2,6-diamine
3,5,6-Trichloro-iV-(5-cyclopropyl-li7-pyrazol-3-yl)pyridin-2-amine (Method 3; 0.05g, 0.2 mmol) and (5)-l-(4-fluorophenyl)ethanamine (0.05g, 0.4 mmol) were dissolved in NMP (2 ml) with DIEA (0.03g, 0.22 mmol). The reaction was heated in a microwave at 200 0C for 30 min. The reaction was cooled to 25 °C, quenched with water (10 ml), and extracted with MTBE (4 x 30 ml). The combined organic fractions were then dried, filtered, and concentrated. The resulting solid was purified by reverse-phase column chromatography (5- 50% CH3CN in H2O over 400 ml) to give the title compound (0.008g, 11%). 1H NMR (400 MHz, CD3OD) δ 7.41 (s, IH)5 7.33-7.30 (m, 2H), 7.02-6.98 (m, 2H), 6.03 (s, 3H), 5.17 (q, J== 6.8 Hz5 IH), 2.02-1.98 (m, IH), 1.59 (d, J= 6.8 Hz, 3H), 1.21-1.65 (m, 2H)5 0.86-0.82 (m, 2H). MS: Calcd.: 406; Found: [M+H]+ 407.
Example 22
N-(5-Cyclopropyl-lH'-pyrazol-3-yl)-A^'-r(16r)-l-(4-fluorophenyl)ethvnpyridine-2,6-diamine tert-Butyl 5 -cy clopropyl-3 -[(6- {[(IS)- 1 -(4-fluorophenyl)ethyl] amino } pyridin-2- yl)amino]-lif-pyrazole-l-carboxylate (Method 21; 146mg) was dissolved in a solution of hydrogen chloride in ether (2.0 M, 2 ml, 4 mmol) and the reaction mixture was stirred at room temperature for 4 hours. The solvent was removed and semi-prep HPLC (Gilson) purification gave the title compound (37 mg, 25%). 1H NMR (CDCl3) δ 0.55 (m, 2H)5 0.70 (m, 2H)5 1.35 (m, 3H), 1.65 (m, IH), 4.53 (m, 2H), 4.91 (br s, IH)5 6.10 (br s, IH)5 6.70 (m, IH), 7.00 (m, 2H), 7.25 (m, 3H). Example 23 dSf)-2-Amino-N-((6-r5-cvclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-('l-(4- fluorophenyl)ethylamino)pyridin-3-vDmethvDacetamide
To a solution of tert-butyl (2-{[(6-[(5~cyclopropyl~lH-pyrazol~3-yl)amino]-5-fluoro- 2-{ [(1»S)-1 -(4-fluoroρhenyl)ethy 1] amino } pyridin-3 -yl)niethyl] amino } -2-oxoethyl)carbamate (Method 22; 0.035g, 0.065 mmol) in dioxane (4 ml), was added an HCl/dioxane solution (4.0 M, 30eq.). The resulting solution was stirred at 25 0C for 3 hrs. The reaction was then concentrated, re-dissolved in MeOH (0.5 ml), and quickly treated with ether (50 ml). The resulting solid was collected to give the HCl salt of the title compound (0.025g, 87%). 1H NMR (400 MHz, CD3OD) δ 7.60 (d, J= 10.7 Hz, IH), 7.47-7.44 (m, 2H), 7.07-7.03 (m, 2H), 5.78 (s, IH), 5.04 (q, J= 6.6 Hz, IH), 4.43-4.40 (m, 2H), 3.79 (s, 2H), 2.01-1.96 (m, IH), 1.66 (d, J= 6.6 Hz, 3H), 1.17-1.13 (m, 2H), 0.82-0.81 (m, 2H). MS: Calcd.: 441; Found: [M+H]+ 442.
Example 24 iV-rr6-('5-Cvclopropyl-lH-pyrazol-3-ylamino')-5-fluoro-2-rr6f)-l-r4- fluorophenyl)ethylamino)pyridin-3-yl)methyl')-5-oxopyrrolidine-2-carboxamide
A round bottom flask was charged with (iS)-3-(aminomethyl)-iV6-(5-cyclopropyl-li/- pyrazol-3-yl)-5-fluoro-7V2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.08g, 0.2 mmol), 5-oxopyrrolidine-2-carboxylic acid loaded TFP resin (1.4 mmol/g loading, 0.2 mmol), and a THF - DCM solution (3 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5- 50% CH3CN in H2O over 400 ml) to give the title compound (0.013g, 10%). 1H NMR (400 MHz, CD3OD) δ 7.41-7.32 (m, 2H), 7.21-7.13 (m, IH), 7.05-6.97 (m, 2H), 6.05 (s, IH), 5.21- 5.02 (m, IH), 4.34-4.19 (m, 3H), 2.44-2.28 (m, 3H), 2.11-1.98 (m, IH), 1.88-1.81 (m, IH), 1.51 (d, J= 5.2 Hz, 3H), 0.99-0.86 (m, 2H), 0.69-0.61 (m, 2H). MS: Calcd.: 495 Found: [M+H]+ 496. Example 25
JV4-(5-Cyclopropyl-lH'-pyrazol-3-yl)-N2-r('S)-l-f4-fluoro-phenyl)-ethyl1-pyridine-2,4-diamine
A mixture of (2-chloro-pyridin-4-yl)-(5-cyclopropyl-lH'-pyrazole-3-yl)-amine (Method 4; 0.116 g, 0.49 mmol), DIEA (0.20 ml, 1.18 mmol), and (,S)-l-(4-fluoro-phenyl)- ethylamine (1.0 ml, 7.4 mmol) was heated to 160 °C in a sealed tube for 2 days. The reaction mixture was concentrated under reduced pressure and purified by reverse-phase prep HPLC (column: mC-PACK- ODS-AQ, 250 x 20 nm, 3.0 x 50 mm; 5-95 % gradient MeCN (0.05% TFA) in water (0.1% TFA); flow rate: 10.0 ml/min). 1H NMR (400 MHz) δ 0.696 (m, 2H), 0.958 (m, 2H), 1.49 (m, 4H), 4.75 (q, IH), 5.60 (s, IH), 7.19 (t, 2H), 7.29 (t, IH), 7.42 (t, 3H)5 7.6 (s, IH), 9.89 (s, IH). MS: Calcd.: 337; Found: [M+H]+ 338.
Example 26 r^-J^-fS-Cvclopropyl-lH-pyrazol-S-vD-Λ^-α-^-fluorophenvnethylVS-nitropyridine^^- diamine A mixture of (5)-6-chloro-iV-( 1 -(4-fluorophenyl)ethyl)-3 -nitropyridin-2-amme
(Method 5; 1.74 g, 5.88 mmol), S-cyclopropyl-l/f-pyrazol-S-amine (0.91 g, 7.36 mmol), and DIEA (1.28 ml, 7.36 mmol) in rc-BuOH (10 ml) was heated in a sealed tube at 160 °C for 60 hrs. The solvent was removed under reduced pressure and the residue was purified by chromatography (hexane - EtOAc = 1 : 1) to give the title compound as a yellow solid (1.35 g, 60%). 1H NMR (400 MHz) δ 12.15 (s, IH), 10.43 (br, IH), 9.19 (br, IH), 8.12 (d, J= 9.2 Hz, IH), 7.45 (m, 2H), 7.17 (m, 2H), 6.25 (br, IH), 6.14 (br, IH), 5.45 (m, IH), 1.87 (m, IH), 1.60 (d, J= 6.8 Hz, 3H), 0.95 (m, 2H), 0.65 (m, 2H). MS: Calcd.: 382; Found: [M+H]+ 383.
Examples 27-30 Following a similar procedure to Example 26, the following compounds were synthesized from a chloronitropyridine by reacting it with an amine.
Figure imgf000061_0001
Figure imgf000062_0001
Example 31
(^-Λ^-(5-Cvclopropyl-lH-pyrazol-3-yl)-iV'2-ri-(4-fluorophenyl)ethvDpyridine-2,3,6-triamine
To a suspension of (5)-i\^-(5-cyclopropyl-li7-pyrazol-3-yl)-iV2-(l-(4- fluorophenyl)ethyl)-3-nitropyridine-2,6-diamine (Example 26; 0.40 g, 1.05 mmol) and zinc dust (0.342 g, 5.23 mmol) in MeOH - THF (1 : 1, 16 ml) was slowly added a saturated aqueous ammonium chloride solution (2.5 ml). The mixture was stirred at 25 0C for 1 hr, then treated with saturated ammonium acetate solution (4 ml). The resulting mixture was stirred for another 30 min. The Zn dust was removed by filtration and the cake was washed with EtOAc (20 ml). The organic layer was separated, washed with brine (10 ml), and dried over Na2SO4. Removal of the solvent gave the title compound at quantitative yield. 1H NMR (400 MHz) δ 11.5 (br, IH), 7.98 (br, IH), 7.43 (m, 2H), 7.07 (m, 2H), 6.67 (d, J= 8 Hz, IH), 6.09 (s, IH), 5.63-5.70 (m, 2H), 5.19 (m, IH), 4.04 (br, 2H), 1.77 (m, IH), 1.46 (d, J= 6.8 Hz, 3H), 0.85 (m, 2H), 0.59 (m, 2H). MS: Calcd.: 352; Found: [M+H]+ 353.
Examples 32-35
Following a similar procedure to Example 31, the following compounds were synthesized from a nitropyridine by reacting it with zinc dust.
Figure imgf000062_0002
Figure imgf000063_0001
Example 36
(^-S-Chloro-A^-fS-cvclopropyl-lH-pyrazol-S-ylVΛ^-q-^-fluorophenvnethylVS- nitropyridin-2,6-diamine
A mixture of (5)-5,6-chloro-N-(l-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amme (Method 13; 0.61 g, 79% pure, 1.46 mmol), S-cyclopropyl-lif-pyrazol-S-amine (0.27 g, 2.19 mmol), and DIEA (0.38 ml, 2.19 mmol) in n-BuOH (5 ml) was heated in a sealed tube at 100 °C for 48 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc = 2 : 1) to give the title compound as a yellow solid (0.57 g, 94%). NMR (400 MHz) 12.34 (s, IH), 9.34 (s, IH), 8.93 (d, J= 7.6 Hz, IH), 8.26 (s, IH), 7.32 (m, 2H), 7.12 (m, 2H), 6.01 (s, IH), 5.29 (m, IH), 1.91 (m, IH), 1.56 (d, J= 7.2 Hz, 3H), 0.96 (m, 2H), 0.65 (m, 2H). MS: Calcd.: 416; Found: [M+H]+ 417.
Examples 37-40 Following a similar procedure to Example 36, the following compounds were synthesized from a chloronitropyridine by reacting it with an amine.
Figure imgf000064_0001
Example 41
(,Sf)-5-Chloro-N5-('5-cvclopropyl-lH"-pyrazol-3-ylViV3-α-r4-fluorophenvDetlivDpyridine-2.3.6- triamine
To a suspension of (5)-3-chloro-iV2-(5-cyclopropyl-lH'-pyrazol-3-yl)-iV6-(l-(4- fluorophenyl)ethyl)-5-nitropyridin-2,6-diamine (Example 36; 0.57 g, 1.37 mmol) and zinc dust (0.447 g, 6.84 mmol) in MeOH : THF (1 : 1, 24 ml) was slowly added saturated ammonium chloride solution (3.5 ml). The reaction mixture was stirred at 25 °C for 2 hours, followed by addition of saturated ammonium acetate solution (5 ml). The resulting mixture was stirred for another 30 minutes. Zn dust was removed by filtration and washed with EtOAc (20 ml). The organic layer was separated, washed with brine (10 ml), dried over Na2S04and the solvent removed to give the title compound. MS: Calcd.: 386; Found: [M+H]+ 387.
Examples 42-45
Following a similar procedure to Example 41, the following compounds were synthesized from a nitropyridine by reacting it with zinc dust.
Figure imgf000065_0001
Example 46
(6r)-6-(5-Cvclopropyl-l/f-pyrazol-3-ylamino)-5-fluoro-2-('l-(4-fluorophenyl)ethylamino^ nicotinic acid
(5)-6-(5-Cyclopropyl-l/f-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)nicotinamide (Example 2; l.Og, 2.5 mmol) was dissolved in a 10% aqueous EtOH solution (10 ml) at 25 0C, followed by addition of solid KOH (2.8g, 50.0 mmol). The reaction solution was heated to 95 °C for 4 days, cooled to 25 °C, and extracted with DCM (2 x 50 ml). The aqueous layer was then acidified to pH 3. The resulting solid W 2
65
(0.55 g), was collected by filtration and dried under vacuum to give the title compound. MS: Calcd.: 399; Found: [M+H]+ 400.
Example 47 r^-N2-r5-Cvcloρropyl-lH"-pyrazol-3-ylViV^-ri-r4-fluoroρhenyl')ethylV3-nitroρyridine-2,6- diamine
A mixture of 6-chloro-iV-(5-cyclopropyl-lH"-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 16; 0.30 g, 1.07 mmol), (5)-l-(4-fluoro-ρhenyl)-ethylamine (0.23 g, 1.61 mmol), and DIEA (0.23 ml, 1.34 mmol) in rc-BuOH (5 ml) was heated in a sealed tube at 165 °C for 18 hrs. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.41 g, 99%). 1HNMR (400 MHz) δ 12.22 (s, IH), 10.98 (s, IH), 8.70 (d, J= 7.2 Hz, IH), 8.10 (d, J = 9.2 Hz, IH), 7.39 (m, 2H), 7.18 (m, 2H), 6.22 (d, J= 9.2 Hz, IH), 6.17 (s, IH), 5.27 (m, IH), 1.89 (m, IH), 1.52 (d, J= 6.4 Hz, 3H), 0.95 (m, 2H), 0.64 (m 2H). MS: Calcd.: 382; Found: [M+H]+ 383.
Examples 48-50
Following a similar procedure to Example 47, the following compounds were synthesized from 6-chloro-iV-(5-cyclopropyl- lH-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 16) and the appropriate amine.
Figure imgf000066_0001
Figure imgf000067_0001
Example 51 f5V3-Chloro-iV'?-f 5-cvclopropyl- lH-pyrazol-3-vD-iV2-r 1 -f4-fluorophenyr)ethvH-5- nitropyridm-2,6-diamine
A mixture of 5,6-chloro-iV-(5-cyclopropyl-lH'-pyrazol-3-yl)-3-nitropyridme-2-amine (Method 17; 0.26 g, 0.83 mmol), (1S)-l-(4-fluoro-phenyl)ethylamine (0.17 g, 1.25 mmol), and DIEA (0.22 ml, 1.25 mmol) in rc-BuOH (5 ml) was heated in a sealed tube at 165 0C for 3 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc = 1 : 1) to give the title compound as a yellow solid (0.34 g, 99%). NMR (400 MHz) 12.29 (s, IH), 10.68 (s, IH), 8.27 (s, IH), 8.24 (d, J= 8.0 Hz, IH), 7.39 (m, 2H), 7.16 (m, 2H), 6.11 (s, IH), 5.42 (m, IH), 1.89 (m, IH), 1.60 (d, J= 7.2 Hz, 3H), 0.95 (m, 2H), 0.61 (m, 2H). MS: Calcd.: 416; Found: [M+H]+ 417.
Examples 52-54 Following a similar procedure to Example 51 , the following compounds were synthesized from the appropriate starting material and amine.
Figure imgf000068_0001
Example 55
GSViVVS-Cvclopropyl- lH-pyrazol-3 -vD-A^-F 1 -f4-fluorophenyr)ethyl1pyridine-2,3 ,6-triamine
To a suspension of (5)-iV2-(5-cyclopropyl-l/i-pyrazol-3-yl)--Vϊ-[l-(4- fluorophenyl)ethyl]-3-nitropyridine-2,6-diamine (Example 47; 0.26 g, 0.68 mmol) and zinc dust (0.223 g, 3.41 mmol) in MeOH : TΗF (1 : 1, 12 ml) was slowly added saturated ammonium chloride solution (1.5 ml). The reaction mixture was stirred at 25 °C for 1 hour, to which was then added saturated ammonium acetate solution (5 ml). The resulting mixture was stirred for another 30 minutes. Zn dust was removed by filtration and washed with EtOAc (20 ml). The organic layer was separated, washed with brine (10 ml), dried over Na2SO4, and concentrated to give the title compound.
Examples 56-62
Following a similar procedure to Example 55, the following compounds were synthesized from a suitable nitro-pyridine.
Figure imgf000069_0001
Example 63
N-r5-Cyclopropyl-l/i'-pyrazol-3-yl)-JV'-(4-fluorobenzyl>)pyridine-2,6-diamme To a flask was added Pd(OAc)2 (22.4 mg, 0.1 mmol), (biphenyl-2- ylmethylene)bis(dimethylphosphine) (60 mg, 0.2 mmol) and sodium tert-butoxide (240 mg, 2.5 mmol). The flask was sealed and refilled with N2. To the mixture was added a solution of 6-bromo-N-(4-fluorobenzyl)pyridin-2-amine (Method 19; 281 mg, 1.0 mmol) and 5- cyclopropyl-lH-pyrazol-3 -amine (123 mg, 1.0 mmol) in toluene (5 ml). The reaction mixture was heated at 110°C overnight. The solvent was removed and EtOAc was added and the mixture was washed with brine and was concentrated. Semi-prep HPLC (Gilson) purification gave the title compound (6.4 mg, 2%). 1H NMR (CDCl3) δ 0.65 (m, 2H), 0.95 (m, 2H), 1.80 (m, IH), 4.43 (m, 2H), 4.91 (br s, IH), 5.60 (br s, IH), 5.80 (m, IH), 6.18 (m, IH), 6.73 (m, IH), 7.00 (m, 2H), 7.25 (m, 3H).
Example 64 r>Sf)-5-Chloro-6-r5-cyclopropyl-lH'-pyrazol-3-ylammo)-2-('l-r5-fluoropyridin-2- vDethylamino)nicotinonitrile
A solution of 2,5-dichloro-6-(5-cyclopropyl-lH"-pyrazol-3-ylamino)nicotinonitrile (Method 43, 0.60 g, 2.04 mmol), DIEA (0.34 g, 2.65 mmol), and (£)-l-(5-fluoropyridin-2- yl)ethanamine (Method 33; 0.90 g, 6.12 mmol) in ra-BuOH was heated tol20 0C for 9 hours. The reaction was then cooled to room temperature, diluted with water (20 ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.42 g, 52%). 1H NMR (400 MHz, CD3OD) δ 8.42 (d, J= 2.7 Hz, IH), 7.61 (s, IH), 7.51-7.49 (m, IH), 7.38-7.32 (m, IH), 6.06 (br s, IH), 5.28-5.22 (m, IH), 1.94-1.88 (m, IH), 1.58 (d, J= 6.9 Hz, 3H), 1.01 (br s, 2H), 0.76-0.75 (m, 2H). MS: Calcd.: 397; Found: [M+H]+ 398.
Example 65
^-A^-rS-Cvclopropyl-lH-pyrazol-S-vD-S-fluoro-A^-ri-^-fluorophenvDethylVS- nitropyridine-2,6-diamine
To a solution of (5)-5,6-difluoro-iV-(l-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 23, 0.6Og, 2.0mmol) in THF (10ml) at room temperature was added 5-cyclopropyl- lH-pyrazol-3 -amine (0.5Og, 4.0mmol), and DIEA (0.26g, 2.0mmol). The reaction was then heated to 55 0C for 24 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.53 g, 66%). 1H NMR (400 MHz, CD3OD) δ 8.00 (d, J= 11. IHz, IH), 7.38-7.35 (m, 2H), 7.07-7.02 (m, 2H), 6.17 (s, IH)5 5.41-5.39 (m, IH), 1.93-1.87 (m, IH), 1.61 (d, J= 7.0Hz, 3H), 1.02-1.00 (m, 2H), 0.69-0.66 (m, 2H). MS: Calcd.: 400; Found: [M+H]+ 401.
Example 66 r^-S-Fluoro-A^-ri-^-fluorophenvDethylVA^-rS-isoproDoxy-lH-pyrazol-S-ylVS- nitropyridine-2,6-diamine
To a solution of (6)-5,6-difluoro-N-(l-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 23; 0.60 g, 2.0 mmol) in THF (10 ml) at room temperature was added 5-isopropoxy- lH-pyrazol-3 -amine (0.50 g, 3.0 mmol), and DIEA (0.29 g, 2.2 mmol). The reaction was then heated to 55 0C for 24 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.34 g, 40%). 1H NMR (400 MHz, CD3OD) δ 8.00 (d, J= 10.9 Hz, IH), 7.45-7.35 (m, 2H), 7.07-7.03 (m, 2H), 5.88- 5.71 (m, IH), 5.48-5.30 (m, IH), 4.58-4.29 (m, IH), 1.68-1.56 (m, 3H), 1.34-1.28 (m, 6H). MS: Calcd.: 418; Found: [M+H]+ 419.
Example 67
(■RN)-2-(6-(5-Cvclopropyl-liJr-pyrazol-3-ylamino)-5-fluoro-3-nitropyridin-2-ylamino)-2-(4- fluorophenvDethanol
To a solution of (5)-2-(5,6-difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) ethanol (Method 25, 0.40 g, 1.3 mmol) in THF (10 ml) at room temperature was added 5- cyclopropyl-li7-pyrazol-3 -amine (0.31 g, 2.6 mmol), and DIEA (0.18 g, 1.4 mmol). The reaction was then heated to 55 0C for 12 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.45 g, 85%). 1H NMR (400 MHz, CDCl3) δ 10.84 (s, IH), 8.02 (d, J= 10.7 Hz, IH), 7.35-7.31 (m, 2H), 7.10-7.06 (m, 2H), 6.21-6.19 (m, IH), 5.80 (br s, IH), 4.07 (dd, J= 11.3, 3.9 Hz, IH), 3.99 (dd, J= 11.3, 6.4 Hz, IH), 1.88-1.86 (m, IH), 1.62 (br s, IH), 0.98-0.95 (m, 2H), 0.70-0.68 (m, 2H). MS: Calcd.: 416; Found: [M+H]+ 417. Example 68 ri?)-2-(5-Fluoro-6-('5-metliyl-l/j'-pyrazol-3-ylammo)-3-nitropyridin-2-ylamino)-2-r4- iluorophenvDethanol
To a solution of (5)-2-(5,6-difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) ethanol (Method 25; 0.60 g, 1.9 mmol) in THF (10 ml) at room temperature was added 5- methyl-lH-pyrazol-3-amine (0.37 g, 3.8 mmol), and DIEA (0.27 g, 2.1 mmol). The reaction was heated to 55 0C for 12 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 :1) to give the title compound (0.51 g, 68%). 1H NMR (400 MHz, CDCl3) δ 10.85 (br s, IH), 8.02 (d, J= 10.5 Hz, IH), 7.34-7.31 (m, 2H), 7.10-7.06 (m, 2H), 6.26-6.25 (m, IH), 5.86 (br s, IH), 5.30-5.27 (m, IH), 4.07 (dd, J= 11.3 and 3.9 Hz, IH), 3.97 (dd, J= 11.1, 6.2 Hz, IH), 2.27 (s, 3H), 1.61 (br s, IH). MS: Calcd.: 390; Found: [M+H]+ 391.
Example 69 r^-S-Chloro-Λ^-Cl-^-fluorophenvDethylVA^-CS-isopropoxy-lH-pyrazol-S-ylVS- nitropyridine-2,6-diamine
A mixture of 5,6-dichloro-N-(5-isopropoxy-lH-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 26, 0.25 g, 0.75 mmol), («S)-l-(4-fiuoro-ρhenyl)-ethylarnme (0.13 g, 0.90 mmol) and DIEA (0.16 ml, 0.94 mmol) in rc-BuOH (3 ml) was heated in a sealed tube at 145 °C for 4 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.32 g, 98%). 1U NMR (400 MHz) δ 12.16 & 11.72 (s, IH), 10.64 &10.58 (s, IH), 8.30 (m, 2H), 7.37 & 7.31 (m, 2H), 7.16 & 7.08 (m, 2H), 5.81 & 5.71 (s, IH), 5.48 & 5.33 (m, IH), 4.60 & 4.21 (m, IH), 1.61 &1.57 (d, J= 6.8 Hz, 3H), 1.25 (m, 6H). MS: Calcd.: 434; Found: [M+H]+ 435.
Example 70 (>Sr)-3-Chloro-A^-ri-r4-fluorophenvnethylVN2-r5-isopropoxy-lH"-pyrazol-3-ylV5- nitropyridine-2,6-diamine
A mixture of 3,6-dichloro-iV-(5-isopropoxy-lH-pyrazol-3-yl)-5-nitropyridin-2-amme (Method 27, 0.25 g, 0.75 mmol), (S)-l-(4-fluoro-phenyl)-ethylamme (0.13 g, 0.90 mmol) and DIEA (0.16 ml, 0.94 mmol) in n-BuOH (3 ml) was heated in a sealed tube at 145 °C for 2 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.32 g, 98%). 1H NMR (400 MHz) δ 12.22 & 11.40 (s, IH), 9.74 & 9.37 (s, IH), 8.93 (d, J= 7.6 Hz, IH), 8.33 & 8.27 (s, IH), 7.34 & 7.27 (m, 2H), 7.12 & 7.05 (m, 2H), 5.75 & 5.62 (s, IH), 5.35 & 5.25 (m, IH), 4.66 & 4.03 (m, IH), 1.55 (d, J= 6.4 Hz, 3H), 1.29 (d, J= 6.0 Hz, 6H). MS: Calcd.: 434; Found: [M+H]+ 435.
Example 71 f^-A/6-(l-(4-FluorophenvπethylVN2-r5-isoproρoxy-lH-pyrazol-3-ylV3-nitropyridine-2,6- diamine
A mixture of 6-chloro-N-(5-isopropoxy-lH-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 28, 0.33 g, 1.1 mmol), (5)-l-(4-fluoro-phenyl)-ethylamine (0.16 g, 1.2 mmol) and DIEA (0.21 ml, 1.2 mmol) in rc-BuOH (3 ml) was heated in a sealed tube at 165 0C for 4 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.43 g, 97%). 1H NMR (400 MHz) δ 12.09, 12.05 & 11.64 (s, IH), 10.94, 10.87 & 10.72 (s, IH), 8.98, 8.76 & 8.70 (d, J= 7.6 Hz, IH), 8.16 & 8.11 (d, J= 9.6 Hz, IH), 7.40-7.33 (m, 2H), 7.22-7.10 (m, 2H), 6.25 & 6.04 (d, J= 9.6 Hz, IH), 6.23 & 5.86 (d, J= 13.6 Hz, IH), 5.31, 5.21 & 4.89 (m, IH), 4.71, 4.59 & 4.27 (m, IH), 1.52 (m, 3H), 1.26 (m, 6H). MS: Calcd.: 400; Found: [M+H]+ 401.
Example 72
(>y)-N-(T6-r5-Cvclopropyl-liJ'-pyrazol-3-ylammo)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino') pyridin-3-yl)methyl)-2-moφholinoacetamide
A solution of (5)-3-(aminomethyl)-iV6-(5-cyclopropyl-lH-pyrazol-3-yl)-5-fluoro-iV2- (l-(4-fluoroρhenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.16 g, 0.42 mmol), 2- morpholinoacetic acid (0.06 g, 0.42 mmol), HBTU (0.16 g, 0.42 mmol) and DIEA (0.16 g, 1.2 mmol) in DCM (3 ml) was stirred at room temperature for 1 hour. The reaction was then quenched with a saturated aqueous solution OfNaHCO3, and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.02 g, 10%). 1H NMR (400 MHz, CD3OD) δ 7.35 (br s, 2H), 7.17 (br s, IH), 7.01-6.97 (m, 2H), 6.06 (br s, IH), 5.16-4.99 (m, IH), 4.30 (br s, 2H), 3.68 (br s, 4H), 3.06 (br s, 2H), 2.48 (br s, 4H), 1.87-1.82 (m, IH), 1.51 (d, J= 6.4 Hz, 3H), 0.91 (br s, 2H), 0.64 (br s, 2H). MS: Calcd.: 511; Found: [M+H]+ 512.
Example 73
(6^-6-("5-Cyclopropyl-lH'-pyrazol-3-ylammoV5-fluoro-2-(l-(4-iluorophenyl)ethylarnino) nicotinaldehyde
((S)-6-(5-Cyclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl) ethylamino)nicotinonitrile (Example 1, 0.4 g, 1.1 mmol) was dissolved in the mixture pyridine-acetic acid-water (1 : 1 : 1, 18 ml total volume) at room temperature, to which was added Raney nickel (0.09 g, 1.1 mmol). The reaction was purged with nitrogen, evacuated, and then placed under hydrogen filled balloon for 18 hours. The reaction mixture was flushed with nitrogen, and filtered to remove the catalyst, which was washed with MeOH (30 ml). The filtrate was then extracted with DCM (5 x 50 ml), washed with aq. NaHCO3, and purified by reverse phase column chromatography (5-30% ACN) to give the title compound (0.18 g, 45%). 1H NMR (400 MHz, CD3OD) δ 9.40 (s, IH), 7.45 (d, J= 10.4 Hz, IH), 7.34-7.31 (m, 2H), 7.05-7.01 (m, 2H), 6.11 (s, IH), 5.26 (s, IH), 1.92-1.86 (m, IH), 1.55 (d, J= 7.0 Hz, 3H)5 1.00-0.98 (m, 2H), 0.71-0.64 (m, 2H). MS: Calcd.: 383; Found: [M+H]+ 384.
Example 74
C$f)-(6-(5-Cvclopropyl-lH-pyrazol-3-ylaminoV5-fluoro-2-(l-(4-fluorophenyl')ethylamino) pyridin-3 -ypmethanol
To a solution of (5)-6-(5-cyclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)nicotinaldehyde (Example 73; 0.10 g, 0.26 mmol) in MeOH (5 ml) at 0 0C was added NaBH4 (0.012 g, 0.33 mmol). The reaction was stirred for 10 minutes, and then quenched with water and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.088 g, 88%). 1H NMR (400 MHz, CD3OD) δ 7.42-7.39 (m, 2H), 7.16-7.01 (m, IH), 7.01 (br s, 2H), 6.06-5.41 (m, IH), 5.19-5.02 (m, IH), 4.52 (br s, 2H), 1.88-1.81 (m, IH), 1.53 (d, J = 6.6 Hz, 3H), 0.97-0.91 (m, 2H), 0.65 (br s, 2H). MS: Calcd.: 385; Found: [M+H]+ 386. W
74
Example 75
CS^-JV2-r5-Cvclopropyl-lH-ρyrazol-3-vn-3-fluoro-7V6-('l-r4-fluorophenvnethvn-5- fmorpholinomethyl)pyridine-2,6-diamine
To a solution of (S)-6-(5-cyclopropyl-7H-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.12 g, 0.31 mmol) in DCE (5 ml) was added morpholine (0.1 g, 1.14 mmol) and NaBH(OAc)3 (0.30 g, 1.5 mmol). The reaction was then stirred for 2 days, quenched with aq. Na2CO3 (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-35% ACN) to give the title compound (0.09 g, 67%). 1H NMR (400 MHz, CD3OD) δ 7.41 (br s, 2H), 7.06-7.02 (m, 3H), 6.13 & 5.44 (s, IH), 5.12 & 4.97 (s, IH), 3.63 (br s, 4H), 3.42 (br s, 2H), 2.41 (br s, 4H), 1.87-1.82 (m, IH), 1.54 (d, J= 6.5 Hz, 3H), 0.96-0.90 (m, 2H), 0.65- 0.64 (m, 2H). MS: Calcd.: 454; Found: [M+H]+ 455.
Example 76
(i?')-2-(4-FluorophenylV2-(6-(5-methyl- lH~-pyrazol-3 -ylamino)-3 -nitropyridin-2- ylaminoiethanol
A mixture of (i?)-2-(6-chloro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) ethanol (Method 29, 0.36 g, 1.2 mmol), 5-methyl-lH"-pyrazol-3 -amine (0.14 g, 1.4 mmol), and DIEA (0.25 ml, 1.4 mmol) in rc-BuOΗ (5 ml) was heated in a sealed tube at 90 °C for 6 days. The solvent was removed under reduced pressure and the residue was purified by column chromatography (EtOAc) to give the title compound as a yellow solid (0.31 g, 73%). 1H NMR (400 MHz) δ 12.06 (s, IH), 10.40 (br, IH), 9.58 (br, IH), 8.11 (d, J= 9.2 Hz, IH), 7.40 (m, 2H), 7.16 (m, 2H), 6.20 (br, IH), 6.02 (s, IH), 5.29 (br, IH), 5.24 (t, J= 4.4 Hz, IH), 3.85 (m, IH), 3.74 (m, IH), 2.20 (s, 3H). MS: Calcd.: 372; Found: [M+H]+ 373.
Example 77
(61-N2-(l-(4-Fluorophenyl)ethvπ-7V6-r5-isopropoxy-lH'-pyrazol-3-yl)-3-nitropyridme-2,6- diamine A mixture of (iS)-6-chloro-N-(l -(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine
(Method 30, 1.08 g, 3.7 mmol), 5-isopropoxy-lH"-pyrazol-3-amme (0.57 g, 4.0 mmol), and DIEA (0.80 ml, 4.6 mmol) in /z-BuOH (10 ml) was heated in a sealed tube at 115 °C for 72 hours. The solvent was removed under reduced pressure and the residue was purified by chromatography (hexane-EtOAc = 3 : 1) to give the title compound as a yellow solid (0.32 g, 22%). MS: Calcd.: 400; Found: [M+H]+ 401.
Example 78 (J?V2-('4-FluorophenvD-2-r6-('5-isopropoxy-lH'-pyrazol-3-ylamino)-5-nitropyridin-2- ylamino)ethanol
A mixture of 6-chloro-iV-(5-isopropoxy-lH-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 28; 0.25 g, 0.84 mmol), (2?)-2-amino-2-(4-fluoroρhenyl)ethanol (0.15 g, 0.97 mmol) and DIEA (0.16 ml, 0.92 mmol) in n-BuOH (3 ml) was heated in a sealed tube at 165 °C for 4 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 2) to give the title compound as a yellow solid (0.30 g, 87%). 1H NMR (400 MHz) δ 12.12, 12.10 & 11.61 (s, IH), 10.94, 10.89 & 10.74 (s, IH), 9.05, 8.82 & 8.73 (d, J= 7.2 Hz, IH), 8.13 & 8.11 (d, J= 9.2 Hz, IH), 7.45-7.32 (m, 2H), 7.20-7.10 (m, 2H), 6.32 & 6.07 (d, J= 9.2 Hz, IH), 5.90, 5.83 & 5.79 (s, IH), 5.23, 5.12 & 4.78 (m, 2H), 4.71, 4.64 & 4.37 (m, IH), 3.69 (m. 2H), 1.34 & 1.29 (d, J= 6.0 Hz, 6H). MS: Calcd.: 416; Found: [M+H]+ 417.
Example 79
(5f)-iV-((6-(5-Cvclopropyl-liJr-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl')ethylammo') pyridin-3-yl)methyl)isoxazole-5-carboxamide
To a solution of (5)-3-(aminomethyl)-iV6-(5-cyclopropyl-lH"-pyrazol-3-yl)-5-fluoro- iV2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.08 g, 0.21 mmol) in DCM- THF mixture (1 : 1, 4 ml) at 0 0C was added 1.0 eq. of isoxazole-5-carboxylic acid loaded TFP resin. The resulting mixture was stirred vigorously for 1 hour at 00C, and then filtered. The remaining resin was then washed with DCM-THF (1 : 1, 2 x 10 ml portions) for 30 min, and then filtered. The combined filtrates were concentrated, and the resulting oil was purified by column chromatography to give the title compound (3.4 mg, 4%). MS: Calcd.: 479; Found: [M+H]+ 480.
Example 80-103
The following compounds were prepared by the procedure similar to that of Example 79 using (5)-3 -(aminomethyl)-iV6-(5-cyclopropyl- lH-pyrazol-3 -yl)-5-fluoro-N2-(l -(4- fluorophenyl)ethyl)pyridme-2,6-diamine (Example 3) and a TFP resin loaded reagent.
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Example 104 ffl-2-Ammo-N-rf6-r5-cvclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-rr>Sl)-l-(4- fluorophenyl')ethylammo)pyridin-3-yl')methyl)-3-methγlbutanamide A solution of (ιS)-3-(aminomethyl)-Λ/6-(5-cyclopropyl-lH"-pyrazol-3-yl)-5-fluoro-Λ/2-
(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.10 g, 0.26 mmol), (S)-2-(tert- butoxycarbonylamino)-3-methylbutanoic acid (0.06 g, 0.26 mmol), and HBTU (0.10 g, 0.26 mmol) in DCM (3 ml) was stirred at room temperature for 1 hour. The reaction was then quenched with a saturated aqueous solution OfNaHCO3, and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was then passed through a silica plug. The resulting foam was placed in dioxane (4 ml) and 4 M HCl in dioxane (ImI) was then added, and the reaction was stirred for 3 hours. The reaction was then concentrated to give a solid which was dissolved in a minimal amount of MeOH (0.5ml) with stirring, followed by fast addition of ether (50 ml). The resulting solid was filtered, washed with ether, and dried to give the title compound (0.033 g, 26%). 1H NMR (400 MHz, CD3OD) δ 7.58 (d, J= 10.7 Hz, IH), 7.49-7.46 (m, 2H), 7.07-7.02 (m, 2H), 5.80 (s, IH)5 5.09-5.04 (m, IH), 4.58 (dd, J= 15.4, 6.8Hz5 IH)54.26 (dd, J= 15.4, 5.2 Hz5 IH), 3.71 (d, J= 6.0 Hz5 IH)5 2.23-2.18 (m5 IH), 2.01-1.97 (m, IH)5 1.63 (d, J= 6.8 Hz5 3H), 1.19- 1.13 (m, 2H)5 1.05-1.03 (m5 6H)5 0.85-0.81 (m, 2H). MS: Calcd.: 483; Found: [M+H]+ 484. Example 105 rS',E)-N2-f5-Cvclopropyl-lH-pyrazol-3-ylV5-('(cvclopropylimino)methylV3-fluoro-A/6-(l-('4- fluorophenyl)ethyl)pyridine-2,6-diamine
To a solution of (iS)-6-(5-cyclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.10 g, 0.26 mmol) in THF (5 ml) was added cyclopropanamine (0.03 g, 0.52 mmol) and NaBH(OAc)3 (0.55 g, 0.26 mmol). The reaction was stirred for 3 hours, quenched with aqueous Na2CO3 (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5-35% ACN) to give the title compound (0.068 g, 62%). 1H NMR (400 MHz) δ 11.92 (s, IH), 9.62 (s, IH), 8.93 (s, IH), 8.35 (s, IH)5 7.39 (d, J= 7.4 Hz, IH), 7.31-7.27 (m, 2H), 7.16-7.11 (m, 2H), 6.10 (s, IH), 5.13-5.10 (m, IH), 2.96-2.94 (m, IH), 1.89-1.80 (m, IH), 1.42 (d, J= 6.9 Hz, 3H), 0.98-0.88 (m, 2H), 0.76-0.63 (m, 2H). MS: Calcd.: 422; Found: [M+H]+ 423.
Example 106
(SVN2-(5-Cvclopropyl-lH-pyrazol-3-ylV3-fluoro-N6-α-C4-fluorophenvnethyl)ρyridine-2.6- diamine
A mixture of N-(5-cyclopropyl-lH'-pyrazol-3-yl)-3,6-difluoropyridm-2-amine
(Method 31, 0.10 g, 0.42 mmol) and (5)-l-(4-fluorophenyl)ethanamine (0.3 g, 2.2 mmol) were heated to 185 0C under microwave conditions (30 min x 3 cycles). The resulting dark oil was purified by column chromatography (DCM-MeOH = 80 : 1) to give the title compound
(0.04 g, 26%). 1H NMR (400 MHz, CD3OD) δ 7.08-6.99 (m, 3H)5 6.67-6.62 (m, 2H), 6.22
(dd, J= 8.9, 2.3 Hz5 IH), 5.04 (s, IH)5 4.64-4.59 (m, IH)5 1.16-1.12 (m, 4H)5 0.30-0.14 (m,
3H)5 0.04-0.02 (m, IH). MS: Calcd.: 355; Found: [M+H]+ 356.
Example 107
(^-A^-CS-Cvclopropyl-lH-pyrazol-S-ylVS-fiuoro-A^-ri-^-fluorophenvDethylVS-
((methylamino^methvDpyridme-2,6-diamine
To a solution of (S)-6-(5-cyclopropyl-lH-pyrazol-3-ylammo)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.10 g, 0.26 mmol) in THF (5 ml) was added methylamine (2.0 M in THF5 0.52 mmol) and NaBH(OAc)3 (0.82 g, 0.39 mmol).
The reaction was stirred for 3 hours, quenched with water, and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting crude imine was dissolved in MeOH (5 ml) and NaBH4 (0.06 g, 0.4 mmol) was added. The reaction was stirred for 10 min, quenched with aq. Na2CO3 (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5- 35% ACN) to give the title compound (0.05 g, 48%). 1H NMR (400 MHz, CD3OD) δ 7.41- 7.38 (m, 2H), 7.10 (d, J= 9:2 Hz, IH), 7.02-6.98 (m, 2H), 6.00-5.52 (br s, IH), 5.05(s, IH), 3.63 (s, 2H), 2.37 (s, 3H), 1.87-1.82 (m, IH), 1.51 (d, J= 6.9 Hz, 3H), 0.93-0.91 (m, 2H), 0.67-0.63 (m, 2H). MS: Calcd.: 398; Found: [M+H]+ 399.
Example 108
(i?)-6-(5-Cvclopropyl-liJr-pyrazol-3-ylamino)-5-fluoro-2-('l-(4-fluoroρhenyl)ethylammo) nicotinonitrile
A solution of 2-chloro-6-(5-cyclopropyl- lH-pyrazol-3-ylamino)-5-fluoro nicotinonitrile (Method 1, 0.3 g, 1.0 mmol) and (i?)-l-(4-fluorophenyl)ethanamine (0.3 g, 2.1 mmol) was added to «-BuOH (2 ml) and DIEA (0.18 g, 1.4 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hours, then cooled to room temperature and concentrated. The resulting residue was purified by column chromatography (DCM-MeOH = 80 : 1) to give the title compound (0.11 g, 26%). 1H NMR (400 MHz, CDCl3) δ 8.44 (br s, IH), 7.37-7.33 (m, 2H), 7.27 (d, J= 9.6 Hz, IH), 7.07-7.03 (m, 2H), 6.11 (s, IH), 5.24-5.20 (m, 2H), 1.87-1.83 (m, IH), 1.60 (d, J= 6.2 Hz, 3H), 1.01-0.98 (m, 2H), 0.79-0.65 (m, 2H). MS: Calcd.: 380; Found: [M+H]+ 381.
Example 109
(^-N-(('6-f5-Cyclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-(l-('4-fluorophenyDethylamino) pyridin-3-vDmethvD- 1,1,1 -trifluoromethanesulfonamide
To a solution of (5)-3-(ammomethyl)-7V6-(5-cyclopropyl-li7-pyrazol-3-yl)-5-fluoro- N2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamme (Example 3, 0.10 g, 0.26 mmol) in THF (5 ml) at room temperature was added 1.1 equivalent of trifluoromethylsulfonyl chloride loaded TFP resin, and DMAP (0.031 g, 0.26 mmol). The reaction was then stirred at room temperature for 15 hours and filtered. The remaining resin was then washed with THF (2 x 10 ml for 20 min), and then combined organic fractions were concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50% ACN) to give the title compound (0.02 g, 15%). 1H NMR (400 MHz, CD3OD) δ 7.40-7.37 (m, 2H), 7.17 (d, J= 10.9 Hz, IH), 7.02-6.97 (m, 2H)5 5.90-5.60 (br s, IH), 5.14-5.12 (m, IH), 4.28-4.25 (m, 2H), 1.88-1.84 (m, IH), 1.54 (d, J= 7.0 Hz, 3H), 0.95-0.93 (m, 2H), 0.67-0.64 (m, 2H). MS: Calcd.: 516; Found: [M+H]+ 517.
Example 110 r^-6-(5-Cvcloρropyl-lH-pyrazol-3-ylaniino)-5-fluoro-2-('l-('5-fluoropyridin-2-yl)ethylamino') nicotinonitrile
A suspension of 6-(5-cyclopropyl-lH-pyrazol-3-ylamino)-2,5-difluoronicotinonitrile (Method 32, 5.75 g, 22.0 mmol), in «-BuOH (28.75 ml) was prepared at room temperature in a 48 ml sealed tube. DIEA (4.98 ml, 28.6 mmol) was then added, followed by the addition of (<S)-l-(5-fluoropyridin-2-yl)ethanamine (Method 33; 4.0 g, 28.6 mmol). The tube was then sealed, and the suspension was heated to 130 0C over 45 minutes. The reaction was then allowed to stir at 130 0C for 18 hours. The reaction was then cooled to room temperature and concentrated by rotary evaporation at 600C to remove π-BuOH. The remaining oil was then taken up in DCM (100 ml) and washed with water (2 x 100 ml). The combined aqueous fractions were then extracted with DCM (100 ml), and the combined organic fractions were dried over Na2SO4, filtered and concentrated. The resulting oil was then purified by column chromatography (DCM, then DCM-MeOH = 100 : 1) to give the title compound (5.2 g, 62%). 1H NMR (400 MHz, CD3OD) δ 8.43 (d, J= 2.5 Hz, IH), 7.60-7.34 (m, 3H), 6.09-5.63 (m, IH), 5.24 (q, J= 7.0 Hz, IH), 1.91 (septet, IH), 1.58 (d, J= 6.6 Hz, 3H), 1.08-0.90 (m, 2H), 0.79-0.70 (m, 2H). MS: Calcd.: 381; Found: [M+H]+ 382.
Example 111 r61-N2-r5-Cvclopropyl-lH-pyrazol-3-vD-3-fluoro-iV6-ri-r4-fluorophenvnethylV5- isopropylpyridine-2,6-diamme
To a solution of (5)-6-(5-cyclopropyl-lH"-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)nicotmaldehyde (Example 73, 0.15 g, 0.39 mmol) in TΗF (6 ml) at 0 0C was added methyl magnesiumbromide (1.4 M TΗF, 0.50 mmol). The reaction was then stirred for 4 hours at room temperature, quenched with water, and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5-50% ACN) to give the title compound (0.10 g, 64%). 1H NMR (400 MHz, CD3OD) δ 7.40-7.37 (m, 2H), 7.12 (d, J- 11.9 Hz, IH), 7.02-6.97 (m, 2H), 5.70 (s, IH), 5.17-5.12 (m, IH), 2.99- 2.96 (m, IH), 1.87-1.82 (m, IH), 1.54 (d, J= 7.0 Hz, 3H)5 1.23-1.21 (m, 6H)3 0.94-0.90 (m, 2H), 0.66-0.63 (m, 2H). MS: Calcd.: 397; Found: [M+H]+ 398.
Example 112 (6^-6-('5-Cvclopropyl-l/i-pγrazol-3-ylaminoV5-fluoro-2-(l-f4-fluorophenyl)ethylaminoV4- (isopropylamino)nicotinonitrile
To a solution of (5)-6-(5-cyclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)-4-iodonicotinonitrile (Example 134, 0.07 g, 0.14 mmol) and DIEA (0.023 g, 0.18 mol) in rc-BuOH (1.5 ml) was added isopropylamine (0.16 g, 2.7 mmol). The reaction was then heated to 185 0C under microwave conditions (1 hour x 4 cycles). The reaction was then cooled to room temperature, DCM (10 ml) was added, and washed with 10% aqueous Na2S2O3. The organic layer was then dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50% ACN) to give the title compound (0.031 g, 51%). 1H NMR (400 MHz5 CD3OD) δ 7.36-7.33 (m, 2H), 7.04-7.00 (m, 2H), 5.99-5.59 (br s, IH)5 5.14 (s, IH)5 4.29-4.23 (m, IH), 1.87-1.83 (m, IH), 1.52 (d, J= 7.0 Hz, 3H)5 1.25 (d, J= 6.2 Hz5 6H)5 0.95-0.94 (m, 2H)5 0.65-0.63 (m, 2H). MS: Calcd.: 437; Found: [M+H]+ 438.
Example 113 fιSr)-6-('5-Cyclopropyl-lH'-pyrazol-3-ylamino')-5-fluoro-2-(l-r4-fluorophenyl')ethylaminoV4- fmethylaminoinicotinonitrile
To a solution of ()S)-6-(5-cyclopropyl-lH"-pyrazol-3-ylamino)-5-fluoro-2-(l-(4- fluorophenyl)ethylamino)-4-iodonicotinonitrile (Example 134, 0.10 g, 0.19 mmol) and DIEA (0.03 g5 0.25 mol) in ra-BuOH (1.5 ml) was added methylamine (2.0 M in THF, 1.9 mmol). The reaction was then heated to 185 0C under microwave conditions (1 hour x 2 cycles). The reaction was then cooled to room temperature, DCM (10 ml) was added, and washed with 10% aqueous Na2S2O3. The organic layer was then dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50% ACN) to give the title compound (0.04 g, 49%). 1H NMR (400 MHz5 CD3OD) δ 7.35 (br s, 2H), 7.04-7.00 (m, 2H)5 5.95 (br s, IH), 5.14 (br s, IH), 3.15 (d, J= 2.7 Hz5 3H), 1.87-1.82 (m, IH)5 1.52 (d, J= 6.8 Hz5 3H), 0.95-0.94 (m, 2H), 0.65-0.63 (m, 2H). MS: Calcd.: 409; Found: [M+H]+ 410. Example 114
(>S^-5-Fluoro-2-π-r4-fluorophenyl)ethylamino)-6-('5-methyl-lH'-pyrazol-3-ylamino>) nicotinonitrile
A suspension of 2,5-difluoro-6-(5-methyl-lH-pyrazol-3-ylamino)nicotinomtrile (Method 41, 0.20 g, 0.85 mmol), DIEA (0.14 g, 1.1 mmol), and (5)-l-(4-fluorophenyl) ethanamine (0.23 g, 1.7 mmol) in n-BuOH (2 ml) was heated to 130 0C for 18 hours. The reaction was then cooled to room temperature, diluted with water (20 ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.27 g, 91%). 1H NMR (400 MHz, CD3OD) δ 7.38-7.32 (m, 3H), 7.03-6.99 (m, 2H)5 5.99 (br s, IH), 5.15-5.14 (m, IH), 2.24 (s, 3H), 1.53 (d, J= 6.8 Hz, 3H). MS: Calcd.: 354; Found: [M+H]+ 355.
Example 115 (>Sr)-5-Fluoro-2-('l-('5-fluoropyridin-2-vDethylamino)-6-(5-methyl-lH'-pyrazol-3-ylamino) nicotinonitrile
A suspension of 2,5-difluoro-6-(5-methyl- lH-pyrazol-3-ylamino)nicotinonitrile (Method 41, 0.24 g, 1.02 mmol), DIEA (0.17 g, 1.3 mmol), and (£>l-(5-fluoropyridin-2- yl)ethanamine (Method 33, 0.21 g, 1.5 mmol) in n-BuOH (2 ml) was heated to 130 0C for 18 hours. The reaction was cooled to room temperature, diluted with water (20ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.20 g, 55%). 1H NMR (400 MHz, CD3OD) δ 8.42 (s, IH), 7.51-7.38 (m, 3H), 6.01 (s, IH), 5.21-5.19 (m, IH), 2.27 (s, 3H), 1.58 (d, J= 6.7 Hz, 3H). MS: Calcd.: 355; Found: [M+H]+ 356.
Example 116
CSVό-^-Cyclopropyl- l//-pyrazol-3 -ylamino)-5-fluoro-2-( 1 -f 5-fluoropyridin-2-yDethylamino) nicotinamide A solution of (,S)-6-(5-cyclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-(l-(5- fluoropyridin-2-yl)ethylamino)nicotinonitrile (Example 110, 0.24 g, 0.62 mmol) in MeOH (20 ml) was prepared at room temperature. An aqueous solution (0.7 ml) of KOH (0.17 g, 3.15 mmol) was then added dropwise, followed by the addition of 0.05 ml of 30% H2O2. The reaction was then heated to 65 0C for 3 hours, cooled to room temperature, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), and washed with water (50 ml). The organic fraction was then dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 30 : 1) to give the title compound (0.13 g, 52%). 1H NMR (400 MHz, CD3OD) δ 8.42 (s, IH), 7.70 (d, J= 12.1 Hz, IH), 7.48- 7.38 (m, 2H)5 6.02 (s, IH), 5.25-5.02 (m, IH), 1.91-1.86 (m, IH), 1.57 (U3 J= 7.0 Hz, 3H), 0.97 (br s, 2H), 0.73 (br s, 2H). MS: Calcd.: 399; Found: [M+H]+ 400.
Example 117 C5r)-iV-(("6-('5-Cvclopropyl-lHr-pyrazol-3-ylammoV5-fiuoro-2-(T^-l-(4-fiuorophenvn ethylammo')pyridin-3-yl')methylV5-oxopyrrolidme-2-carboxamide
To a DCM (10ml) solution of (5)-3-(ammomethyl)-N6-(5-cyclopropyl-lH-pyrazol-3- yl)-5-fluoro-Λ/2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.45 g, 1.17 mmol) and HBTU (0.44 g, 1.17 mmol) cooled at 0 0C was added a solution of (S)-S- oxopyrrolidine-2-carboxylic acid (0.15 g, 1.17 mmol) in DMF (5 ml), followed by the addition of DIEA (0.14 g, 1.17 mmol). The reaction was then stirred at room temperature for 1 hour and quenched with 20 ml of aqueous NaHCO3, and extracted with DCM (2 x 30 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 20 : 1) to give the title compound (0.30 g, 51%). 1H NMR (400 MHz, CD3OD) δ 7.35-7.32 (m, 2H), 7.10 (d, J= 10.9 Hz, IH), 7.00-6.96 (m, 2H), 5.80-5.65 (br s, IH), 5.06-5.05 (m, IH), 4.30-4.15 (m, 3H), 2.45- 2.24 (m, 3H), 2.05-2.00 (m, IH), 1.85-1.80 (m, IH), 1.48 (d, J= 6.8 Hz, 3H), 0.91-0.89 (m, 2H), 0.63-0.62 (m, 2H). MS: Calcd.: 495; Found: [M+H]+ 496.
Example 118 ri?ViV-r('6-(5-Cvclopropyl-lH"-pyrazol-3-ylammoV5-fluoro-2-((SVl-(4-fluorophenvn ethylamino)pyridm-3-vDmethyl)-5-oxopyrrolidine-2-carboxamide
To a DCM (10 ml) solution of (5)-3-(aminomethyl)-iV6-(5-cyclopropyl-lH"-pyrazol-3- yl)-5-fluoro-iV2-(l-(4-fluorophenyl)ethyl)pyridme-2,6-diamine (Example 3; 0.45 g, 1.17 mmol) and HBTU (0.44 g, 1.1 7mmol) cooled at 0 0C was added a solution of (R)S- oxopyrrolidine-2-carboxylic acid (0.15 g, 1.17 mmol) in DMF (5 ml), followed by the addition of DIEA (0.14 g, 1.17 mmol). The reaction was then stirred at room temperature for 1 hour and quenched with 20 ml aqueous NaHCO3, and extracted with DCM (2 x 30 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 20 : 1) to give the title compound (0.25 g, 43%). 1H NMR (400 MHz, CD3OD) δ 7.37-7.34 (m, 2H), 7.14 (d, J= 10.9 Hz, IH), 7.02-6.97 (m, 2H), 5.80-5.65 (br s, IH), 5.07 (br s, IH), 4.33-4.16 (m, 3H), 2.46- 2.22 (m, 3H), 2.05-1.98 (m, IH), 1.88-1.81 (m, IH), 1.51 (d, J= 6.8 Hz, 3H), 0.93-0.92 (no, 2H), 0.66-0.62 (m, 2H). MS: Calcd.: 495; Found: [M+H]+ 496.
Example 119
(5f)-5-Fluoro-2-d-C5-fluoropyridin-2-yl')ethylammo)-6-('5-isopropoxy-lH'-pyrazol-3-ylammo) nicotinonitrile
A solution of 2,5-difluoro-6-(5-isopropoxy- lH-pyrazol-3-ylamino)nicotinonitrile (Method 42, 0.30 g, 1.07 mmol), DIEA (0.16 g, 1.29 mmol), and (S)-I -(5-fluoropyridin-2- yl)ethanamine (Method 33; 0.22 g, 1.6 mmol) in rc-BuOH (3 ml) was heated to 130 0C for 18 hours. The reaction was then cooled to room temperature, diluted with water (20 ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (hexanes-EtOAc = 3 : 1) to give the title compound (0.25 g, 58%). 1H NMR (400 MHz, CD3OD) δ 8.40 (s, IH), 7.56-7.55 (m, 2H), 7.45 (d, J= 10.5 Hz, IH), 5.42 (s, IH), 5.25-5.22 (m, IH), 4.63 (br s, IH), 1.60 (d, J= 7.0 Hz, 3H), 1.34 (d, J= 6.1 Hz, 6H). MS: Calcd.: 399; Found: [M+H]+ 400.
Example 120
6-r('5-Cvclopropyl-l/f-pyrazol-3-yls)aminol-2-(rαSf)-l-(3,5-difluoropyridin-2- yDethyllamino|-5-iluoronicotinonitrile Following a similar procedure to the synthesis of Example 1, the title compound was synthesized from 6-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2,5-difluoronicotinonitrile (Method 32) and (S)-l-(3,5-difluoropyridin-2-yl)ethanamine (Method 50). 1H NMR (400 MHz) δ 0.68 (m, 2 H), 0.95 (m, 2 H), 1.45 (d, J = 6 Hz, 3 H), 1.87 (m, 1 H), 5.48 (m, 1 H), 6.19 (s, 1 H), 6.69 (m, 1 H), 7.63 (d, 1 H), 7.98 (m, 1 H), 8.51 (s, 1 H), 9.58 (s, 1 H), 12.15 (s, 1 H). MS: Calcd.: 399; Found: [M+H]+ 400. Example 121
^)-5-Chloro-6-(5-cvclopropyl-lH-pyrazol-3-ylammoV2-('l-(5-fluoropyrimidin-2- yDethylamino)nicotmonitrile
A mixture of 2,5-dichloro-6-(5-cyclopropyl-lH-pyrazol-3-ylamino)nicotinonitrile (Method 43, 0.17 g, 0.58 mmol), (S)-l-(5-fluoroρyrimidm-2-yl)emanamine HCl salt (Method 55, 0.186 g, 0.87 mmol), and DIEA (0.60 ml, 3.5 mmol) in ra-BuOH (3 ml) was heated in a sealed tube at 130 0C for 44 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane— EtOAc = 1 : 1) to give the title compound as a white solid (0.095 g, 41%). 1H NMR (400 MHz) δ 12.16 (s, IH), 8.88 (s, 2H), 8.52 (s, IH), 7.84 (s, IH), 7.05 (d, J =7.2 Hz, IH), 5.98 (s, IH), 5.28 (m, IH), 1.84 (m, IH), 1.57 (d, J =1.2 Hz, 3H), 0.96 (m, 2H)3 0.71 (m, 2H). MS: Calcd.: 398; Found: [M+H]+ 399.
Example 122 iV-IS-rd^-l-dS-Cvano-ό-ffS-cvclopropyl-lH-pyrazol-S-vDaminoi-S-fluoropyridin^- yl) amino)ethyl]-2-fluorophenyl}methanesulfonamide and Example 123 iV-{5-[(lιSf)-l-({3-Cyano-6-[(5-cyclopropyl-lH'-pyrazol-3-yl)ammol-5-iluoropyridin-2- yl}ammo)ethyl1-2-fluorophenvUmethanesulfonamide
To a 10-ml microwave vessel was added, 2-chloro-6-[(5-cyclopropyl-l/f-pyrazol-3- yl)amino]-5-fluoronicotinonitrile (Method 1, 600 mg, 2.3 mmol), iV-[5-(l-aminoethyl)-2- fluorophenyl]methanesulfonamide (Method 61, 500 mg, 2.3 mmol), DIEA (0.5 ml, 2.76 mmol), and n-butanol (5 ml). The vessel was sealed and subjected to microwave heating at 150 0C for 5 hours (CEM Discover System). The resulting mixture was then purified by silica gel chromatography using 5% MeOΗ/DCM. The racemic product obtained was then chirally purified by ΗPLC on Chiralcel OJ column (500 x 50mm, 20 microns) using 50:25:25:0.1% of hexane/MeOΗ/EtOΗ/diethylamine at 118 ml/min. The chiral purification gave 220 mg of iV- {5-[(li?)-l-({3-cyano-6-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-5-fluoropyridin-2- yl}amino)ethyl]-2-fluorophenyl}methanesulfonamide 1H NMR: δ 11.77 - 12.26 (br s, IH), 9.51 (s, IH), 9.34 - 9.48 (br s, IH), 7.62 (d, J=10.55 Hz3 IH), 7.39 (d, J=8.29 Hz3 IH)3 7.02 - 7.23 (m, 3H)3 6.00 (s, IH)3 5.07 - 5.24 (m, IH), 2.95 (s, 3H), 1.81 - 1.95 (m, IH), 1.49 (d, J=7.54 Hz, 3H), 0.88 - 0.97 (m, 2H), 0.57 - 0.68 (m, 2H). MS: Calcd.: 473; Found: [M+H]+ 474 and 223 mg ofN-{5-[(15)-l-({3-cyano-6-[(5-cyclopropyl-lHr-ρyrazol-3-yl)amino]-5- fluoropyridin-2-yl}amino)ethyl]-2-fluorophenyl}methanesulfonamidel; 1HNMR: 11.73 - 12.38 (br s, IH), 9.42 (s, IH), 8.41 - 9.12 (br s, IH), 7.61 (d, J=I 1.30 Hz, IH), 7.37 (d, J=7.54 Hz, IH), 6.96 - 7.24 (m, 3H), 6.02 (s, IH), 5.05 - 5.26 (m, IH), 2.90 (s, 3H), 1.79 - 1.96 (m, IH), 1.49 (d, J=6.78 Hz, 3H), 0.89 - 0.98 (m, 2H), 0.59 - 0.67 (m, 2H). MS: Calcd.: 473; Found: [M+H]+ 474.
Example 124
5-Chloro-2-[rri^-l-r5-fluoroρyridin-2-vDethyllaminol-6-rr5-methyl-lH'-ρyrazol-3- yl*)amino]nicotinonitrile
To a 10-ml microwave vessel was added, 2,5-dichloro-6-[(5-methyl-lH-pyrazol-3- yl)amino]nicotinonitrile (Method 60, 8 mmol), [(16)-l-(5-fluoropyridin-2-yl)ethyl]amine
(Method 33, 8 mmol, 97wt% solution in dioxane), DIEA (0.3 ml, 1.66 mmol), and n-butanol (4 ml). The vessel was then sealed and subjected to microwave heating at 150 °C for 3 hours. After 3 hours, more 2-pyridyl amine (100 mg, 0.69 mmol) was added. The resulting mixture was purified by silica gel chromatography (Biotage Horizon System) using an isocratic system of 15:0.5:0.5% of DCM/EtOAc/MeOH to give 312 mg of the title compound. 1H NMR: 12.04 (br s, IH), 8.41 - 8.63 (m, 2H), 7.84 (s, IH), 7.56 - 7.71 (m, IH), 7.40 (dd, J=8.67, 4.14 Hz, IH), 7.28 (s, IH), 5.86 (s, IH), 5.06 - 5.25 (m, IH), 2.17 (s, 3H), 1.51 (d, J=7.54 Hz, 3H). MS: Calcd.: 371/373; Found: [M+H]+ 372/374.
Example 125
■^-^-[l-riS-Cvano-ό-ffS-cvclopropyl-l.H-pyrazol-S-yDaminoJ-S-fluoropyridin^- ylj ammo)ethyl1-2-fluorophenvU acetamide
To a 10-ml microwave reaction vessel was added, 6-[(5-cyclopropyl-lH-pyrazol-3- yl)amino]-2,5-difluoronicotinonitrile (Method 32, 300 mg, 1.13 mmol), iV-[5-(l-aminoethyl)- 2-fluorophenyl] acetamide (Method 66, 331 mg, 1.7 mmol), and DIEA (0.8 ml, 4.6 mmol) in n-butanol (4 ml). The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 25-35% EtOAc (20% v/v MeOH) in hexanes to give 180 mg (36% isolated yield) of the title compound. 1H NMR: 9.66 (br s, 1 H) 9.43 (s, 1 H) 7.81 (d, J-6.03 Hz, 2 H) 7.60 (d, J=I 1.30 Hz, 1 H) 6.92 - 7.21 (m, 3 H) 5.98 (s, 1 H) 5.13 (t, J=7.16 Hz, 1 H) 2.05 (s, 3 H) 1.76 - 1.92 (m, 1 H) 1.46 (d, J=6.78 Hz, 3 H) 0.82 - 0.95 (m, J=8.29 Hz, 2 H) 0.54 - 0.66 (m, 2 H). MS: Calcd.: 437; Found: [M+H]+ 438. Example 126
N-{5-Fl-({3-Cyano-6-r(5-cvclopropyl-lH-pyrazol-3-yl')aminol-5-fluoropyridm-2- yU amino^ethyl]-2 -fluorophenyl! cyclopropanecarboxamide
To a 10-ml microwave reaction vessel was added 6-[(5-cyclopropyl-lH-pyrazol-3- yl)amino]-2,5-difluoronicotinonitrile (Method 32, 431 mg, 1.65 mmol), N-[5-(l-aminoethyl)- 2-fluorophenyl]cyclopropanecarboxamide (Method 69, 550 mg, 2.5 mmol), and DIEA (1.15 ml, 6.6 mmol) in n-butanol (5 ml). The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 25-35% EtOAc (20% v/v MeOH) in hexanes to give 267 mg (35% isolated yield) of the title compound. 1H NMR: 11.99 (s, 1 H) 9.91 (s, 1 H) 9.42 (s, 1 H) 7.88 (d, J=6.03 Hz, 1 H) 7.59 (d, J=10.55 Hz, 1 H) 6.95 - 7.20 (m, 3 H) 5.99 (s, 1 H) 5.02 - 5.21 (m, 1 H) 1.89 - 2.03 (m, 1 H) 1.76 - 1.89 (m, 1 H) 1.45 (d, J=7.54 Hz, 3 H) 0.87 (t, J=8.67 Hz, 2 H) 0.75 (d, J=6.03 Hz, 4 H) 0.54 - 0.66 (m, 2 H). MS: Calcd.: 463; Found: [M+H]+ 464.
Example 127 ό-rCS-Cvclopropyl-lH-pyrazol-S-vDaminol-S-fluoro^-irdiS^-l-fό-fluoropyridm-S- vDethyliaminolnicotmonitrile and Example 128 ό-IYS-Cyclopropyl- lH-pyrazol-3-vDaminol-5-fluoro-2- { \(1R)- 1-f 6-fluoropyridin-3- yl) ethyl] amino } nicotinonitrile
To a 10-ml microwave reaction vessel was added 6-[(5-cyclopropyl-lH-pyrazol-3- yl)amino]-2,5-difluoronicotinonitrile (Method 32, 1 g, 4 mmol), l-(6-fluoropyridin-3- yl)ethanamine (Method 76, 560 mg, 4 mmol), and DIEA (0.84, 4.8 mmol) in n-butanol (5 ml). The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was then concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 1-4% MeOH in DCM to give 380 mg (25% isolated yield) of 6-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-5-fluoro-2- {[l-(6-fluoropyridin-3-yl)ethyl]amino}nicotinonitrile. The racemic product obtained was then chirally purified by HPLC on Chiralpak AS column (500 x 50mm, 20 microns) using
80:10:10:0.1% of hexane-MeOH-EtOH-diethylamine at 118 ml/min. The chiral purification gave 145 mg of 6-[(5-cyclopropyl-li7-pyrazol-3-yl)amino]-5-fluoro-2-{[(l)S)-l-(6- fluoropyridin-3-yl)ethyl]amino}nicotinonitrile: 1HNMR: 9.43 (s, 1 H) 8.08 (s, 1 H) 7.84 - 8.00 (m, 1 H) 7.61 (d, J=I 1.30 Hz3 1 H) 7.18 (d, J=7.54 Hz, 1 H) 7.04 - 7.13 (m, 1 H) 5.94 (s,
1 H) 5.15 (t, J=7.54 Hz, 1 H) 1.81 - 1.97 (m, 1 H) 1.51 (d, J=7.54 Hz3 3 H) 0.92 (d, J=6.03 Hz, 2 H) 0.64 (s, 2 H). MS: Calcd.: 381; Found: [M+H]+ 382; and 137 mg of 6-[(5- cyclopropyl-lH-pyrazol-3-yl)amino]-5-fluoro-2-{[(li?)-l-(6-fluoropyridin-3- yl)ethyl]amino}nicotinonitrile: 1H NMR: 9.42 (s, 1 H) 8.08 (s, 1 H) 7.93 (t, J=8.29 Hz, 1 H) 7.61 (d, J=10.55 Hz, 1 H) 7.18 (d, J=8.29 Hz, 1 H) 7.08 (dd, J=8.29, 3.01 Hz, 1 H) 5.94 (s, 1 H) 5.15 (t, J=7.54 Hz, 1 H) 1.81 - 1.96 (m, 1 H) 1.51 (d, J=7.54 Hz, 3 H) 0.91 (d, J=8.29 Hz,
2 H) 0.64 (s, 2 H). MS: Calcd.: 381; Found: [M+H]+ 382.
Example 129
5-Fluoro-2-{ri-("5-fluoropyrimidin-2-yl)ethyllammo|-6-f(5-methyl-lH"-pyrazol-3- vDaniinolnicotinonitrile
A mixture of l-(5-fluoropyrimidin-2-yl)ethanamine (Method 72, 0.05 g, 0.35mmol),
2,5-difluoro-6-[(5-methyl-lH-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.06 g, 0.25 mmol), and DIEA (0.12 ml, 0.7 mmol) in π-BuOH (3 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours.
The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.016 g,
15%). LC-MS, 357 (M+l). 1H NMR (400 MHz, MeOD) δ 8.70 (s, 2H)3 7.45 (d, IH), 6.40 (br, IH), 5.45 (q IH)3 2.35 (s, 3H), 1.65 (d, 3H).
Example 130
5-Chloro-2-{ri-('5-fluoropyrimidin-2-yl')ethyllammo|-6-r(5-methyl-lH-pyrazol-3- vπaminolnicotinonitrile A mixture of l-(5-fluoropyrimidin-2-yl)ethanamine (Method 72, 0.05 g, 0.35 mmol),
235-dichloro-6-[(5-methyl-l/i-pyrazol-3-yl)amino]nicotinonitrile (Method 60, 0.06 g, 0.25 mmol), and DIEA (0.12 ml, 0.7 mmol) in π-BuOH (10 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours.
The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.017 g,
15%). LC-MS, 373 (M+l). 1H NMR (400 MHz, MeOD) δ 8.75 (s3 2H)3 7.45 (s, IH), 6.40 (s,
IH)3 5.45 (br IH)3 2.35 (s, 3H), 1.60 (d, 3H). Example 131 iV-IS-rfl^-l-flS-Cvano-S-fluoro-ό-rrS-methyl-lH-pyrazol-S-vDaminoipyridin^- yl I amino)ethyl1 -2-fluorophenyl| methanesulfonamide and Example 132 N-lS-rd-RVl-rO-Cvano-S-fluoro-ό-rrS-methyl-lH-pyrazol-S-vDaminoipyridin^- yl}ammo)ethyl]-2-fluorophenyl)methanesulfonamide
A mixture of N-[5-(l-aminoethyl)-2-fluorophenyl]methanesulfonamide (Method 61, 0.2 g, 0.86 mmol), 2,5-difluoro-6-[(5-methyl-lH-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.2 g, 0.8 mmol), and DIEA (0.3 ml, 2.1 mmol) in rc-BuOH (4 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.16 g, 35%). The resulting racemic compound was separated by a Chiralpak AS-H SFC HPLC column (25 % MeOH) to two enantiomers (The retention time of the first elute Example 131 (S-isomer) was 7 min, and the retention time of the second elute Example 132 (R-isomer) was 8.5 min). LC-MS, 448 (M+l). 1H NMR (400 MHz, MeOD) δ 7.45 (d, IH), 7.40 (d, IH), 7.20 (s, IH), 7.10 (t, IH), 6.00 (s, IH), 5.20 (br IH), 2.90 (s, 3H), 2.20 (s, 3H), 1.60 (d, 3H).
Example 133
5-Fluoro-2- ( [ 1 -(5-fluoropyrimidin-2-yl)ethyl]amino| -6-[Y5-isopropoxy- lH-pyrazol-3- vDaminoinicotinonitrile
A mixture of l-(5-fluoropyrimidin-2-yl)ethanamine (Method 72, 0.05 g, 0.35mmol),
2,5-difluoro-6-[(5-methyl-lH'-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.05 g, 0.25 mmol), and DIEA (0.12 ml, 0.7 mmol) in n-BuOH (4 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 0C for 6 hrs.
The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.006 g,
5%). LC-MS, 401 (M+l). 1H NMR (400 MHz, MeOD) δ 8.70 (s, 2H), 7.50 (d, IH), 5.50 (s, IH), 5.45 (br, IH), 4.60 (m, IH), 1.60 (d, 3H), 1.25 (d, 6H). Example 134
('5f)-6-(5-Cvclopropyl-lH'-pyrazol-3-ylamino)-5-fluoro-2-('l-(4-fluorophenyl)ethylaminoV4- iodonicotinonitrile
A solution of 2-chloro-6-(5-cyclopropyl- lH-pyrazol-3-ylamino)-5-fluoro-4- iodonicotinonitrile (Method 39, 0.28 g, 0.69 mmol), (S)-l-(4-fluorophenyl)ethanamine (0.19 g, 1.3 mmol), and DIEA (0.11 g, 0.90 mmol) in n-BuOH (1 ml) was heated to 140 0C for 18 hours. The reaction was diluted with water (10 ml), extracted with DCM (2 x 20 ml) and the combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.07 g, 20%). MS: Calcd.: 506; Found: [M+H]+ 507.
Preparation of starting materials
Method 1 2-ChIOrQ-O-(S-CyClQPrQPyI- lH-pyrazol-S-ylammoVS-fluoronicotinonitrile
A solution of S-cyclopropyl-lH-pyrazol-S -amine (1.9g, 16.0 mmol) in CH3CN (20 ml) was added dropwise to a solution of 2,6-dichloro-5-fluoronicotinonitrile (3.0g, 16.0 mmol) and triethylamine (2.1g, 20.0 mmol) in CH3CN (80 ml) at 25 °C. The resulting solution was then heated to 82 °C for 18 hrs, and then cooled to 25 °C, at which point the product precipitated from solution. The resulting solid was filtered, and washed with CH3CN (100 ml) to give the title compound (3.2g, 73%). MS: Calcd.: 277; Found: [M+H]+ 278.
Method 2
2-Chloro-5-fluoro-6-('5-isopropoxy-li:/-pyrazol-3-ylamino)nicotinonitrile A solution of 5-isopropoxy-17f-pyrazol-3-amine (0.96g, 6.8 mmol), 2,6-dichloro-5- fluoronicotinonitrile (1.3g, 6.8 mmol), and triethylamine (0.9g, 8.8 mmol) in THF (30 ml) was heated to 60 °C for 4 days, and then cooled to 25 °C, at which point the product precipitated. The resulting solid was filtered and washed with hexanes (100 ml) to give the title compound (LOg, 50%). MS: Calcd.: 295; Found: [M+H]+ 296. Method 3
3,5,6-Trichloro-A^-(5-cyclopropyl-liJr-pyrazol-3-γlN)pyridin-2-amine
A solution of 2,3,5, 6-tetrachloropyridine (0.2Og, 0.9 mmol), 5-cyclopropyl-lH- pyrazol-3 -amine (0.2Og, 1.8 mmol), and triethylamine (O.lOg, 1.4 mmol) in NMP (2 ml) was heated in a microwave at 200 °C for 30 min. The reaction was cooled to 25 °C, quenched with water (10 ml), and extracted with MTBE (4 x 30 ml). The combined organic fractions were then dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.035g, 12%). MS: Calcd.: 303; Found: [M+H]+ 303.
Method 4 (2-Chloro-pyridin-4-ylV(5-cvclopropyl-lH"-pyrazole-3-ylVamine
A mixture of 4-iodo-2-chloropyridine (0.26 g, 1.1 mmol), 3-amino-5-cyclopropyl- pyrazole-1-carboxylic acid tert-butyl ester (0.20 g, 0.89 mmol), Pd2dba3 (0.016 g, 2 mol%), Xantphos (0.031 g, 6 mol%), and Cs2CO3 (0.41 g, 1.3 mmol) in degassed toluene (4 ml) was purged with N2 and heated to 100 0C in a sealed tube for 2 days. The mixture was diluted with THF and filtered to remove Cs2CO3. The filtrate was concentrated under reduced pressure and purified by column chromatography (hexane - EtOAc = 3 : 1) to give the title compound (0.10 g, 48%). MS: Calcd.: 234; Found: [M+H]+ 235.
Method 5 (iSr)-6-Chloro-iV-(l-f4-fluorophenyl')ethyl)-3-nitropyridin-2-amine
To a mixture of 2,6-dichloro-3-nitropyridine (2.26 g, 10.8 mmol) and potassium carbonate (1.29 g, 9.34 mmol) in anhydrous CH3CN (20 ml), was added (5)-l-(4-fluoro- phenyl)-ethylamine (1.00 g, 7.19 mmol) dropwise at 0 0C. The reaction mixture was stirred at 25 °C for 17 hrs. The solid was removed by filtration and the resulted cake was washed with EtOAc (20 ml). The combined filtrate was concentrated and purified by column chromatography (hexane - EtOAc = 10 : 1) to give the title compound as a yellow solid (1.74 g, 82%). 1H NMR (400 MHz) δ 8.65 (d, J= 7.6 Hz, IH), 8.43 (d, J= 8.4 Hz, IH), 7.51 (m, 2H), 7.16 (m, 2H), 6.81 (d, J= 8.8 Hz, IH), 5.37 (m, IH), 1.59 (d, J= 6.8 Hz, 3H). Methods 6-9
Following a similar procedure to Method 5, the following compounds were synthesized from a 2,6-dichloro-3-nitropyridine by reacting it with an amine.
Figure imgf000097_0001
Method 10
2-Amino-2-('4-fluorophenyl)propane- 1 ,3-diol
A suspension of 2-(4-fluorophenyl)-2-nitroproane-l,3-diol (Method 11; 4.5 g, 20.9 mmol) and Raney nickel (0.45 g, 5.23 mmol) in MeOH (50 ml) was degassed and stirred under H2 (48 psi) for 2 hours. The catalyst was removed by filtration. The filtrate was concentrated and recrystallized from hexane : EtOAc (1 : 1) to give the title compound (2.35 g, 61%) as a white solid. NMR (400 MHz) 7.55 (m, 2H), 7.07 (m, 2H), 4.65 (t, J= 5.2 Hz, 2H), 3.49 (m, 4H), 1.76 (s, 2H). Method 11
2-(4-FluorophenvD-2-nitroproane-l,3-diol
To a solution of l-fluoro-4-(nitromethyl)benzene (Method 12; 10.0 g, 80% pure; 52 mmol) and TEA (15.1 ml, 108.3 mmol) in dioxane (50 ml) was added formaldehyde (8.6 ml, 116 mmol) dropwise at 0 °C. After addition, the reaction was slowly warmed up to 25 °C overnight. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc = 10 : 1) to give the title compound as a white solid
(4.5 g, 41%). NMR (400 MHz) 7.41 (m, 2H), 7.22 (m, 2H), 5.39 (t, J= 5.2 Hz, 2H), 4.22 (m,
4H).
Method 12
1 -Fluoro-4-Cnitromethyl)benzene
A mixture of l-(bromomethyl)-4-fluorobenzene (11.52 g, 61 mmol) and AgNO2 (11.3 g, 73 mmol) in benzene (200 ml) was stirred vigorously at 25 °C for 25 hrs. The solid was removed by filtration and washed with ether (500 ml). The combined organic was concentrated to give the title compound (10.0 g, 80% pure; 85%) which was used without further purification. NMR (400 MHz, CDCl3) 7.44 (m, 2H), 7.18 (m, 2H), 5.42 (s, 2H).
Method 13 (lSr)-5.6-Chloro-N-d-(4-fluorophenvπethylV3-nitropyridin-2-amine
To a mixture of 2,3,6-trichloro-5-nitropyridine (1.00 g, 4.40 mmol) and potassium carbonate (0.79 g, 5.7 mmol) in anhydrous acetonitrile (10 ml) was added (^-l-^-fluoro- phenyl)-ethylamine (0.64 g, 4.62 mmol) dropwise at 0 °C. After addition, the reaction mixture was stirred at 25 0C for 17 hours. The solid was removed by filtration and washed with EtOAc (20 ml). After evaporation of the solvent, the resulted residue was purified by column chromatography (hexane : EtOAc = 10 : 1) to give the title compound as a yellow solid (0.61 g, 79% pure, 33%). NMR (400 MHz, CDCl3) 8.46.(br s, 2H), 7.36 (m, 2H), 7.03 (m, 2H), 5.40 (m, IH), 1.63 (d, J= 6.8 Hz, 3H).
Methods 14-15
Following a similar procedure to Method 13, the following compounds were synthesized from a 2,3,6-trichloro-5-nitropyridine by reacting it with an amine.
Figure imgf000099_0001
Method 16
6-Chloro-N-("5-cvclopropyl-lH-pyrazol-3-ylV3-nitropyridin-2-amine
To a solution of 2,6-dichloro-3-nitropyridine (0.67 g, 3.2 mmol) and DIEA (0.46 ml, 2.65 mmol) in EtOH (20 ml) was added 5-cyclopropyl-lH-pyrazol-3-amine (0.26 g, 2.12 mmol) solution in EtOH (5 ml) dropwise at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 24 hrs. The solvent was removed under reduced pressure and the resulted residue was purified by column chromatography (hexane - EtOAc = 5 : 1) to give the title compound as a yellow solid (0.58 g, 98%). 1H NMR (400 MHz) 512.36 (s, IH), 10.20 (s, IH), 8.54 (d, J= 8.4 Hz, IH), 7.01 (d, J= 8.4 Hz, IH), 6.39 (d, J= 1.6 Hz, IH), 1.94 (m, IH), 0.96 (m, 2H), 0.71 (m, 2H). MS: Calcd.: 279; Found: [M+H]+ 280.
Method 17
5,6-Chloro-N-('5-cyclopropyl-l/i'-pyrazol-3-ylV3-nitropyridme-2-amine To a solution of 2,3,6-trichloro-5-nitropyridine (1.62 g, 7.10 mmol) and DIEA (1.24 ml, 7.1 mmol) in THF (25 ml) was added dropwise a solution of 5-cyclopropyl-lH-pyrazol-3- amine (0.70 g, 5.68 mmol) in THF (5 ml) at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 24 hours. The solvent was removed under reduced pressure and the resulted residue was purified by column chromatography (hexane : EtOAc = 1.5 : 1) to give the title compound as a yellow solid (0.83 g, 47%). NMR (400 MHz) 12.39 (s, IH), 10.12 (s, IH), 8.77 (d, J= 1.2 Hz, IH), 6.35 (s, IH), 1.95 (m, IH), 0.96 (m, 2H), 0.71 (m, 2H). MS: Calcd.: 313; Found: [M+H]+ 314. Method 18
Following a similar procedure to Method 17, the following compound was synthesized from a 2,3,6-trichloro-5-nitropyridine by reacting it with the appropriate amine.
Meth Product NMRMS Amine 1
18 (i?)-2-(3,6-Dichloro- (400 MHz) 8.46 (s, IH), 8.22 (d, J= 8 .0 Hz, (R)-2-amino-2-
5-nitropyridin-2- IH), 7.45 (m, 2H), 7.16 (m, 2H), 5.22 (m, (4-fluoro ylamino)-2-(4- IH), 5.05 (t, J= 6.0 Hz, IH), 3.87 (m, IH), phenyl)ethanol fluorophenyl)ethanol 3.72 (m, IH)
Method 19
6-Bromo-iV-(4-fluorobenzyl)ρyridin-2-amine
To a suspension of 6-bromopyridin-2-amine (500 mg, 2.89 mmol), sodium tert- butoxide (695 mg, 7.24 mmol) in anhydrous toluene (20 ml) was added A- fluorobenzylchloride (415 mg, 2.90 mmol) at room temperature. The reaction mixture was heated at 100 °C overnight. EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (10-14% EtOAc in hexanes) gave the title compound (506 mg, 63%). 1H NMR (CDCl3) δ 4.40 (m, 2H), 4.95 (br s, IH), 6.20 (m, IH), 6.73 (m, IH), 7.00 (m, 2H), 7.25 (m, 3H).
Method 20
6-CMoro-N-r(liS)-l-(4-fluorophenyl)ethyllpyridin-2-amine
To a 25 ml round bottom flask was added Pd(OAc)2 (45 mg, 0.2 mmol), (biphenyl-2- ylmethylene)bis(dimethylphosphine) (120 mg, 0.4 mmol) and sodium tert-butoxide (480 mg, 5.0 mmol). The flask was sealed and refilled with N2. To the mixture was added a solution of 2,6-dichloropyridine (300 mg, 2.0 mmol) and [(15)-l-(4-fluorophenyl)ethyl]amine (306 mg, 2.2 mmol) in toluene (4 ml). The reaction mixture was heated at 85 °C overnight. The solvent was removed and EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (10-40% EtOAc in hexanes) gave the title compound (339 mg, 68%). 1H NMR (CDCl3) δ 1.55 (m, 3H), 4.66 (m, IH), 5.07 (br s, IH), 6.01 (m, IH), 6.54 (m, IH), 7.00 (m, 2H), 7.25 (m, 3H). Method 21 ter^-Butyl 5-cvclopropyl-3-r(6-{r(l^)-l-(4-fluorophenyl)ethyl1amino}pyridm-2-yl)aminol- lH-pyrazole- 1 -carboxylate
To a 25 ml round bottom flask was added Pd2(dba)3 (84 mg, 0.092 mmol), (biphenyl- 2-ylmethylene)bis(dimethylphosphine) (55 mg, 0.184 mmol) and sodium tert-butoxide (132 mg, 1.38 mmol). The flask was sealed and refilled with N2. To the mixture was added a solution of 6-chloro-iV-[(l-S)-l-(4-fluorophenyl)ethyl]pyridm-2-amine (Method 20; 230 mg, 0.92 mmol) and fert-butyl S-amino-S-cyclopropyl-lH-pyrazole-l-carboxylate (223 mg, 1.0 mmol) in toluene (4 ml). The reaction mixture was heated at 110 0C overnight. Solvent was removed and EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (15-40% EtOAc in hexanes) gave the title compound (146 mg, 36%). 1H NMR (CDCl3) δ 0.80 - 1.00 (m, 4H), 1.60 (m, 3H), 1.65 (s, 9H), 1.95 (m, IH), 4.71 (m, IH), 4.75 (m, IH), 5.75 (m, IH), 6.09 (m, IH), 6.21 (s, IH), 7.00 (m, 2H), 7.23 (m, 2H), 7.30 (m, IH), 9.40 (s, IH).
Method 22 te^ButvU2-{r(64f5-cvclopropyl-lH-pyrazol-3-yl)aminol-5-fluoro-2-{r(l<y)-l-('4- fluorophenvDethyliaminolpyridin-S-vDmethv^aminol^-oxoethvDcarbamate
A round bottom flask was charged with (S)-3-(aminomethyl)-iV6-(5-cyclopropyl-lH:- pyrazol-3-yl)-5-fluoro-iV2-(l-(4-fluorophenyl)ethyl)pyridme-2,6-diamme (Example 3; 0.07g, 0.18 mmol), 2-(fert-butoxycarbonyl)acetic acid loaded TFP resin (1.15 mmol/g loading, 0.18 mmol), and a THF - DCM solution (1 : 1, 4 ml) at 0 °C. The resulting solution was shaken vigorously at 0 0C for 2 hrs and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5- 50% CH3CN in H2O over 400 ml) to give the title compound (0.035g, 35%). MS: Calcd.: 541; Found: [M+H]+ 542.
Method 23 (-S)-5,6-Difluoro-N-fl-r4-fluorophenyl)emylV3-m1τopyridin-2-amine
A solution of 2,3,6-trifluoro-5-nitropyridine (Method 24, 2.Og, 11.2 mmol) in THF (50ml) was cooled to 0 0C. (5)-l-(4-Fluorophenyl)ethanamine (1.56g, 11.2mmol) was added and the reaction was stirred at 0 0C for 30 minutes. The reaction was quenched with water (50 ml) and then extracted with DCM (2 x 75 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (hexane-DCM = 1 : 1) to give the title compound (2.3 g, 70%).
Method 24
2,3,6-Trifluoro-5-nitroρyridine
To neat 2,3,6-trifluoropyridine (12.Og, 90mmol) was slowly added fuming HNO3 (142g, 2254 mmol) and H2SO4 (133g, 1353mmol) slow enough to keep the internal temperature below 400C. Upon completion of the addition, the resulting solution was heated to 60 0C for 30minutes, and then cooled to 0 0C. Ice water (21) was added, and the reaction was extracted with hexanes (2 x 300 ml) and then DCM (1 x 300 ml). The combined organic fractions were dried over Na2SO4, filtered, and concentrated to give the title compound (8.1 g, 50%), which was used without further purification.
Method 25
(>Sl-2-(5,6-Difluoro-3-nitropyridin-2-ylammo)-2-('4-fluorophenyl')ethanol
A solution of 2,3,6-trifluoro-5-nitropyridine (1.2 g, 6.7 mmol) in THF (40 ml) was cooled to 0 0C. (i?)-2-ammo-2-(4-fluorophenyl)ethanol (1.0 g, 6.7 mmol) was then added and the reaction was stirred at 0 0C for 30 minutes. The reaction was quenched with water (50 ml) and then extracted with DCM (2 x 75 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (1.2 g, 57%). The product was carried over to the next step without characterization.
Method 26
5,6-Dichloro-iV-('5-isopropoxy-lH-pyrazol-3-ylV3-nitropyridin-2-amine
To a mixture of 2,3,6-tf chloro-5-nitropyridine (2.61 g, 11.4 mmol) and DIEA (1.90 ml, 11.4 mmol) in TΗF (50 ml) was added the 5-isopropoxy-lH-pyrazol-3-amine (1.20 g, 8.50 mmol) at 0 0C. After addition, the reaction mixture was stirred at 25 0C for 5 days. The solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (hexane-EtOAc = 2.5 : 1) to give the title compound as a yellow solid (0.77 g, 27%). 1H NMR (400 MHz) δ 12.26 & 11.64 (s, IH), 10.42 & 10.04 (s, IH), 8.81 & 8.77 (s, IH), 6.02 & 5.94 (s, IH), 4.70 & 4.48 (m, IH)3 1.32 (d, J= 6.0 Hz, 3H)5 1.27 (d, J= 6.0 Hz, IH). MS: Calcd.: 331; Found: [MH-H]+ 332.
Method 27 3 ,6-DiChIOrO-JV-(S-JSOPrOpQXy- lH-pyrazol-3-yl)-5-nitropyridin-2-amme
To a mixture of 2,3,6-trichloro-5-nitropyridine (2.61 g, 11.4 mmol) and DIEA (1.90 ml, 11.4 mmol) in TΗF (50 ml) was added 5-isopropoxy-lH-pyrazol-3-amine (1.20 g, 8.50 mmol) at 0 0C. After addition, the reaction mixture was stirred at 25 0C for 5 days. The solvent was removed under reduced pressure and the resulted residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.51 g, 18%). 1H NMR (400 MHz) δ 12.22 & 11.35 (s, IH), 10.12 & 9.80 (s, IH), 8.64 & 8.54 (s, IH), 5.95 & 5.84 (s, IH), 4.70 & 4.46 (m, IH), 1.27-1.32 (m, 6H). MS: Calcd.: 331; Found: [M+H]+ 332.
Method 28
6-Chloro-iy-r5-isopropoxy-lH"-pyrazol-3-yl)-3-nitropyridin-2-amine
To a solution of 2,6-dichloro-3-nitropyridine (0.51 g, 2.7 mmol) and DIEA (0.39 ml, 2.2 mmol) in THF (10 ml) was added the 5-isopropoxy-lH-pyrazol-3-amine (0.25 g, 1.8 mmol) solution at 0 0C. After addition, the reaction mixture was stirred at 25 0C for 3 days and 60 °C for 24 hours. The solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (hexane-EtOAc = 3 : 1) to give the title compound as a yellow solid (0.33 g, 63%). 1H NMR (400 MHz) δ 12.25 & 11.66 (s, IH), 10.46 & 10.13 (s, IH), 8.58 & 8.55 (d, J= 8.8 Hz, IH), 7.11 & 7.02 (d, J= 8.8 Hz, IH), 6.08 & 5.97 (s, IH), 4.70 & 4.48 (m, IH), 1.32 & 1.27 (d, J= 6.0 Hz, 6 H). MS: Calcd.: 297; Found: [M+H]+ 298.
Method 29 (i?V2-(6-Chloro-3-nitropyridin-2-ylamino)-2-(4-fluorophenvDethanol
To a mixture of 2,6-dichloro-3-nitropyridine (0.933 g, 4.83 mmol) and potassium carbonate (0.58 g, 4.19 mmol) in anhydrous acetonitrile (10 ml) was added (i?)-2-amino-2-(4- fluoro phenyl)ethanol (1.00 g, 7.19 mmol) at 0 0C. The resulting reaction mixture was stirred at 25 0C for 18 hours. The solid was removed by filtration and washed with EtOAc (20 ml). After evaporation of the solvent, the resulting residue was purified by column chromatography (hexane-EtOAc = 5 : 1) to give the title compound as a yellow solid (0.77 g, 61%). 1H NMR (400 MHz) δ 8.96 (d, J= 7.6 Hz, IH), 8.46 (d, J= 8.4 Hz, IH)5 7.45 (m, 2H),
7.15 (m, 2H), 6.81 (d, J = 8.8 Hz, IH), 5.27 (m, 2H), 3.80 (m, 2H).
Method 30 (5)-6-Chloro-iV-(l-r4-fluorophenyl')ethylV3-nitropyridin-2-aniine
To a mixture of 2,6-dichloro-3-nitropyridine (2.26 g, 10.8 mmol) and potassium carbonate (1.29 g, 9.34 mmol) in anhydrous CH3CN (20 ml), was added (5)-l-(4-fluoro- phenyl)-ethylamine (1.00 g, 7.19 mmol) dropwise at 0 0C. The reaction mixture was stirred at 25 0C for 17 hours. The solid was removed by filtration and the resulted cake was washed with EtOAc (20 ml). The combined filtrate was concentrated and purified by column chromatography (hexane-EtOAc = 10 : 1) to give the title compound as a yellow solid (1.74 g, 82%). 1H NMR (400 MHz) δ 8.65 (d, J= 7.6 Hz, IH), 8.43 (d, J= 8.4 Hz, IH), 7.51 (m, 2H),
7.16 (m, 2H), 6.81 (d, J= 8.8 Hz, IH), 5.37 (m, IH), 1.59 (d, J= 6.8 Hz, 3H).
Method 31
N-(5-Cyclopropyl-lH"-pyrazol-3-ylV3,6-difluoropyridin-2-amme
A solution of tert-butyl S-amino-S-cyclopropyl-lH-pyrazole-l-carboxylate (1.00 g, 4.49 mmol) in TΗF (15ml) was cooled to -78 0C. t-BuLi (1.7 M in TΗF, 4.15 mmol) was added dropwise and the resulting solution was stirred for 30 min. at -78 0C. A solution of 2,3,6-trifluoropyridine (0.46 g, 3.4mmol) in TΗF (5ml) was added, and the resulting solution was stirred for 5 min at -78 0C, and then the reaction was warmed to 0 0C, and stirred at that temperature for 30 min. The reaction was quenched with aq. NH4Cl and extract with EtOAc (2 x 20 ml). The organic fractions were dried over Na2SO4, filtered, and concentrated. The resulting oil was then placed in ACN (15 ml) at 0 0C, and N-trimethylsilylimidazole (0.5 ml) was added. The reaction was stirred for 20 min, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.10 g, 12%). MS: Calcd.: 236; Found: [M+H]+ 237.
Method 32 6-(5-Cvclopropyl-liJr-pyrazol-3-ylaminoV2,5-difluoronicotinonitrile
A solution of 2,5,6-trifluoronicotinonitrile (30.0 g, 189.8 mmol) in ACN (240 ml) was prepared in a 11 3 -neck flask at room temperature and then cooled to -5 0C using an ice-salt bath. An addition funnel containing triethylamine (29.1 ml, 208.8 mmol) and a second addition funnel containing a solution of S-cyclopropyl-lH-pyrazol-θ-amine (25.7 g, 208.8 mmol) in ACN (160 ml) were placed on top of the reaction flask. A total of 5 ml of triethylamine was added quickly dropwise to the reaction. The reaction was allowed to stir for 5 min, followed by the simultaneous dropwise addition of the remaining triethylamine and 5- cyclopropyl-lH-pyrazol-3-amine solution at a rate slow enough to keep the internal temperature at or below 5 0C. Upon completion of the addition, the reaction was allowed to stir for 1 hour at 0 0C, at which point no starting material remained, and the reaction was filtered through a fritted funnel. The remaining solids were washed with 0 0C ACN (3 x 100 ml). The solid product was then dried under vacuum for 30 minutes to give the title compound (25.2 g, 51 %) which was used without further purification. 1H NMR (400 MHz, CD3OD) δ 7.81-7.77 (m, IH), 6.33 (s, IH), 1.91 (septet, IH), 0.99-0.98 (m, 2H), 0.76-0.73 (m, 2H). MS: Calcd.: 261; Found: [M+H]+ 262.
Method 33 (ιSyi-(5-Fluoropyridin-2-yl)ethanamine
To the solution of (5)-tert-butyl-l-(5-fluoropyridin-2-yl)ethylcarbamate (Method 34, 12.8 g, 53.3 mmol) in DCM (100 ml) was added HCl/dioxane solution (107 ml, 4 N, 428 mmol). The reaction was stirred at room temperature for 3 hours. The solvent was removed and 50 ml of saturated sodium bicarbonate was added. The resulting aqueous solution was extracted with ether (6 x 400 ml), dried over sodium sulfate and concentrated to give the title compound (7.30 g, 98%) as pale yellow oil. 1H NMR (400 MHz) δ 8.44 (d, J= 2.8 Hz, IH), 7.66 (m, IH), 7.53 (m, IH), 4.01 (q, J= 6.8 Hz, IH), 1.94 (b, 2H), 1.26 (d, J= 6.8 Hz, 3H). MS: Calcd.: 140; Found: [M+H]+ 141.
Method 34 dSVfert-Butyl- 1 -(5-fluoropyridin-2-vDethylcarbamate
The solution of (5)-iV-(l-(5-fluoropyridin-2-yl)ethyl)acetamide (Method 35, 11.0 g, 60.37 mmol), DMAP (1.48 g, 12.07 mmol) and Boc2O (26.35 g, 120.7 mmol) in THF (100 ml) was stirred at 50 °C for 20 hours. After cooled to room temperature, lithium hydroxide monohydrate (5.19 g, 123.8 mmol) and water (100 ml) were added. The reaction was stirred at room temperature for 5 hours and diluted with ether (200 ml). The organic layer was separated, washed with brine (100 ml), and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (Hexane-EtOAc = 5 : 1) to give the title compound as a pale yellow oil (13.6 g, 94%). 1H NMR (400 MHz) δ 8.46 (d, J = 2.8 Hz, IH), 7.69 (m, IH), 7.35-7.41 (m, 2H), 4.67 (m, IH), 1.37 (s, 9H), 1.32 (d, J= 7.2 Hz, 3H). MS: Calcd.: 240; Found: [M+H]+ 241.
Method 35 r^-A/"-ri-C5-Fluoropyridin-2-vDethvDacetamide iV-(l-(5-fluoroρyridin-2-yl)vinyl)acetamide (Method 36, 11.0 g, 61.1 mmol) in MeOH (120 ml) under N2 was added (+)-l,2-bis((2S, 5S)-2,5-diethylphospholano)benzene (cyclooctadiene)rhodium(I)trifluoromethanesulfonate (0.441 g, 0.611 mmol). The solution was transferred to a high pressure bomb and charged 150 psi H2. The reaction stirred at room temperature and maintained inside pressure between 120-150 psi for 7 hours. The solvent was removed and the resulted residue was purified by column chromatography (EtOAc) to give the title compound as a white solid (9.8 g, 88%). 1H NMR (400 MHz) δ 8.49 (d, J= 2.4 Hz, IH), 8.32 (d, J= 7.6 Hz, IH), 7.66 (m, IH), 7.39 (dd, J= 4.4 and 8.8 Hz, IH), 4.95 (m, IH), 1.85 (s, 3H), 1.34 (d, J= 7.2 Hz, 3H). MS: Calcd.: 182; Found: [M+H]+ 183. Enantiomeric excess determined by HPLC (Chiralpak IA; 70:30 CO2MeOH), 95.3% ee.
Method 36
N-( 1 -(5-Fluoropyridm-2-yl')vinyl')acetamide A solution of MeMgBr (170.3 ml, 510.98 mmol) in ether was diluted with 170 ml of anhydrous THF and cooled to 0 °C. 5-Fluoropicolinontrile (Method 37, 53.6 g, 425.82 mmol) in THF (170 ml) was added dropwise. The reaction was stirred at 0 °C for 30 minutes, then diluted with DCM (170 ml). Acetic anhydride (48.3 ml, 510.98 mmol) in DCM (100 ml) was added dropwise at 0 0C. After addition, the reaction was warmed to room temperature and stirred at room temperature for 8 hours. Saturated sodium bicarbonate solution (50 ml) was added and extracted with EtOAc (2 x 200 ml). The combined organic was dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (hexane-EtOAc = 2.5 : 1) to give the title compound as a white solid (26.6 g, 35%). 1H NMR (400 MHz) δ 9.37 (s, IH), 8.57 (d, J= 2.8 Hz, IH), 7.81 (m, 2H), 6.01 (s, IH), 5.52 (s, IH), 2.08 (s, 3H). MS: Calcd.: 180; Found: [M+H]+ 181. Method 37
5-Fluoropicolinontrile
2-Bromo-5-fluoropyridine (93.0 g, 528 mmol), Zn dust (8.29 g, 127 mmol), zinc cyanide (40.3 g, 343 mmol), diphenylphosphinoferrocene (11.7 g, 21.1 mmol) and Pd2dba3 (9.68 g, 10.6 mmol) in anhydrous DMA (300 ml) was heated at 95 °C for 3 hours. After cooled to room temperature, brine (100 ml) and ether (500 ml) was added. The solid formed was removed by filtration and washed with ether (300 ml). The organic layer was separated, washed with brine (200 ml) and dried over sodium sulfate, and concentrated. After removal of solvent, the resulted residue was purified by column chromatography (hexane-DCM = 1 : 1) to give the title compound as a white solid (49 g, 72%). 1H NMR (400 MHz) δ 8.82 (d, J= 2.8 Hz, IH), 8.21 (dd, J= 4.4 and 8.8 Hz, IH), 8.05 (dd, J= 2.8 and 8.8 Hz, IH).
Method 38
6-Fluoro-iV-methoxy-N-methvmicotmamide To a solution of 6-fluoronicotinic acid (10 g, 70.9 mmol) in DCM (200 ml), was added
N,O-Dimethylhydroxylamine hydrochloride (7.3 g, 74.8 mmol), N-(3-Dimethylaminopropyl)- JV'-ethylcarbodiimide hydrochloride (15 g, 78.5 mmol), and triethylamine (22 ml, 156 mmol). The reaction mixture was allowed to stir at room temperature for 16 hours. The reaction was partitioned with water, layers were cut, and organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue obtained was purified by a silica gel filtration using EtOAc-DCM (4:1) to give 7.2 g (55% isolated yield) of the title compound. 1H NMR: 8.48 (s, 1 H) 8.21 (t, J=8.29 Hz, 1 H) 7.27 (dd, J=8.29, 3.01 Hz, 1 H) 3.54 (s, 3 H) 3.27 (s, 3 H).
Method 39 2-Chloro-6-('5-cvclopropyl-lH'-pyrazol-3-ylamino)-5-fluoro-4-iodonicotinonitrile
The crude 2,6-dichloro-5-fluoro-4-iodonicotinonitrile (8.0 g, 25.2 mmol), Et3N (3.3 g, 32.8 mmol) and 5-cyclopropyl-lH-pyrazol-3-amine (3.1 g, 25.2 mmol) were placed in ACN (50 ml) and the resulting solution was heated to 80 0C for 24 hours. The reaction was cooled to room temperature, filtered, and the resulting solid was washed with cold ACN, dried, and collected to give the title compound (3.0 g, 29%). MS: Calcd.: 403; Found: [M+H]+ 404. Method 40
2,6-Dichloro-5-fluoro-4-iodonicotinonitrile
To a solution of diisopropylamine (15.9 g, 157 mmol) in THF (400 ml) at -78 0C was added 72-butyllithium (2.5 M hexanes, 154 mmol), and the solution was stirred at -78 0C for 30 minutes. The lithium diisopropylamide solution was then added slowly dropwise to a -78 0C solution of 2,6-dichloro-5-fluoronicotinonitrile (10.0 g, 52.3 mmol) and iodine (26.5 g, 104 mmol) in THF (175 ml). Upon completion of the addition, the reaction was allowed to warm slowly to room temperature, and stirred at room temperature for 12 hours. An aqueous 10% Na2S2O3 solution (500 ml) was added and the reaction was extracted with EtOAc (3 x 300 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated to give the title compound (14.5 g, 87%) as a brown solid that was used without further purification.
Method 41 2,5-Difluoro-6-f5-methyl-lH-pyrazol-3-ylammo)nicotinonitrile
To a solution of 2,5,6-trifluoronicotinonitrile (1.0 g, 6.3 mmol) and triethylamine (0.83 g, 8.2 mmol) in ACN (30 ml) at O0C was added 5 -methyl- lH-pyrazol-3 -amine (0.67 g, 6.9 mmol). The reaction was stirred at 00C for 1 hour, at which point the reaction was filtered. The resulting solid was washed with cold ACN, dried and collected to give the title compound (0.44 g, 29%). MS: Calcd.: 235; Found: [M+H]+ 236.
Method 42
2,5-Difluoro-6-f5-isopropoxy-lH-pyrazol-3-ylamino)nicotinonitrile
To a solution of 2,5,6-trifluoronicotinonitrile (3.0 g, 19.0 mmol) and triethylamine (2.5 g, 24.7 mmol) in ACN (30 ml) at 0 0C was added 5-isopropoxy-l/f-pyrazol-3-amine (2.95 g, 20.9 mmol) in ACN (15 ml). The reaction was stirred at 0 0C for 1 hour, at which point the reaction was diluted with water (50 ml) and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2SO4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 :1) to give the title compound (0.48 g, 9%). MS: Calcd.: 279; Found: [M+H]+ 280. Method 42 (alternative procedure) 2,5-Difluoro-6-(5-isopropoxy-lH"-ρyrazol-3-ylamino)nicotinonitrile tert-Butyl 5-(5-cyano-3,6-difluoropyridin-2-ylamino)-3-isopropoxy-lH-pyrazole-l- carboxylate (Method 79, 10.6g, 27.9mmol), was placed in DCM (500ml) at room temperature. A 4.0 M solution of HCl (16.3g, 447mmol) in dioxane was added dropwise, and upon completion of the addition the reaction was allowed to stir for an additional 30 minutes. The reaction was concentrated to dryness, and dissolved in DCM (300ml) with a minimal amount of MeOH (5ml) to aid solubility. A saturated aqueous solution OfNa2CO3 (300ml) was added, and the reaction was stirred vigorously for 30 minutes. The layers were allowed to separate, and the organic fraction was dried (Na2SO4), filtered, and concentrated. The resulting residue was slurried with cold DCM (approx. 50ml), filtered, and the remaining solid was washed with DCM and dried to give the title compound (5.5g, 70%). MS: Calcd.: 279; Found: [MH-H]+ 280.
Method 43
2,5-Dichloro-6-(5-cyclopropyl-l//'-pyrazol-3-ylamino)nicotinonitrile
To a solution of 2,5,6-trichloronicotinonitrile (Method 44, 1.0 g, 4.8 mmol) and DIEA (0.81 g, 6.2 mmol) in n-BuOH (5 ml) was added S-cyclopropyl-lH-pyrazol-S-amme (2.3 g, 19.3 mmol). The reaction was heated to 60 0C for 2 hours, at which point the reaction was cooled to room temperature and concentrated. The resulting residue was diluted with 10 ml ACN, and stored at 00C for 1 hour. The solids that formed were then filtered, washed with cold ACN, dried and collected to give the title compound (0.62 g, 43%). MS: Calcd.: 294; Found: [M+H]+ 295.
Method 44
2,5,6-Trichlorom'cotinonitrile
A suspension of 2,5,6-trichloronicotinamide (Method 45, 2.3 g, 10.2 mmol) in POCl3 (20 ml) was heated to 90 0C for 1 hour. The reaction was then cooled to room temperature, and the POCl3 was removed under vacuum. The resulting residue was taken up in DCM (50 ml) and ice water (50 ml) was then added, followed by the careful addition of an aqueous solution OfNa2CO3 until pH 8 was achieved. The organic fraction was then dried over Na2SO4, filtered, and concentrated to give the title compound (2.1 g, 80%) which was used without further purification. 1H NMR (400 MHz, CD3OD) δ 8.54 (s, IH). Method 44 (alternative procedure) 2 , 5 ^-Trichloronicotinonitrile
To a solution of 2,4,5,6-tetrachloronicotinonitrile (7.6 g, 31.4 mmol) in MeOH/THF (230ml/230 ml) was added zinc dust (4.0 g, 62.8 mmol) slowly at 0°C and the saturated NH4Cl solution (105 ml) and the mixture was stirred for 30 minutes. TLC indicated that the reaction is complete. Saturated NH4OAc solution (180 ml) was added to the mixture and the mixture was allowed to stir at room temperature for 30 minutes. The mixture was filtered and was washed with EtOAc (500 ml). The filtrate was washed with brine and dried and concentrated to give a solid. ISCO column purification gave the title compound (4.63 g, 71%). 1H NMR (CDCl3): δ 8.97 (s, 1 H).
Method 45
2,5,6-Trichloronicotinamide
A solution of 2,5,6-trichloronicotinoyl chloride (Method 46, 2.5 g, 10.2 mmol) in dioxane (20 ml) was added dropwise to 10 ml ammonium hydroxide (28% NH3 in water) at
0 0C. Upon completion of the addition, the reaction was allowed to stir for an additional 10 minutes, and then extracted with DCM (3 x 50 ml). The combined organic fractions were dried over Na2SO4, filtered, and concentrated to give the title compound (2.3 g, 100%), which was used without further purification.
Method 46
2,5,6-Trichloronicotmoyl chloride
To a suspension of 2,5,6-trichloronicotinic acid (Method 47, 2.3 g, 10.2 mmol) in
DCM (25 ml) at room temperature was added oxalyl chloride (3.0 g, 24.4 mmol) and 3 drops of dry DMF. After 30 minutes, the resulting clear solution was concentrated to dryness to give the title compound (2.5 g, 100%), which was immediately used without further purification.
Method 47
2,5,6-Trichloronicotinic acid A suspension of 2,3,6-trichloro-5-methylpyridine (Method 48, 11.8 g, 60.0 mmol) in water (400 ml) was heated to 100 0C. Portionwise, KMnO4 (28.5 g, 180.2 mmol) was then added over 12 hours. The reaction was then allowed to stir for 2 days at 100 0C, over which time an additional 1O g of KMnO4 was added portionwise. When no starting material remained, the hot reaction was filtered, washed with hot water (2 x 75 ml), and the resulting filtrate was allowed to cool to room temperature. The aqueous filtrate was then extracted with EtOAc (3 x 100 ml), and then concentrated to a 50 ml volume. This aqueous solution was then cooled to 0 0C and adjusted to pH 1-2 with 6.0 M HCl. The resulting solid was then collected by filtration, washed with cold water, and dried to give the title compound (2.5 g, 18%) that was used without further purification.
Method 48
2,3 ,6-Trichloro-5-methylpyridine A well powdered mixture of 3-methylpiperidine-2,6-dione (Method 49, 15.0 g, 118 mmol) and PCl5 (155.0 g, 743 mmol) was slowly heated to 1500C and kept at that temperature for 2 hours. The resulting solution was then cooled to room temperature, and slowly poured onto ice. The resulting precipitate was filtered, washed with cold water, and dried. The resulting precipitate was then recrystallized from a mixture of EtOH-petroleum ether (1 : 8) to give the title compound (11.8 g, 51%).
Method 49
3-Methylpiperidine-2,6-dione
A solution OfH2SO4 (80ml), acetic acid (500ml) and 2-methylpentanedinitrile (128.0 g, 1184 mmol) was stirred at room temperature. An aqueous solution of acetic acid (100 ml in 32 ml water) was then added dropwise. Upon completion of the addition, the reaction was heated to 130 0C for 1 hour. The reaction was then allowed to cool to room temperature and filtered to remove solids, which were washed with acetic acid (100 ml). The filtrate was then concentrated until a residue resulted. This residue was poured into water (0.75 1), and adjusted to pH 5 with Na2CO3. The resulting solid was collected by filtration and washed with cold water to give the title compound (101 g, 67%) which was used without further purification.
Method 50
(Sπ-f3,5-Difluoropyridin-2-yl)ethanamine To a solution of (S)-tert-butyl- 1 -(3,5-difluoropyridin-2-yl)ethylcarbamate (Method 51 ,
2.05 g, 7.94 mmol) in DCM (15 ml) was added HCl/dioxane (15.9 ml, 4 N, 63.5 mmol). The reaction was stirred at room temperature for 3 hours. The solvent was removed and 10 ml of saturated sodium bicarbonate was added. The resulting aqueous solution was extracted with ether (5 x 100 ml), dried over sodium sulfate and concentrated to give the title compound (1.1 g, 88%) as a pale yellow oil. 1H NMR (400 MHz) δ 8.46 (d, J= 2.0 Hz, IH), 7.85 (m, IH), 4.23 (q, J= 6.8 Hz, IH), 1.90 (b, 2H), 1.27 (d, J= 6.8 Hz, 3H). MS: Calcd.: 158; Found: [M+H]+ 159.
Method 51 ("SVfert-Butyl-l-(3,5-difluoropyridin-2-yl)ethylcarbamate
A solution of (S)-iV-(l-(3,5-difiuoroρyridin-2-yl)ethyl)acetamide (Method 52, 2.0 g, 9.99 mmol), DMAP (0.244 g, 2.00 mmol), and BoC2O (6.54 g, 30.0 mmol) in THF (20 ml) was stirred at 50 °C for 40 hours. After cooling to room temperature, lithium hydroxide monohydrate (0.671 g, 16.0 mmol) and water (20 ml) were added. The reaction was stirred at room temperature for 18 hours. To which was added ether (100 ml). The organic layer was separated, washed with brine (50 ml) and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (hexane-EtOAc = 5:1) to give the title compound as a colourless oil (2.05 g, 79%). 1H NMR (400 MHz) δ 8.45 (s, IH), 7.87 (m, IH), 7.24 (d, J= 7.6 Hz IH)5 4.92 (m, IH), 1.34 (s, 9H), 1.32 (d, J= 7.2 Hz, 3H). MS: Calcd.: 258; Found: [M+H]+ 259. Enantiomeric excess was determined by HPLC (Chiralpak ADH; 98:2 CO2/MeOH), 93.6 % ee.
Method 52
(SViV-α-('3.5-Difiuoropyridin-2-vnethvDacetamide
To a solution of 7V-(l-(3,5-difluoropyridin-2-yl)vinyl)acetamide (Method 53, 2.2 g, 11.1 mmol) in MeOH (20 ml) under N2 was added (+)-l,2-bis((2S, 5S)-2,5-dimethyl phospholano)benzene (cyclooctadiene^hodiumφtrifluoromethanesulfonate (0.074 g, 0.111 mmol). The solution was transferred to a high-pressure bomb and charged 150 psi H2. The reaction stirred at room temperature and maintained inside pressure between 120-150 psi for 24 hours. The solvent was removed and the resulted residue was purified by column chromatography (EtOAc) to give the title compound as a white solid (2.0 g, 90%). 1HNMR (400 MHz) δ 8.47 (d, J= 2.4 Hz, IH), 8.34 (d, J= 7.2 Hz, IH), 7.89 (m, IH), 5.21 (m, IH), 1.81 (s, 3H), 1.34 (d, J= 6.8 Hz, 3H). MS: Calcd.: 200; Found: [M+H]+ 201. Method 53
N-(l-(3,5-Difluoropyridm-2-yl)vinyl)acetamide
To a mixture of (Z)-l-(3,5-difluoropyridin-2-yl)ethanone oxime (Method 54, 12.5 g, 72.6 mmol), acetic anhydride (54.8 ml, 581 mmol), and iron powder (32.4 g, 581 mmol) in DMF (100 ml) was added TMSCl (0.01 ml, 0.073 mmol). The reaction mixture was stirred at room temperature for 18 hours, then diluted with ether (300 ml) and filtered through a short pad of celite. The filtrate was concentrated and the residue was partitioned between 200 ml of EtOAc and 50 ml of saturated sodium bicarbonate. The organic layer was separated and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (hexane-EtOAc = 2:1) to give the title compound as a white solid (2.70 g, 19%). 1H NMR (400 MHz) δ 9.55 (s, IH), 8.51 (d, J= 2.0 Hz, IH), 7.97 (m, IH), 5.87 (s, IH), 5.14 (s, IH), 1.99 (s, 3H). MS: Calcd.: 198; Found: [M+H]+ 199.
Method 54 (Zyi-(3,5-Difluoropyridin-2-yl)ethanone oxime
To a solution of 3,5-difluoropicolinonitrile (10.0 g, 71.4 mmol) in THF (200 ml) was added methylmagnesium bromide (61.2 ml, 85.7 mmol) in THF solution at 0 0C. The reaction was stirred at room temperature for 1.5 hours. Saturated sodium bicarbonate solution (50 ml) was added, extracted with ether (100 ml), and dried over sodium sulfate. The solvent was removed. The residue (11.2 g, 71.28 mmol), hydroxylamine hydrochloride (9.907 g, 142.6 mmol) and sodium acetate (11.70 g, 142.6 mmol) in EtOH (100 ml) and water (50 ml) was heated at reflux for 3 hours. The solvent was removed and diluted with 50 ml of saturated sodium bicarbonate and extracted with EtOAc (2 x 200 ml). After dried over sodium sulfate, the solvent was removed and the title compound was used directly in next step without purification.
Method 55 dS)-l-('5-Fluoropyrimidin-2-yl')ethanamine
To a solution of (5)-tert-butyl-l-(5-fluoropyrimidin-2-yl)ethylcarbamate (Method 56, 0.21 g, 0.87 mmol) in DCM (5 ml) was added HCl (1.3 ml, 5.2 mmol) in dioxane. The reaction was stirred at room temperature for 3 hours. The solvent was removed give (<S)-l-(5- fluoropyrimidin-2-yl)ethanamine as HCl salt as white solid (quantitative). MS: Calcd.: 141; Found: [M+H]+ 142. Method 56
(S)-tert-Butyl- 1 -f 5-fluoropyrimidin-2-yl)ethylcarbamate
(5)-iV-(l-(5-fluoroρyrimidin-2-yl)ethyl)acetaπiide (Method 57, 0.20 g, 1.09 mmol), DMAP (0.027 g, 0.22 mmol) and BoC2O (0.60 g, 2.73 mmol) in THF (10 ml) was stirred at 50 °C for 40 hours. After cooled to room temperature, lithium hydroxide monohydrate (0.094 g, 2.24 mmol) and water (10 ml) was added. The reaction was stirred at room temperature for 9 hours. Ether (30 ml) was added, organic layer was separated, washed with brine (20 ml) and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (Hex-EtOAc=5:l) to give the title compound as a pale yellow oil (0.21 g, 80%). 1H NMR (400 MHz) 8.84 (s, 2H), 7.24 (d, J= 7.6 Hz, IH), 4.74 (m, IH), 1.35 (s, 12H). MS: Calcd.: 241; Found: [M+H]+ 242.
Method 57
("»y)-iV-(l-r5-Fluoropyrimidin-2-vDethyl)acetamide N-(l-(5-Fluoropyrimidin-2-yl)vinyl)acetamide (Method 58, 0.10 g, 0.55 mmol) in
MeOH (5 ml) under N2 was added (+)-l,2-bis((25r, 56)-2,5-diethylphospholano)benzene (cyclooctadieneyhodiumφtrifluoromethanesulfonate (0.04 g, 0.0055 mmol). The solution was transferred to a high pressure bomb and charged 150 psi H2. The reaction stirred at room temperature for 4 hours. The solvent was removed and the resulted residue was purified by column chromatography (EtOAc) to give the title compound as a white solid (0.096 g, 95%). 1H NMR (400 MHz) 8.84 (d, J= 0.8 Hz, 2H), 8.34 (d, J= 7.6 Hz5 IH), 5.00 (m, IH), 1.84 (s, 3H)5 1.37 (d, J= 6.8 Hz5 3H). MS: Calcd.: 183; Found: [M+H]+ 184. Enantiomeric excess determined by HPLC (Chiralpak IA; 95:5 CO2MeOH)5 >99% ee.
Method 58
N-( 1 -('5-Fluoropyrimidin-2-yl')vinvDacetamide
5-Fluoropyrimidine-2-carbonitrile (Method 59, 1.0 g, 8.1 mmol) in THF (10 ml) was added a solution of MeMgBr (3.3 ml, 9.75 mmol) in ether drop wise at 0 0C. After addition, the reaction was warmed to room temperature, stirred at room temperature for 1 hour and then diluted with DCM (10 ml). Acetic anhydride (1.23 ml, 13.0 mmol) was added in one portion. The reaction was stirred at room temperature for 1 hour and 40 0C for 1 hour. Saturated sodium bicarbonate solution (10 ml) was added and extracted with EtOAc (2x20 ml). The combined organic was dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (hexane-EtOAc = 2.5 : 1) to give the title compound as a white solid (0.38 g, 26%). 1H NMR (400 MHz) 9.34 (s, IH), 8.95 (s, 2H), 6.25 (s, IH), 6.03 (s, IH), 2.11 (s, 3H). MS: Calcd.: 181; Found: [M+H]+ 182.
Method 59
5-Fluoropyrimidine-2-carbonitrile
A 10 ml microwave vial was charged with 2-chloro-5-fluoropyrimidine (2.0 g, 15.09 mmol), Pd2(dba)3 (0.549 g, 0.6 mmol), DPPF (0.67 g, 1.21 mmol), zinc cyanide (1.15 g, 9.81 mmol), and zinc dust (0.237 mg, 3.62 mmol). The flask was evacuated and backfilled with N2, and anhydrous dimethylacetamide. The vial was mounted onto a Personal Chemistry microwave reactor and heated at 100 0C for 10 hours. The reaction mixture was diluted with EtOAc and then washed with brine three times. The organic layer was obtained and evaporated to dryness. The dried residue was purified by silica gel chromatography (By ISCO Combiflash with gradient EtOAc and hexanes) to afford the title compound as a creamy solid (1.50 g, 80%). GC-MS: 123 (M); 1H NMR (CDCl3) δ 8.80 (s, 2H).
Method 60
2,5 -Dichloro-6- \(5 -methyl- lH-pyrazol-3 -yl)ammo]nicotinomtrile
To a 25-ml, round-bottom flask, was added 2,5,6-trichloronicotinonitrile (Method 44, 1 g, 4.8 mmol), 5-methyl-lH-pyrazol-3-amine (466 mg, 4.8 mmol), DIEA (1.1 ml, 6.3 mmol), and EtOH (5 ml) and set to heat at 55 °C for 16 hours. The resulting mixture was then purified by silica gel chromatography (Biotage Horizon System) using 25-75% EtOAc/hexanes to give 770 mg of the title compound. 1H NMR: 12.36 (s, IH) 9.68 (s, IH) 8.39 (s, IH) 6.32 (s, IH) 2.29 (s, 3H). MS: Calcd.: 268; Found: [M+H]+ 267/269.
Method 61 N-[5-(l-Aminoethyl)-2-fluorophenyl]methanesulfonamide iV-{2-Fluoro-5-[(lZ)-iV-hydroxyethanimidoyl]phenyl}methanesulfonamide (Method 62, 200 mg, 812 μmol) was dissolved in 15 ml THF, to which was added Raney nickel 2800 slurry in water (200 μl). The mixture was charged with nitrogen and stirred over 1 arm of hydrogen. After 1 hour, MeOH (4 ml) was added and the reaction mixture was stirred overnight. The following morning the solution was filtered through celite, and the cake washed with MeOH, and the organic layer was concentrated to a yellow solid which was dried under high vacuum (181 mg, 96%). 1H NMR: 1.26 (d, 3 H, CH3), 2.92 (s, 3 H, SO2Me)5 3.33 (HOD), 4.04 (q, 1 H, CH), 5.70 (br, 2 H, NH2), 7.06-7.16 (m, 2 H, Ar), 7.35 (m, 1 H, Ar). LC/MS: 0.79 min, 231.08 (M-H)".
Method 62
N-{2-Fluoro-5-[dZ)-N-hvdroxyethanimidoyl]phenvUmethanesulfonamide
In a 100 ml Round bottom flask was added. N-(5-acetyl-2- fluorophenyl)methanesulfonamide (Method 63, 1.41 g, 6.10 mmol), hydroxylamine hydrochloride (847 mg, 12.2 mmol), sodium acetate (1.25 g, 15.24 mmol) and 30 ml water. The mixture was heated to 50°C and then 10 ml EtOH was added to dissolve the contents. The mixture was continued heating at 50 °C for 1 hour, then fitted with a reflux condenser and refluxed at 80 °C for 2 hours, (note: the solution turns homogeneous at 80°C). The solution was cooled to room temperature (note: crystals develop), rotovapped to remove traces of EtOH, cooled on an ice bath and filtered off-white crystals. The crystalline product was washed with ice cold water and air dried to obtain the white crystalline product (1.47 g, 98%.) TLC (1:1 Hexanes:EtOAc): Rf 0.50. 1HNMR: 2.12 (s, 3 H, Me), 3.02 (s, 3 H, SO2Me), 3.32 (HOD), 7.29 (m, 1 H, Ar), 7.48 (m, 1 H, Ar), 7.68 (m, 1 H, Ar), 9.67 (s, 1 H, NH), 11.31 (s, 1 H, OH). LC/MS: 1.70 min, 247.04 (M+l)+.
Method 63
N-(5-Acetyl-2-fluorophenvDmethanesulfonamide
3-Amino-4-fluoroacetophenone (Method 64, 1.00 g, 6.53 mmol) and pyridine (503 μl,
6.53 mmol) were stirred in 10 ml DCM over a blanket of nitrogen at 00C.
Methanesulfonylchloride (505 μl, 6.53 mmol) was added dropwise and the reaction was stirred at 0°C for 5 minutes and warmed to room temperature and stirred for 3 hours.
Quenched with 30 ml IN HCl, and extracted with 30 ml DCM. Washed organic layer with
Brine, dried over Na2SO4 and concentrated to orange oil, and dried under high vacuum.
Yellow solid/crystals develop which were triturated with hexanes, redissolved in DCM and evaporated and dried under high vacuum to obtain an off-white/yellow solid (1.42 g, 94%.) TLC (1:1 Hexanes:EtOAc): Rf 0.46. 1H NMR (CDCl3): δ 2.60 (s, 3 H, COMe), 3.08 (s, 3 H,
SO2Me), 6.56 (br, 1 H, NH), 7.23 (dd, 1 H, Ar), 7.81 (m, 1 H, Ar), 8.16 (m, 1 H, Ar). LC/MS:
1.66 min, 230.08 (M-I)" Method 64
3 - Amino-4-fluoroacetophenone
In a 250 ml round bottom flask was added 3-nitro-4-Fluoroacetophenone (5.00 g, 27.3 mmol) and HCl (12M, 13ml.) The solution was cooled to 0°C on an ice bath, and SnCl2 (15.5 g, 81.9 mmol) dissolved in 20 ml of water, was added dropwise over a 15 minute period. (Note: The reference material indicates the reaction is exothermic after 1 equivalent addition of Tin Chloride.) After complete addition the reaction mixture was stirred at 0°C for 10 min, warmed to room temp, brought to reflux for 15 minutes, cooled back to room temp and stirred for 2 hours. The mixture was poured over ice (150 g) and adjusted to pH 12 with 50% NaOH at 0°C. The resulting yellow emulsion was extracted with ether (2x150 ml), washed with brine (1x30 ml), dried over sodium sulfate and concentrated to a yellow solid. The solid was triturated with hexanes and dried to obtain a yellow solid (3.61 g, 86%). TLC (1 : 1 Hexanes:EtOAc): Rf 0.63. 1HNMR (CDCl3): δ 7.44 (m, 1 H, Ar), 7.34 (m, 1 H, Ar), 7.04 (m, 1 H, Ar), 4.32 (br, 2 H, NH), 2.54 (s, 3 H, Me). LC/MS 1.67 min, 154.07 (M+l)+
Method 65 l-f6-Fluoropyridm-3-vDethanone
To a cold solution (-78 °C) of 6-fluoro-N-methoxy-iV-methyrnicotinamide (Method 38, 7.2 g, 39 mmol) in THF (130 ml), was added methyl magnesium bromide (20 ml, 59 mmol, 3M solution in ether) dropwise. The cooling bath was removed and reaction mixture was allowed to warm to room temperature and stir for 2 hours. The reaction was quenched with 3N HCl solution, layers were cut, and organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to afford 3.8 g (70% yield) of the title compound. 1H NMR (CDCl3) δ 8.80 (s, 1 H) 8.29 - 8.43 (m, 1 H) 6.98 - 7.06 (m, 1 H) 2.62 (s, 3 H).
Method 66 N-[5-π-AminoethylV2-fluorophenvπacetamide
To a round, bottom flask was added N- {2-fluoro-5-[(12)-7V-hydroxyethanimidoyl] phenyl} acetamide (Method 67, 715 mg, 3.4 mmol) and AcOH (0.5 ml) in EtOH (20 ml), followed by the addition of Palladium on carbon (146 mg, 10wt%) under N2 atmosphere. Once the catalyst was added, the system was evacuated and purged with hydrogen (atmospheric pressure). This process was performed several times to ensure complete saturation of hydrogen to the system. The reaction was then allowed to stir for 16 hours at room temperature. The heterogeneous mixture was then filtered over a pad of Celite and the filtrate was concentrated in vacuo to give quantitative yield of the title compound. 1H NMR: 9.67 (s, 1 H) 7.80 (d, J=7.54 Hz, 1 H) 7.07 - 7.19 (m, 2 H) 4.00 (q, J=6.28 Hz, 1 H) 2.06 (s, 3 H) 1.15 - 1.30 (m, 3 H).
Method 67
JV- {2-Fluoro-5-[dZ)-N-hydroxyethanimidoyl]phenyl} acetamide
To a round, bottom flask was added iV-(5-acetyl-2-fluorophenyl)acetamide (Method 68, 1.17 g, 6 mmol), hydroxyl amine hydrochloride salt (834 mg, 12 mmol), and NaOAc (1.2 g, 15 mmol) in waterEtOH solution (20 ml, 3:1). The resulting mixture was then set to heat at 50 °C for 1 hour. The reaction was allowed to cool to room temperature and partitioned with EtOAc. The layers were cut and the organic layer was then dried over Na2SO4, filtered and concentrated in vacuo. The crude residue obtained was then purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 5-50% EtOAc in DCM to give 815 mg of the title compound (60% overall yield, 2 steps). 1H NMR: 11.22 (s, 1 H) 9.75 (s, 1 H) 8.22 (dd, J=7.54, 1.88 Hz, 1 H) 7.30 - 7.46 (m, 1 H) 7.24 (dd, J=10.93, 8.67 Hz, 1 H) 1.98 - 2.18 (m, 6 H).
Method 68 N-(5-Acetyl-2-fluorophenvDacetamide
To a round, bottom flask was added 3-amino-4-fluoroacetophenone (Method 64, 1 g, 6.54 mmol) in DMF (15 ml), followed by the addition of acetyl chloride (0.56 ml, 7.84 mmol) and DIEA (2.3 ml, 13.08 mmol). The solution was set to stir at room temperature. The reaction appeared complete by TLC after 30 min. The reaction was then quenched with water and partitioned with EtOAc. The layers were cut, followed by an additional wash of the aqueous with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude residue obtained (1.17 g), was used directly in the next step. 1H NMR (CDCl3) δ 8.94 (d, J=7.54 Hz, 1 H) 7.71 (d, 1 H) 7.43 (s, 1 H) 7.15 (s, 1 H) 2.56 - 2.60 (m, 3 H) 2.21 - 2.28 (m, 3 H). Method 69 iy-|"5-(l-Aminoethyl)-2-fluorophenyl1cvclopropanecarboxamide
To a round, bottom flask was added N-{2-fluoro-5-[(lZ)-N- hydroxyethanimidoyljphenyljcyclopropanecarboxarnide (Method 70, 458 mg, 1.94 mmol) and HOAc (1 ml) in EtOH (25 ml), followed by the addition of Palladium on carbon (100 mg, 10wt%) under N2 atmosphere. Once the catalyst was added, the system was evacuated and purged with hydrogen (atmospheric pressure). This process was performed several times to ensure complete saturation of hydrogen to the system. The reaction was then allowed to stir for 16 hours at room temperature. The heterogenous mixture was then filtered over a pad of celite and the filtrate was concentrated in vacuo to give quantitative yield of the title compound. 1H NMR: 9.99 (s, 1 H) 7.85 (d, J=8.29 Hz, 1 H) 7.17 (s, J=8.29 Hz, 2 H) 4.03 (d, J=6.03 Hz, 1 H) 1.90 - 2.04 (m, 1 H) 1.26 (d, J=6.78 Hz, 3 H) 0.78 (d, J=6.03 Hz, 4 H)
Method 70 N-{2-Fluoro-5-|"('lZ)-JV-hvdroxyethanimidoyl]phenyl}cvclopropanecarboxamide
To a round, bottom flask was added iV-(5-acetyl-2- fluorophenyl)cyclopropanecarboxamide (Method 71, 458 mg, 2.07 mmol), hydroxyl amine hydrochloride salt (288 mg, 4.14 mmol), and NaOAc (424 mg, 5.17 mmol) in water-EtOH solution (7 ml, 3:1). The reaction mixture was set to heat at 50 °C for 1 hour. As the reaction reached desired temperature, no dissolution was observed, thus more EtOH (7 ml) was added for dissolution to occur. The reaction was complete after 1 hour and concentrated in vacuo. The title compound (458 mg, 94% yield) was used directly in next step. 1H NMR: 11.32 (s, 1 H) 10.10 (s, 1 H) 8.19 (d, J=6.03 Hz, 1 H) 7.30 - 7.44 (m, 1 H) 7.23 (s, 1 H) 2.09 (s, 3 H) 2.01 (s, 1 H) 0.79 (s, 4 H).
Method 71 JV-(5-Acetyl-2-fluorophenyl)cvclopropanecarboxamide
To a round, bottom flask was added 3-amino-4-fluoroacetophenone (Method 64, 1 g, 6.54 mmol), cyclopropyl carboxylic acid (0.62 ml, 7.84 mmol), HATu (2.5 g (6.57 mmol), and DIEA (2.3 ml, 13.08 mmol) in DMF (15 ml). The reaction mixture was allowed to stir at room temperature for 16 hours. The reaction mixture was quenched with water and partitioned with EtOAc. The layers were cut, followed by an additional wash of the aqueous with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude residue obtained was then purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 5-15% EtOAc in DCM to give 458 mg of the title compound (32% isolated yield). 1H NMR: 10.16 (s, 1 H) 8.53 (dd, J=7.91, 2.26 Hz, 1 H) 7.67 - 7.82 (m, 1 H) 7.40 (dd, J=10.55, 8.67 Hz, 1 H) 2.54 (s, 3 H) 1.95 - 2.09 (m, 1 H) 0.78 - 0.88 (m, 4 H).
Method 72 l-C5-Fluoropyrimidin-2-vDethanamine
A round-bottom flask containing 2-(l-azidoethyl)-5-fluoropyrimidine (Method 73, 0.60 g, 3.59 mmol) was charged with 10% Pd/C (0.191 g) and was evacuated and backfilled with H2 via a filled balloon. MeOH (10 ml) was added, and the mixture was allowed to stir at room temperature for 3 hours. The mixture was filtered through a plug of diatomaceous earth, which was subsequently washed well with MeOH. The filtrates were concentrated to give the title compound as a pale yellow oil (0.50 g, 99%). 1H NMR (CDCl3) δ 8.60 (s, 2H), 4.65 (br s 2H), 4.10 (m, IH), 1.20 (d, 3H).
Method 73
2-d -AzidoethylV5-fluoropyrimidine
A round-bottom flask containing l-(5-fluoropyrimidin-2-yl)ethanol (Method 74, 0.79 g, 5.55 mmol) was charged with triethylamine (0.67 g, 6.66 mmol) and anhydrous DCM (10 ml). The solution was cooled to 0 0C, and methanesulfonyl chloride (0.70 g, 4.1 mmol) was added dropwise. The resulting mixture was allowed to stir at room temperature for 2 hours, at which point the volatile components were removed using a rotary evaporator. The residue was dissolved in DMF (15 ml) and treated with sodium azide (0.72 g, 11.1 mmol). The resulting mixture was stirred at room temperature for 60 hours. It was then partitioned between EtOAc and brine. The organic layer was obtained, dried (Na2SO4), and evaporated to dryness. The crude material was purified by silica gel chromatography (by ISCO Combiflash with gradient EtOAc and hexanes) to afford the title compound as a colourless oil (0.60 g, 65% yield over two steps). GC-MS, 167 (M), 138 (M-N2), 125 (M-N3); 1H NMR (CDCl3) δ 8.60 (s, 2H), 4.60 (m, IH), 1.65 (d, 3H). Method 74 l-(5-Fluoropyrimidin-2-yl)ethanol l-(5-Fluoropyrimidin-2-yl)ethanone (Method 75, 0.77 g) was dissolved in MeOH (15 ml), and the solution was cooled to 0 °C. NaBH4 (0.210 g, 5.55 mmol) was added. The mixture was stirred at room temperature for 1 hour and then partitioned between EtOAc and H2O. The organic extract was washed with brine, dried (Na2SO4), filtered, and concentrated to give the title compound as a yellowish oil (0.79 g, 99%). 1H NMR (CDCl3) δ 8.65 (s, 2H), 5.20 (m, IH), 4.00 (br s, IH), 1.80 (d, 3H).
Method 75 l-(5-Fluoropyrimidin-2-yl)ethanone
A round-bottom-flask containing 5-fluoropyrimidine-2-carbonitrile (Method 59, 1.50 g, 12.19 mmol) was charged with anhydrous THF (30 ml) under N2. The solution was cooled to 0 °C, and a solution of MeMgBr (4.90 ml of a 3.0 M solution in ether, 14.62 mmol) was added dropwise. After 2 hours at 0 °C, the reaction mixture was quenched with ice water and extracted with EtOAc. The organic extract was washed with brine, dried over Na2SO4, and evaporated to dryness to give the title compound as an oil (0.778 g, yield 46%). GC-MS, 140 (M); 1H NMR (CDCl3) δ 8.65 (s, 2H), 2.65 (s, 2H).
Method 76 l-(6-Fluoropyridin-3-vDethanamine
To a slurry of Raney Nickel in EtOH solution (75 ml), under inert atmosphere, was added l-(6-fluoropyridin-3-yl)ethanone oxime (Method 77, 2.3 g, 14.9 mmol). The system was purged with hydrogen and evacuated several times to ensure complete saturation with hydrogen. The reaction, after 2 hours stirring at room temperature, was filtered over celite and filtrate collected was concentrated in vacuo to give 2 g (95% isolated yield) of the title compound. 1H NMR: 8.16 (s, 1 H) 7.97 (t, J=8.29 Hz, 1 H) 7.09 (dd, J=8.29, 3.01 Hz, 1 H) 4.03 (q, J=6.78 Hz, 1 H) 1.23 (d, J=6.03 Hz, 3 H).
Method 77
1 -(6-Fluoropyridin-3-yl)ethanone oxime
To a 200-ml, round bottom flask was added, l-(6-fluoropyridin-3-yl)ethanone (Method 65, 2.5 g, 17.9 mmol), hydroxylamine hydrochloride (2.5 g, 35.8 mmol), and NaOAc (3.7 g, 44.8 mmol) in a solution of water-EtOH (65 ml, 3.3:1). The resulting mixture was heated to 50 0C for 1 hour. The reaction was then allowed to cool to room temperature, partitioned with EtOAc, layers were cut, and organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to afford the title compound in quantitative yield. 1H NMR: 11.49 (s, 1 H) 8.47 (s, 1 H) 8.17 - 8.27 (m, 1 H) 7.21 (dd, J=8.29, 3.01 Hz, 1 H) 2.17 (s, 3 H).
Method 78 tert-Butyl S-amino-S-isopropoxy-lH-pyrazole-l-carboxylate
A solution of 5-isopropoxy-lH-pyrazol-3-amine (3.5g, 24.8mmol) in DCM (100ml) was prepared at room temperature. A 4.5M aqueous KOH solution (1 l.lg, 198mmol) was added dropwise, followed by the addition of di-tert-butyl dicarbonate (5.68g, 26mmol) in DCM (20ml). The resulting reaction was then stirred vigorously for 30 hours, at which point water (200ml) was added and the layers were allowed to separate. The organic fraction was separated, dried (Na2SO4), filtered, and then concentrated. The resulting oil was purified by column chromatography (100: 1 DCMMeOH) to give the title compound (5.4g, 90%). MS: Calcd.: 241; Found: [M+H]+ 242.
Method 79 tert-Butyl 5 -(5 -cyano-3 ,6-difluoropyridin-2-ylamino)-3 -isopropoxy- 1 H-pyrazole- 1 - carboxylate
A solution of tert-butyl 5-amino-3-isopropoxy-lH-pyrazole-l-carboxylate (Method 78, 4.Og, 16.4mmol) in THF (45ml) was cooled to -780C. A 1.0M THF solution of LiHMDS (2.6 Ig, 15.6mmol) was added dropwise and the reaction was stirred at -780C for 30 minutes. A -780C solution of 2,5,6-trifluoronicotinonitrile (1.3g, 8.2mmol) in THF (20ml) was added dropwise via cannula to the above anion solution. Upon completion of the addition, the resulting reaction was allowed to stir for 10 minutes at -780C, and was then quenched with water (100ml). The reaction was allowed to warm to room temperature, extracted with DCM (3 x 100ml), dried (Na2SO4), filtered, and then concentrated to give the title compound (95% conversion by LCMS) which was used without further purification. MS: Calcd.: 379; Found: [M+H]+ 380. Utility
The compounds of the present invention have utility for the treatment of cancer by inhibiting the tyrosine kinases, particularly the Tries and more particularly Trie A and B. Methods of treatment target tyrosine kinase activity, particularly the Trk activity and more particularly Trk A and B activity, which is involved in a variety of cancer related processes. Thus, inhibitors of tyrosine kinase, particularly the Tries and more particularly Trk A and B, are expected to be active against neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, fibrosarcoma and osteosarcoma. Tyrosine kinase inhibitors, particularly the Trk inhibitors and more particularly Trk A and B inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to autoimmune, inflammatory, neurological, and cardiovascular diseases.
In addition, the compounds of the invention are expected to be of value in the treatment or prophylaxis of cancers selected with up regulated of constitutively activated Trk kinases, including but not limited to, oncogenic rearrangements leading to ETV6-TrkC fusions, TRP-TrkA fusions proteins, AML-ETO (t8;21), autocrine or paracrine signalling leading to elevated serum levels of NGF, BDNF, neurotropins or tumours with constitutively active Trk associated with disease aggressiveness, tumour growth and proliferation or survival signalling.
Compounds of the present invention have been shown to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B, as determined by the Trk A Assay described herein.
Compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B. These would be provided in commercial kits comprising a compound of this invention Trk A Assay Format
Trk A kinase activity was measured for its ability to phosphorylate synthetic tyrosine residues within a generic polypeptide substrate using an Amplified Luminescent Proximity Assay (Alphascreen) technology (PerkinElmer, 549 Albany Street, Boston, MA).
To measure Trk A kinase activity, the intracellular domain of a HIS-tagged human Trk A kinase (amino acids 442-796 of Trk A, Swiss-Prot Primary Accession Number P04629) was expressed in SF9 cells and purified using standard nickel column chromatography. After incubation of the kinase with a biotinylated substrate and adenosine triphosphate (ATP) for 20 minutes at room temperature, the kinase reaction was stopped by the addition of 30 mM ethylenediaminetetraacetic acid (EDTA). The reaction was performed in 384 well microtitre plates and the reaction products were detected with the addition of strepavidin coated Donor Beads and phosphotyrosine-specific antibodies coated Acceptor Beads using the EnVision Multilabel Plate Reader after an overnight incubation at room temperature.
Figure imgf000124_0001
Although the pharmacological properties of the compounds of the formula (I) vary with structural change, in general activity possessed by compounds of the formula (I) may be demonstrated at IC5O concentrations (concentrations to achieve 50% inhibition) or doses in the range of (0.01 μM to 10 μM).
When tested in the above in- vitro assay the Trk inhibitory activity of the following examples was measured at the following ICs0S.
Figure imgf000124_0002

Claims

Claim
Figure imgf000125_0001
(I) wherein:
R1 and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, Λ^Λf-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1 -6alkyl)carbamoyl,
N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyi)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R1 and R2 independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R7; one of X1, X2, X3 and X4 is =N-, the other three are independently selected from =CR8-, =CR9- and =CR10-;
R3 is hydrogen or optionally substituted C1-6alkyl; wherein said optional substituents are selected from one or more R11; R4 and R34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, Q-βalkanoylarnino, JV-(C 1-6alkyi)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
A is a direct bond or Ci-2alkylene; wherein said C1-2alkylene may be optionally substituted by one or more R14; Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15;
R5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2.6alkynyl, Ci-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, iV-(C1-6alkyl)carbamoyl, ΛζiV-(C1_6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl,
N,N-(C1-6alkyl)2sulphamoyl, Ci-6alkylsulphonylamino, carbocyclyl-R37- or heterocyclyl-R38-; wherein R5 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17 ; n is 0, 1, 2 or 3; wherein the values of R5 may be the same or different; R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Cj-βalkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)ammo, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl,
N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, JV,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R25- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from
R19;
R6, R11, R12, R14, R16 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, Ci-6alkanoyloxy, iV-(C1-6alkyl)amino, ΛζiV-(C1-6alkyl)2amino, C1-6alkanoylamino, iV-(Ci-6alkyl)carbamoyl,
N,N-(C1-6alkyl)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1 -6alkyl)sulphamoyl, N1N-(C i -6alkyl)2sulphamoy 1, C \ -6alkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, Rπ, R12, R14, R16 and R18 independently of each other may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R7, R13, R15, R17, R19 and R21 are independently selected from Ci-6alkyl, Ci-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, iV-(C1-6alkyl)carbamoyl, iV,iV-(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R7, R13, R15, R17, R19 and R21 independently of each other may be optionally substituted on carbon by on or more R22;
R20 and R22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C^alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, Q-βalkanoyl, Ci-6alkanoyloxy, iV-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, iV-(C1-6alkyl)carbamoyl, N,iV-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(Ci-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, C1-6alkylsulphonyl-iV-(C1-6alkyl)amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 and R22 independently of each other may be optionally substituted on carbon by one or more R23; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24;
R25, R26, R27, R28, R35, R36, R37 and R38 are independently selected from a direct bond, -O-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(O)N(R31)-, -S(O)5-, -NH=CH-, -SO2N(R32)- or -N(R33)SO2-; wherein R29, R30, R31, R32 and R33 are independently selected from hydrogen or C1-6alkyl and s is 0-2;
R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, iV-ethylcarbamoyl, iV,./V-dmiethylcarbamoyl, iV,iV-diethylcarbamoyl, N-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, iV-methylsulphamoyl, iV-ethylsulphamoyl, ΛζiV-dmiethylsulphamoyl, iV,N-diethylsulphamoyl, iV-methyl-iV-ethylsulphamoyl or phenyl; and
R24 is selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N-(C1-6alkyl)carbamoyl, 7V,iV-(C1-6alkyi)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof.
2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein R1 is C1-6alkyl, C1-6alkoxy and cyclopropyl.
3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in either claim 1 or claim 2 wherein R2 is hydrogen.
4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-3 wherein X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-.
5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-4 wherein R3 is hydrogen.
6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-5 wherein R4 and R34 are independently selected from hydrogen or C1-6alkyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy.
7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 wherein A is a direct bond.
8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-7 wherein Ring C is phenyl, pyridyl or pyrimidinyl.
9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-8 wherein R5 is selected from halo, C1-6alkanoylamino, C1-6alkylsulphonylamino or carbocyclyl-R37-; wherein R37 is -C(O)N(R31)-; wherein R31 is hydrogen.
10. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9 wherein n is 1 or 2; wherein the values of R5 may be the same or different.
11. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10 wherein R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C1-6alkyl, Q-βalkanoyl, iV-(Ci-6alkyl)amino or carbocyclyl-R -; wherein R , R and R independently of each other may be optionally substituted on carbon by one or more R18; R is selected from hydroxy, amino, N-(C1-6alkyl)amino, C1-6alkanoylamino,
C1-6alkylsulphonylamino, carbocyclyl-R - or heterocyclyl-R -; wherein R may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R20 is selected from halo, amino, C1-6alkyl, N,iV-(C1-6alkyl)2amino, C1-6alkylsulphonyl-iV-(Ci-6alkyl)amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 may be optionally substituted on carbon by one or more R23; R is selected from C1-6alkylsulphonyl; R is dimethylamino or phenyl; and
R27, R28, R35 and R36 are independently selected from a direct bond, -C(O)N(R31)-, -NH=CH- or -SO2N(R32)-; wherein R31 and R32 are independently selected from hydrogen or Ci-βalkyl.
12. A compound of formula (I) :
Figure imgf000129_0001
(I) wherein: R1 is methyl, f-butyl, isopropoxy or cyclopropyl;
R2 is hydrogen;
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-; R3 is hydrogen;
R4 and R34 are independently selected from hydrogen, methyl or hydroxymethyl;
A is a direct bond;
Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl;
R5 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino; n is 1 or 2; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl, (R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, (S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl, mesylaminomethyl, morpholinomethyl, benzoylaminomethyl, pyrid-3-yl-carbonylaminomethyl, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl, 6-morpholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl, 5-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl, 4-dimethylaminobenzylcarbonylaminomethyl, 2-(iV-(isopropyl)-N-(mesyl)amino)acetylammomethyl, 2-(7V-(phenethyl)-iV-(mesyl)amino)acetylaminomethyl, 1-mesylpiperidin-l-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl, tetrahydro-2H-thiopyran-4-yl-carbonylaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl, 3-phenylpropionylaminomethyl, 2-(7V-benzoyl-iV-methylamino)acetylaminomethyl, 4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl, 2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl, pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl, (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino; or a pharmaceutically acceptable salt thereof.
13. A compound of formula (I) :
Figure imgf000131_0001
(I) selected from:
(iS)-6-(5-cyclopropyl-l/f-ρyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-4-
(methylamino)nicotinonitrile;
(5)-6-(5-cyclopropyl- li7-ρyrazol-3 -ylamino)-5-fluoro-2-( 1 -(5-fluoropyridin-2~ yl)ethylamino)nicotinonitrile;
(»S)-5-fluoro-2-(l-(5-fluoropyridin-2-yl)ethylamino)-6-(5-isopropoxy-lH-pyrazol-3- ylamino)nicotinonitrile;
(iS)-6-(5-cyclopropyl-lH'-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-4-
(isopropylamino)nicotinonitrile; (5)-5-chloro-6-(5-cycloρroρyl- lH"-pyrazol-3 -ylamino)-2-( 1 -(5-fmoropyridin-2- yl)ethylamino)nicotinonitrile;
6- [(5-cyclopropyl- lH-pyrazol-3 -yl)amino] -2-{[(l«S}-l -(3 ,5 -difluoropyridin-2- yl)ethyl]amino}-5-fluoronicotinonitrile;
()S)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-l/-r-pyrazol-3- ylamino)nicotinonitrile;
(»S)-6-(5-cyclopropyl- lH"-pyrazol-3-ylamino)-5-fluoro-2-(l -(4- fluorophenyl)ethylamino)nicotinonitrile;
(i?)-6-(5-cyclopropyl-lH"-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluoroρhenyl)-2- hydroxyethylamino)nicotinonitrile; or (i?)-5-fluoro-2-(l -(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy- lH"-pyrazol-3- ylamino)nicotinonitrile; W
131 or a pharmaceutically acceptable salt thereof.
14. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, which process comprises of: Process a) reaction of a compound of formula (II):
Figure imgf000132_0001
(ID wherein Pg is a nitrogen protecting group; with a compound of formula (III):
Figure imgf000132_0002
(IH) wherein L is a displaceable group;
Process b) for compounds of formula (I) wherein R4 is hydroxymethyl and R34 is hydrogen; reaction of a compound of formula (II) with an epoxide of formula (IV):
Figure imgf000132_0003
(IV)
Process c) reacting a compound of formula (V):
Figure imgf000133_0001
(V) with hydrazine;
Process d) reacting a compound of formula (VI):
Figure imgf000133_0002
(VI) wherein L is a displaceable group; with an amine of formula (VII):
Figure imgf000133_0003
(VII) Process e) reacting a compound of formula (VIII):
Figure imgf000134_0001
(VHI) wherein L is a displaceable group; with an amine of formula (IX):
Figure imgf000134_0002
(IX)
Process j) reacting an amine of formula (X):
Figure imgf000134_0003
(X) with a compound of formula (XI):
Figure imgf000134_0004
(XI) wherein L is a displaceable group; and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt.
15. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use as a medicament.
16. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, in the manufacture of a medicament for use in the inhibition of Trk activity.
17. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
18. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, in the manufacture of a medicament for use in the production of an antiproliferative effect.
19. A method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13.
20. A method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13.
21. A method of producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13.
22. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
5 23. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trie activity.
0 24. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.
5 25. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
0 26. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use in the inhibition of Trk activity.
27. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use in the treatment or prophylaxis of cancer. 5
28. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use in the production of an anti-proliferative effect.
29. The method or use according to claims 17, 20, 24 or 27 wherein said cancer is selected i0 from congenital fibrosarcoma, mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, melanoma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma and leukaemia.
PCT/GB2006/000334 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors WO2006082392A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
JP2007553688A JP5139084B2 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
BRPI0606793A BRPI0606793A8 (en) 2005-02-04 2006-02-01 compound or a pharmaceutically acceptable salt thereof, process for the preparation and use thereof, methods for inhibiting trk activity, treating or prophylaxis cancer, and producing an antiproliferative effect in a warm-blooded animal and pharmaceutical composition
MEP-2011-563A ME02645B (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
CN2006800101082A CN101155800B (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
CA2595834A CA2595834C (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PL06701619T PL1846394T3 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2007009437A MX2007009437A (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors.
US11/815,140 US8324252B2 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
ES06701619T ES2375735T3 (en) 2005-02-04 2006-02-01 USEFUL PIRAZOLILAMINOPIRIDINE DERIVATIVES AS QUINASE INHIBITORS.
KR1020077020258A KR101302945B1 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP06701619A EP1846394B1 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
DK06701619.6T DK1846394T3 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives suitable as kinase inhibitors
SI200631240T SI1846394T1 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
NZ561145A NZ561145A (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
AU2006210710A AU2006210710B2 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
AT06701619T ATE530545T1 (en) 2005-02-04 2006-02-01 PYRAZOLYLAMINOPYRIDINE DERIVATIVES SUITABLE AS KINASE INHIBITORS
IL184674A IL184674A (en) 2005-02-04 2007-07-17 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
NO20073791A NO341112B1 (en) 2005-02-04 2007-07-20 (S) -5-Fluoro-2- (1- (5-fluoropyridin-2-yl) ethylamino) -6- (5-isopropoxy-1H-pyrazol-3-ylamino) nicotinonitrile or a pharmaceutically acceptable salt thereof
HK08101578.0A HK1114374A1 (en) 2005-02-04 2008-02-13 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
HR20110962T HRP20110962T1 (en) 2005-02-04 2011-12-21 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
US13/688,790 US8835465B2 (en) 2005-02-04 2012-11-29 Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US65005305P 2005-02-04 2005-02-04
US60/650,053 2005-02-04
US65332905P 2005-02-16 2005-02-16
US60/653,329 2005-02-16
US72163305P 2005-09-29 2005-09-29
US60/721,633 2005-09-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/815,140 A-371-Of-International US8324252B2 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
US13/688,790 Continuation US8835465B2 (en) 2005-02-04 2012-11-29 Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
WO2006082392A1 true WO2006082392A1 (en) 2006-08-10

Family

ID=36177856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000334 WO2006082392A1 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Country Status (30)

Country Link
US (2) US8324252B2 (en)
EP (2) EP1846394B1 (en)
JP (1) JP5139084B2 (en)
KR (1) KR101302945B1 (en)
CN (1) CN101155800B (en)
AR (1) AR056184A1 (en)
AT (1) ATE530545T1 (en)
AU (1) AU2006210710B2 (en)
BR (1) BRPI0606793A8 (en)
CA (1) CA2595834C (en)
CY (2) CY1115078T1 (en)
DK (2) DK2383268T3 (en)
ES (2) ES2375735T3 (en)
HK (2) HK1114374A1 (en)
HR (1) HRP20110962T1 (en)
HU (1) HUE025671T2 (en)
IL (1) IL184674A (en)
ME (1) ME02645B (en)
MX (1) MX2007009437A (en)
MY (1) MY149512A (en)
NO (1) NO341112B1 (en)
NZ (1) NZ561145A (en)
PL (2) PL2383268T3 (en)
PT (2) PT1846394E (en)
RS (1) RS52061B (en)
SA (1) SA06270007B1 (en)
SI (2) SI1846394T1 (en)
TW (1) TWI370127B (en)
UY (1) UY29360A1 (en)
WO (1) WO2006082392A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2008053812A1 (en) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and medicinal use thereof
WO2008054292A1 (en) * 2006-11-01 2008-05-08 Astrazeneca Ab Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
EP2083624A2 (en) * 2006-10-18 2009-08-05 Merck & Co., Inc. 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
WO2009110475A1 (en) * 2008-03-04 2009-09-11 石原産業株式会社 Process for production of 3-amino-2-chloro-6- trifluoromethylpyridine
WO2010020810A1 (en) * 2008-08-19 2010-02-25 Astrazeneca Ab 2-(imidaz0lylamin0)-pyridine derivatives and their use as jak kinase inhibitors
JP2010526128A (en) * 2007-05-04 2010-07-29 アストラゼネカ アクチボラグ 9- (pyrazol-3-yl) -9H-purin-2-amine and 3- (pyrazol-3-yl) -3H-imidazo [4,5-B] pyridin-5-amine derivatives and for the treatment of cancer Their use of
WO2011076419A1 (en) 2009-12-24 2011-06-30 Almirall, S.A. Imidazopyridine derivatives as jak inhibitors
WO2011101161A1 (en) 2010-02-18 2011-08-25 Almirall, S.A. Pyrazole derivatives as jak inhibitors
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2012010883A2 (en) 2010-07-19 2012-01-26 Astrazeneca Ab Pharmaceutical depot for 5-fluoro-2 [ [ (1s) -1- (5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
WO2012069202A1 (en) 2010-11-26 2012-05-31 Almirall,S.A. Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
EP2589592A1 (en) * 2010-06-30 2013-05-08 FUJIFILM Corporation Novel nicotinamide derivatives or salts thereof
WO2013183578A1 (en) 2012-06-04 2013-12-12 第一三共株式会社 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9051310B2 (en) 2011-12-28 2015-06-09 Fujifilm Corporation Nicotinamide derivative or salt thereof
US9540351B2 (en) 2013-09-18 2017-01-10 Axikin Pharmaceuticals, Inc. Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
WO2017157885A1 (en) 2016-03-16 2017-09-21 Bayer Cropscience Aktiengesellschaft N-(cyanobenzyl)-6-(cyclopropyl-carbonylamino)-4-(phenyl)-pyridine-2-carboxamide derivatives and related compounds as pesticides and plant protection agents
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020233645A1 (en) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 Macrolide derivatives, preparation method and application thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013337742B2 (en) * 2012-11-05 2017-11-23 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
HRP20211813T1 (en) 2014-08-11 2022-03-04 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
TW201618775A (en) 2014-08-11 2016-06-01 艾森塔製藥公司 Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, a PD-1 inhibitor and/or a PD-L1 inhibitor

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022596A1 (en) 1995-12-18 1997-06-26 Zeneca Limited Quinazoline derivatives
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
WO1998013354A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Quinazoline derivatives and pharmaceutical compositions containing them
WO1999002166A1 (en) 1997-07-08 1999-01-21 Angiogene Pharmaceuticals Ltd. Use of colchinol derivatives as vascular damaging agents
WO2000040529A1 (en) 1999-01-07 2000-07-13 Angiogene Pharmaceuticals Ltd. Colchinol derivatives as vascular damaging agents
WO2000041669A2 (en) 1999-01-15 2000-07-20 Angiogene Pharmaceuticals Ltd. Benzimidazole vascular damaging agents
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2002022601A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2005049033A1 (en) * 2003-11-17 2005-06-02 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosyne kinases
WO2005103010A2 (en) * 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200000840A1 (en) 1998-02-17 2001-02-26 Туларик, Инк. ANTI-VIRUS DERIVATIVES OF PYRIMIDINE
DE19917785A1 (en) 1999-04-20 2000-10-26 Bayer Ag New 2,4-diamino-pyrimidine derivatives useful as microbicides in protection of plants and materials and as herbicides
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
HUP0202682A3 (en) 1999-09-10 2003-03-28 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
AU2735201A (en) 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
BR0113574A (en) 2000-08-31 2003-07-22 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
EP1317446A1 (en) 2000-09-01 2003-06-11 Glaxo Group Limited Oxindole derivatives
EP1339680A1 (en) 2000-09-01 2003-09-03 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
KR100909665B1 (en) * 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same
CA2433018A1 (en) 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US7015231B2 (en) 2001-09-27 2006-03-21 Smithkline Beecham Corporation Chemical compounds
SE0104140D0 (en) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
JP2003231687A (en) 2002-02-04 2003-08-19 Japan Tobacco Inc Pyrazolyl condensed ring compound and pharmaceutical use thereof
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
PL1656372T3 (en) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US20060069110A1 (en) 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
EP1831216A2 (en) 2004-12-23 2007-09-12 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
ATE519759T1 (en) 2004-12-30 2011-08-15 Exelixis Inc PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHODS OF APPLICATION
EP1853602B1 (en) 2005-02-16 2010-07-14 AstraZeneca AB Chemical compounds
AU2006215386B2 (en) * 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
CN101208093A (en) * 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
CA2607727A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
EP1888561A1 (en) * 2005-05-05 2008-02-20 AstraZeneca AB Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
BRPI0610184A2 (en) * 2005-05-16 2012-09-25 Astrazeneca Ab compound, pharmaceutically acceptable salt of a compound, process for preparing a compound or a pharmaceutically acceptable salt thereof, use of a compound or a pharmaceutically acceptable salt thereof, methods for inhibiting trk activity, for cancer treatment or prophylaxis and for producing an antiproliferative effect on a warm-blooded animal, and, pharmaceutical composition
EP2388259A1 (en) * 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
TW200817391A (en) * 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022596A1 (en) 1995-12-18 1997-06-26 Zeneca Limited Quinazoline derivatives
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
WO1998013354A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Quinazoline derivatives and pharmaceutical compositions containing them
WO1999002166A1 (en) 1997-07-08 1999-01-21 Angiogene Pharmaceuticals Ltd. Use of colchinol derivatives as vascular damaging agents
WO2000040529A1 (en) 1999-01-07 2000-07-13 Angiogene Pharmaceuticals Ltd. Colchinol derivatives as vascular damaging agents
WO2000041669A2 (en) 1999-01-15 2000-07-20 Angiogene Pharmaceuticals Ltd. Benzimidazole vascular damaging agents
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2002022601A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2005049033A1 (en) * 2003-11-17 2005-06-02 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosyne kinases
WO2005103010A2 (en) * 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
T.W. GREEN: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY AND SONS

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
WO2006123113A3 (en) * 2005-05-16 2007-01-04 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
AU2006248780B2 (en) * 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP2083624A2 (en) * 2006-10-18 2009-08-05 Merck & Co., Inc. 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
EP2083624A4 (en) * 2006-10-18 2010-06-16 Merck Sharp & Dohme 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
WO2008053812A1 (en) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and medicinal use thereof
WO2008054292A1 (en) * 2006-11-01 2008-05-08 Astrazeneca Ab Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
JP2010526128A (en) * 2007-05-04 2010-07-29 アストラゼネカ アクチボラグ 9- (pyrazol-3-yl) -9H-purin-2-amine and 3- (pyrazol-3-yl) -3H-imidazo [4,5-B] pyridin-5-amine derivatives and for the treatment of cancer Their use of
EP2251329A1 (en) * 2008-03-04 2010-11-17 Ishihara Sangyo Kaisha, Ltd. Process for production of 3-amino-2-chloro-6- trifluoromethylpyridine
EP2251329A4 (en) * 2008-03-04 2012-03-21 Ishihara Sangyo Kaisha Process for production of 3-amino-2-chloro-6- trifluoromethylpyridine
JP2009235062A (en) * 2008-03-04 2009-10-15 Ishihara Sangyo Kaisha Ltd Method for producing 3-amino-2-chloro-6-(trifluoromethyl)pyridine
WO2009110475A1 (en) * 2008-03-04 2009-09-11 石原産業株式会社 Process for production of 3-amino-2-chloro-6- trifluoromethylpyridine
WO2010020810A1 (en) * 2008-08-19 2010-02-25 Astrazeneca Ab 2-(imidaz0lylamin0)-pyridine derivatives and their use as jak kinase inhibitors
WO2011076419A1 (en) 2009-12-24 2011-06-30 Almirall, S.A. Imidazopyridine derivatives as jak inhibitors
WO2011101161A1 (en) 2010-02-18 2011-08-25 Almirall, S.A. Pyrazole derivatives as jak inhibitors
EP2589592A1 (en) * 2010-06-30 2013-05-08 FUJIFILM Corporation Novel nicotinamide derivatives or salts thereof
TWI561512B (en) * 2010-06-30 2016-12-11 Fujifilm Corp Novel nicotinamide derivative or salt thereof
EP2589592A4 (en) * 2010-06-30 2014-01-01 Fujifilm Corp Novel nicotinamide derivatives or salts thereof
US8895585B2 (en) 2010-06-30 2014-11-25 Fujifilm Corporation Nicotinamide derivative or salt thereof
WO2012010883A3 (en) * 2010-07-19 2012-09-07 Astrazeneca Ab Pharmaceutical depot for 5-fluoro-2 [ [ (1s) -1- (5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile
WO2012010883A2 (en) 2010-07-19 2012-01-26 Astrazeneca Ab Pharmaceutical depot for 5-fluoro-2 [ [ (1s) -1- (5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2012069202A1 (en) 2010-11-26 2012-05-31 Almirall,S.A. Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
US9051310B2 (en) 2011-12-28 2015-06-09 Fujifilm Corporation Nicotinamide derivative or salt thereof
US9382237B2 (en) 2012-03-16 2016-07-05 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9346792B2 (en) 2012-03-16 2016-05-24 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9365556B2 (en) 2012-03-16 2016-06-14 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9751887B2 (en) 2012-06-04 2017-09-05 Daiichi Sankyo Company, Limited Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
WO2013183578A1 (en) 2012-06-04 2013-12-12 第一三共株式会社 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR
US9187489B2 (en) 2012-06-04 2015-11-17 Daiichi Sankyo Company, Limited Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
US9540351B2 (en) 2013-09-18 2017-01-10 Axikin Pharmaceuticals, Inc. Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9730914B2 (en) 2014-12-23 2017-08-15 Axikin Pharmaceuticals 3,5-diaminopyrazole kinase inhibitors
WO2017157885A1 (en) 2016-03-16 2017-09-21 Bayer Cropscience Aktiengesellschaft N-(cyanobenzyl)-6-(cyclopropyl-carbonylamino)-4-(phenyl)-pyridine-2-carboxamide derivatives and related compounds as pesticides and plant protection agents
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020233645A1 (en) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 Macrolide derivatives, preparation method and application thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
IL184674A0 (en) 2007-12-03
EP1846394B1 (en) 2011-10-26
EP2383268A1 (en) 2011-11-02
AU2006210710A1 (en) 2006-08-10
RS52061B (en) 2012-04-30
HUE025671T2 (en) 2016-04-28
SI2383268T1 (en) 2016-02-29
BRPI0606793A2 (en) 2009-12-01
KR20070107107A (en) 2007-11-06
KR101302945B1 (en) 2013-09-06
NO20073791L (en) 2007-08-30
US20080139561A1 (en) 2008-06-12
HK1163677A1 (en) 2012-09-14
DK1846394T3 (en) 2012-01-16
SA06270007B1 (en) 2010-11-22
MY149512A (en) 2013-09-13
UY29360A1 (en) 2006-10-02
HRP20110962T1 (en) 2012-01-31
CY1115078T1 (en) 2016-12-14
CY1119077T1 (en) 2018-01-10
HK1114374A1 (en) 2008-10-31
ES2555063T3 (en) 2015-12-28
EP1846394A1 (en) 2007-10-24
NO341112B1 (en) 2017-08-28
PT1846394E (en) 2012-01-05
SI1846394T1 (en) 2012-06-29
AU2006210710B2 (en) 2009-12-10
TWI370127B (en) 2012-08-11
JP5139084B2 (en) 2013-02-06
ATE530545T1 (en) 2011-11-15
EP2383268B1 (en) 2015-09-02
CA2595834A1 (en) 2006-08-10
US20130090358A1 (en) 2013-04-11
IL184674A (en) 2012-07-31
NZ561145A (en) 2011-02-25
ES2375735T3 (en) 2012-03-05
ME02645B (en) 2012-04-30
DK2383268T3 (en) 2015-09-14
PL2383268T3 (en) 2016-02-29
US8835465B2 (en) 2014-09-16
CN101155800B (en) 2012-05-23
JP2008528664A (en) 2008-07-31
PT2383268E (en) 2015-12-21
BRPI0606793A8 (en) 2018-03-13
US8324252B2 (en) 2012-12-04
PL1846394T3 (en) 2012-04-30
CA2595834C (en) 2013-04-30
CN101155800A (en) 2008-04-02
AR056184A1 (en) 2007-09-26
MX2007009437A (en) 2007-08-16

Similar Documents

Publication Publication Date Title
DK2383268T3 (en) PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
AU2006248780B2 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
AU2006215394B2 (en) Chemical compounds
AU2006215386B2 (en) Chemical compounds
NZ567584A (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP1888561A1 (en) Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 184674

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006210710

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2595834

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007/06212

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/009437

Country of ref document: MX

Ref document number: 2007553688

Country of ref document: JP

Ref document number: 12007501673

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006210710

Country of ref document: AU

Date of ref document: 20060201

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006210710

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006701619

Country of ref document: EP

Ref document number: 6476/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 07090213

Country of ref document: CO

Ref document number: 561145

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007132976

Country of ref document: RU

Ref document number: 1020077020258

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200680010108.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006701619

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11815140

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0606793

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: P-2011/0563

Country of ref document: RS